



UNIVERSITY OF LEEDS

This is a repository copy of *Oral 11 $\beta$ -HSD1 inhibitor AZD4017 improves wound healing and skin integrity in adults with type 2 diabetes mellitus: a pilot randomised controlled trial.*

White Rose Research Online URL for this paper:  
<https://eprints.whiterose.ac.uk/183255/>

Version: Accepted Version

---

**Article:**

Ajjan, RA, Hensor, EMA, Del Galdo, F et al. (13 more authors) (2022) Oral 11 $\beta$ -HSD1 inhibitor AZD4017 improves wound healing and skin integrity in adults with type 2 diabetes mellitus: a pilot randomised controlled trial. *European Journal of Endocrinology*. ISSN 0804-4643

<https://doi.org/10.1530/EJE-21-1197>

---

© 2022 The authors 2022. This is an author produced version of an article published in *European Journal of Endocrinology*. Uploaded in accordance with the publisher's self-archiving policy.

**Reuse**

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



[eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk)  
<https://eprints.whiterose.ac.uk/>

1 **Oral 11 $\beta$ -HSD1 inhibitor AZD4017 improves wound healing and skin**  
2 **integrity in adults with type 2 diabetes mellitus: a pilot randomised**  
3 **controlled trial**

4 **AUTHORS**

5 RA Ajjan<sup>1</sup>, MD, EMA Hensor<sup>2,3</sup>, PhD, F Del Galdo<sup>2,3</sup>, MD, K Shams<sup>2,3</sup>, MD, A Abbas<sup>1</sup>, MD,  
6 RJ Fairclough<sup>4</sup>, PhD, L Webber<sup>5</sup>, BSc, L Pegg<sup>5</sup>, BSc, A Freeman<sup>4</sup>, BSc, AE Taylor<sup>6,7</sup>, PhD,  
7 W Arlt<sup>6,7,8</sup>, MD, AW Morgan<sup>1,3</sup>, MD, AA Tahrani<sup>6,7,8</sup>, MD, PM Stewart<sup>3,9</sup>, MD, DA  
8 Russell<sup>1,10</sup>, MD, A Tiganeşcu<sup>1,3</sup>, PhD.

9 **AFFILIATIONS**

10 <sup>1</sup>Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK

11 <sup>2</sup>Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds,  
12 UK

13 <sup>3</sup>NIHR Leeds Biomedical Research Center, Leeds Teaching Hospitals, NHS Trust, Leeds,  
14 UK

15 <sup>4</sup>Emerging Innovations Unit, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca,  
16 Cambridge, UK

17 <sup>5</sup>Emerging Portfolio Development, Late Oncology, Oncology R&D, AstraZeneca,  
18 Cambridge, UK

19 <sup>6</sup>Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK

20 <sup>7</sup>Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners,  
21 Birmingham, UK

22 <sup>8</sup>NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS  
23 Foundation Trust, Birmingham, UK

24 <sup>9</sup>Faculty of Medicine and Health, University of Leeds, Leeds, UK

25 <sup>10</sup>Leeds Vascular Institute, Leeds Teaching Hospitals NHS Trust, Leeds, UK

## 26 **CORRESPONDING AUTHOR**

27 Ana Tiganeşcu, Ph.D. University of Leeds, LICAMM, LIGHT Laboratories, Leeds, LS2 9NL.

28 Email: [a.tiganescu@leeds.ac.uk](mailto:a.tiganescu@leeds.ac.uk)

## 29 **RUNNING HEAD**

30 AZD4017 improves wound healing in diabetes

## 31 **KEYWORDS**

32 Diabetes, wound healing, skin, epidermal barrier, glucocorticoids, cortisol, 11beta-  
33 hydroxysteroid dehydrogenase, transepidermal water loss, clinical trial

## 34 **COUNTS**

35 Word count: 3386. Table count: 4. Figure count: 4.

## 36 **ABSTRACT**

37 **Background.** Chronic wounds (e.g., diabetic foot ulcers) reduce quality of life, yet  
38 treatments remain limited. Glucocorticoids (activated by the enzyme 11 $\beta$ -hydroxysteroid  
39 dehydrogenase type 1, 11 $\beta$ -HSD1) impair wound healing. **Objectives.** Efficacy, safety, and  
40 feasibility of 11 $\beta$ -HSD1 inhibition for skin function and wound healing. **Design.** Investigator-  
41 initiated, double-blind, randomized, placebo-controlled, parallel-group phase 2b pilot trial.  
42 **Methods.** Single-center secondary care setting. Adults with type 2 diabetes mellitus without  
43 foot ulcers were administered 400mg oral 11 $\beta$ -HSD1 inhibitor AZD4017 (n=14) or placebo

44 (n=14) bi-daily for 35 days. Participants underwent 3mm full-thickness punch skin biopsies  
45 at baseline and day 28; wound healing was monitored after 2 and 7 days. Computer-generated  
46 1:1 randomization was pharmacy-administered. Analysis was descriptive and focused on  
47 confidence interval estimation. Of 36 participants screened, 28 were randomized. **Results.**  
48 Exploratory proof-of-concept efficacy analysis suggested AZD4017 did not inhibit 24-hour  
49 *ex vivo* skin 11 $\beta$ -HSD1 activity (primary outcome; difference in % conversion per 24 hours  
50 1.1% (90% CI -3.4%, 5.5%)) but reduced systemic 11 $\beta$ -HSD1 activity by 87% (69-104%).  
51 Wound diameter was 34% (7-63%) smaller with AZD4017 at day 2, and 48% (12-85%)  
52 smaller after repeat wounding at day 30. AZD4017 improved epidermal integrity but  
53 modestly impaired barrier function. Minimal adverse events were comparable to placebo.  
54 Recruitment rate, retention and data completeness were 2.9/month, 27/28 and 95.3%,  
55 respectively. **Conclusion.** A phase 2 trial is feasible, and preliminary proof-of-concept data  
56 suggests AZD4017 warrants further investigation in delayed healing e.g. diabetic foot ulcers.  
57 **Trial registration.** Clinicaltrials.gov NCT03313297, www.isrctn.com ISRCTN74621291.  
58 **Funding.** MRC MC\_PC\_15046, National Institute for Health Research NF-SI-0514-10090.

## 59 **ABBREVIATIONS**

60 11 $\beta$ -HSD, 11 $\beta$ -hydroxysteroid dehydrogenase; AE, adverse event, CONSORT, Consolidated  
61 Standards of Reporting Trials; ECG, electrocardiogram; ELISA, enzyme-linked  
62 immunosorbent assay; GC, glucocorticoid; GC-SHEALD, Glucocorticoids and Skin Healing  
63 in Diabetes; HbA1c, glycated hemoglobin A1c; NIHR, National Institute for Health  
64 Research; OCT, optical coherence tomography; TEWL, transepidermal water loss;  
65 [THF+alloTHF]/THE, tetrahydrocortisol + 5 $\alpha$ -tetrahydrocortisol/tetrahydrocortisone.

66 **SIGNIFICANCE STATEMENT**

67 Stress hormone activation by the enzyme 11 $\beta$ -hydroxysteroid dehydrogenase type 1 impairs  
68 skin function (e.g. integrity) and delays wound healing in animal models of diabetes, but  
69 effects in human skin were previously unknown.

70 Skin function was evaluated in response to treatment with an 11 $\beta$ -hydroxysteroid  
71 dehydrogenase type 1 inhibitor (AZD4017), or placebo, in people with type 2 diabetes.

72 Importantly, AZD4017 was safe and well-tolerated.

73 This first-in-humans randomized, controlled, clinical trial found novel evidence that 11 $\beta$ -  
74 hydroxysteroid dehydrogenase type 1 regulates skin function in humans, including improved  
75 wound healing, epidermal integrity and increased water loss.

76 Results warrant further studies in conditions of impaired wound healing e.g. diabetic foot  
77 ulcers to evaluate 11 $\beta$ -hydroxysteroid dehydrogenase type 1 as a novel therapeutic target for  
78 chronic wounds.

79 **INTRODUCTION**

80 Chronic, non-healing wounds (e.g., diabetic foot ulcers) are a common and worldwide health  
81 problem of substantial medical and socioeconomic importance (1). Costs for wound care in  
82 the UK are estimated to be £2.03 to £3.8 million per 100,000 population (2, 3). The profound  
83 atrophic effects of glucocorticoids (GC) on human skin structure and function are well  
84 documented, including increased transepidermal water loss (TEWL), skin thinning and  
85 delayed wound healing (4-11). 11 $\beta$ -hydroxysteroid dehydrogenase (11 $\beta$ -HSD) isozymes  
86 regulate local GC availability independently of circulating levels (12). In skin, 11 $\beta$ -HSD1 is  
87 widely expressed and induced by GC in a forward-feedback manner (13, 14).

88 11 $\beta$ -HSD1 activity increases during wound healing (15) and 11 $\beta$ -HSD1 inhibition improves  
89 wound healing in preclinical models of GC excess, aging and diabetes (13, 16-18). Therefore,  
90 11 $\beta$ -HSD1 inhibition may aid wound healing, particularly in conditions associated with  
91 increased systemic GC levels, such as diabetes (19, 20). However, the ability of systemic  
92 11 $\beta$ -HSD1 inhibitors to regulate skin function in humans is unknown.

93 We conducted this randomized controlled trial to evaluate the effect of 11 $\beta$ -HSD1 inhibition  
94 on skin function and wound healing in patients with type 2 diabetes mellitus.

## 95 **PATIENTS AND METHODS**

96 We have summarized the trial methods in brief here but for full details please refer to the  
97 final approved trial protocol provided in Supplementary S1.

### 98 **Study Approval**

99 Informed consent was obtained after the nature and possible consequences of the study had  
100 been explained. Full ethical approval was acquired from North West Greater Manchester  
101 Central Research Ethics Committee 17/NW/0283 before initiation of recruitment. The  
102 reported investigations were carried out in accordance with the principles of the Declaration  
103 of Helsinki as revised in 2008.

104 **Study design**

105 **This was a randomized, double-blind, parallel-group, placebo-controlled, phase 2 pilot**  
106 **trial in people with type 2 diabetes. Participants were recruited between March 28,**  
107 **2018, and January 23, 2019 (first to last randomized participant telephone invitations),**  
108 **and the last participant’s last follow-up call (telephone discharge) was on April 3, 2019.**  
109 **A total of 28 participants (22 male, 6 female) were randomized, and 27 completed the**  
110 **35-day oral AZD4017 or placebo treatment.****Selection of sample size**

111 Published guidance for pilot studies recommended a sample size of 12 participants per arm  
112 (21). To achieve this sample size, the study was designed to randomize 15 participants per  
113 arm to allow for a 20% drop-out rate.

114 **Data Monitoring**

115 Data monitoring was carried out during the trial by the study management team and the  
116 sponsor. Independent oversight of the study, including interim safety monitoring, was  
117 conducted by an independent data monitoring and ethics committee.

118 **Randomization and blinding**

119 Participants and the study team were blinded to the randomization process, and other blinding  
120 procedures included mitigation of accidental unblinding, semi-blind interim safety analyses,  
121 and independent data monitoring and ethics committee oversight. Dosing compliance was  
122 monitored by completion of diary cards by participants and by counting the number of tablets  
123 remaining at each study visit.

124 **Treatments and withdrawal criteria**

125 Participants received either oral AZD4017 (400 mg) or matched oral placebo twice daily for  
126 35 days. For full treatment and compliance details, and AZD4017 withdrawal criteria, please  
127 refer to the protocol (Supplementary S1).

128 **Study endpoints**

129 The primary endpoint was 24-hour 11 $\beta$ -HSD1 activity in skin (efficacy) at baseline and day  
130 28. Pre-specified secondary endpoints were:

- 131 • Systemic 11 $\beta$ -HSD1 activity at baseline and day 35
- 132 • AZD4017 quantification in skin at day 28 and in plasma at day 35
- 133 • Safety variables at baseline and days 7, 28, 35 and 42
- 134 • Urinary cortisol to cortisone metabolite analysis at baseline and day 35 (to assess  
135 systemic GC levels)
- 136 • Skin function variables at baseline and days 2, 7, 28, 30, and 35
- 137 • Feasibility variables throughout the study

138 **Wound healing**

139 All individuals underwent two full thickness 3 mm skin punch biopsies at baseline, repeated  
140 in the contralateral arm on day 28; wound healing was assessed on days 2 and 7 post-  
141 wounding (treatment days 2, 7, 30 and 35).

142 **Statistical analysis**

143 A detailed standalone statistical analysis plan (SAP) was developed and finalized before  
144 breaking of the blind and processing of primary outcome samples.

145 In this pilot study, the analysis was descriptive throughout, so no inferential hypotheses were  
146 formally tested. As pre-specified in the SAP, analysis followed published recommendations,  
147 which state that the focus in pilot trials should be on descriptive statistics and estimation  
148 using a range of CIs other than 95% and interpreting these using the minimum clinically  
149 important difference (22).

150 For each outcome, differences were adjusted for gender, age, baseline glycosylated hemoglobin  
151 A1c (HbA1c), and (where applicable) the baseline value of the outcome. Primary two-sided  
152 90% confidence intervals (CIs) were supplemented with CIs ranging from 75-95%, in line  
153 with recommendations . Adjusted differences were obtained via regression modelling; linear  
154 regression was used unless data did not meet the model assumptions and a suitable  
155 transformation could not be found. As pre-specified in the SAP, in these instances quantile  
156 (median) regression was used instead; this estimates the difference in the medians instead of  
157 the means, makes fewer assumptions about the data, and is less sensitive to outliers than  
158 linear regression.

159 Because minimum clinically important differences have not been established in this  
160 population for the outcomes investigated, we additionally reported percentage differences  
161 relative to the mean or median with placebo as a guideline. Analyses were conducted in Stata  
162 16.1 (StataCorp 2019. College Station, Texas, United States). For further details, see  
163 Supplementary S2.

## 164 **RESULTS**

165 A Consolidated Standards of Reporting Trials (CONSORT) flow diagram is presented in  
166 Figure 1. In addition to the main findings, Supplementary S3 presents full descriptive  
167 summaries of efficacy (Table S1) and laboratory safety variables (Table S2), compliance data  
168 (Table S3), unadjusted differences in primary and secondary efficacy outcomes (Table S4),

169 sensitivity analyses after outlier removal (Table S5), unadjusted and adjusted changes from  
170 baseline (Tables S6-S7), additional pre-specified sensitivity analyses (Table S8-S10),  
171 correlations between AZD4017 compliance and efficacy outcomes (Table S11), full  
172 laboratory safety data (Tables S12-S15) and sample sizes for future trials (Table S16).

173 Differences between groups are presented with 90% CI, unless otherwise stated.

#### 174 **Participant demographics and baseline variables**

175 The two randomized arms were well balanced for participant demographics, baseline  
176 efficacy, and laboratory safety variables (Table 1).

#### 177 **Efficacy**

##### 178 *Primary outcome: skin 11 $\beta$ -HSD1 activity*

179 Median 11 $\beta$ -HSD1 activity (% conversion per 24 hours) by radioassay at day 28 was similar  
180 in both treatments after adjustment for baseline activity, baseline HbA1c, age, and sex. The  
181 median was 11.8% with placebo and 12.8% with AZD4017, with a difference of 1.1% (-3.4,  
182 5.5, Figure 2a, Table 2). This outcome was unaffected in sensitivity analysis after removal of  
183 two baseline samples that were considered unreliable.

184 Another sensitivity analysis that used an alternative enzyme-linked immunosorbent assay  
185 (ELISA) method had an acceptable correlation with the radioassay method at baseline  
186 ( $\rho=0.70$ ) but not at day 28 ( $\rho=0.19$ ) (Figure S1, Table 3). ELISA results were consistent  
187 with the radioassay method. Therefore, the pilot data offered no proof-of-concept of 11 $\beta$ -  
188 HSD1 inhibition by AZD4017 in skin, in contrast to the systemic effects detailed below.

##### 189 *Systemic 11 $\beta$ -HSD1 activity*

190 Systemic 11 $\beta$ -HSD1 activity was inferred from 24hr urinary steroid metabolite ratios  
191 tetrahydrocortisol + 5 $\alpha$ -tetrahydrocortisol/tetrahydrocortisone ([THF+alloTHF]/THE) by

192 liquid chromatography-tandem mass spectrometry (23). In contrast to skin, systemic 11 $\beta$ -  
193 HSD1 activity, was lower with AZD4017; the adjusted median was 1.00 with placebo and  
194 0.13 with AZD4017, and the difference was -0.87 (-1.04, -0.69) (Figure 2b, Table 2). All  
195 supplementary CIs up to 95% excluded 0, suggesting that median systemic 11 $\beta$ -HSD1  
196 activity may be at least 69% (median 87%) lower in participants taking AZD4017. As  
197 anticipated, the results showed no evidence that urinary cortisol/cortisone ratio (a measure of  
198 systemic 11 $\beta$ -HSD2 activity that deactivates cortisol to cortisone; unplanned analysis) was  
199 affected by AZD4017. The adjusted median was 0.71 with placebo and 0.65 with AZD4017;  
200 the difference was -0.06 (-0.19, 0.07, Figure 2c).

#### 201 *Wound healing*

202 Based on maximal granulation tissue width (a marker of early wound healing), the mean  
203 wound gap 2 days after each of the separate biopsies was lower with AZD4017 at all levels of  
204 confidence. The mean difference was -0.52mm (-0.95mm, -0.10mm) at day 2 and -0.65mm (-  
205 1.15mm, -0.016mm) at day 30, corresponding to a 7% to 63% (mean 34%) and 12% to 85%  
206 (mean 48%) narrower wound gap diameter, respectively, with AZD4017 (Figure 3a-b, Table  
207 2). Representative wound healing images for participants treated with placebo and AZD4017  
208 are presented in Figure 3c.

209 Based on maximal clot depth (a marker of late wound healing), the data showed no indication  
210 of a difference on either day 7 or day 35 (Table 2).

#### 211 *Epidermal barrier function*

212 The epidermal barrier is essential in guarding against water loss and infection. Barrier defects  
213 are associated with a range of skin pathologies e.g. atopic dermatitis (24) and functions are  
214 regulated by GC in a complex manner (25), but the role of 11 $\beta$ -HSD1 is unknown.

215 TEWL, the gold-standard measure of epidermal barrier function, was on average 33% higher  
216 with AZD4017 on day 35 (Figure 3d, Table 2), but 90% CI included 0. At lower levels of  
217 confidence, resting TEWL was higher with AZD4017 and in sensitivity analysis (which  
218 excluded potentially unreliable values) the 90% CI was 3% to 88%.

### 219 *Epidermal integrity*

220 Epidermal integrity contributes to skin resilience against mechanical damage (wounding),  
221 measured by resistance to sequential tape stripping of epidermal layers.

222 The number of tapes required to achieve the same degree of barrier disruption (TEWL of 40-  
223 50 g/h/m<sup>2</sup>) was 7% to 91% (mean 43%) higher with AZD4017 (Figure 3e, Table 2),  
224 equivalent to an additional 16.8 tapes.

### 225 *Epidermal barrier recovery*

226 The first set of post-disruption recovery measurements, collected between baseline and day 7,  
227 provided no proof of concept for a difference in TEWL (Table 2).

228 The second set of post-disruption recovery measurements, collected between day 28 and day  
229 35, indicated higher TEWL with AZD4017 at 3 hours and 48 hours, at 80% to 85%  
230 confidence, although the CIs were wide (Figures 3f and 3g, Table 2). By 168 hours after  
231 disruption, there was no difference (Table 2).

232 Together with pre-disruption epidermal barrier findings, these preliminary results suggest a  
233 novel role for skin 11 $\beta$ -HSD1 in the maintenance of epidermal barrier homeostasis, which  
234 would require confirmation in larger future trials

235 *Epidermal thickness*

236 Although the observed median epidermal thickness was greater with AZD4017 at day 35,  
237 median skin thickness could be between 8% thinner and 26% thicker with AZD4017 (Table  
238 2).

239 *Skin hydration*

240 Dry skin is less resistant to wounding and is common in people with diabetes (26).

241 Although the observed median hydration was higher with AZD4017, consistent with proof of  
242 concept, hydration could be between 7% lower and 37% higher in those receiving AZD4017  
243 (Table 2).

244 *Sudomotor nerve function*

245 Reduced sudomotor nerve function is a leading cause of chronic foot ulcers (27) but  
246 regulation by GC is unknown.

247 Averaged across all sites, there was no proof-of-concept of a difference in sudomotor  
248 function; results suggested function could be between 14% worse and 10% better with  
249 AZD4017 (Table 2). There was also no proof-of-concept (and CIs included only modest  
250 potential differences in either direction) when results were averaged for hands and feet  
251 separately.

252 Sensitivity analyses indicated worse foot sudomotor function with AZD4017 at 75%  
253 confidence, but all other results from this additional analysis were consistent with the main  
254 findings.

255 **Compliance**

256 Mean diary card compliance was >97.9% in both arms at all visits and > 99.6% at day 35.  
257 Mean treatment compliance at each visit was >95.2% in both arms and >97.9% at day 35;  
258 overall treatment compliance was 84% to 101% with placebo and 93% to 101% with  
259 AZD4017. Drug exposure data in plasma and skin did not indicate any discrepancies between  
260 reported compliance rates and actual exposure, which suggests that participants had correctly  
261 adhered to their assigned treatment regimen.

262 As anticipated, AZD4017 levels in day 28 skin biopsies and day 35 plasma samples  
263 correlated moderately (Spearman's rho=0.54; Figure S2), further validating drug tissue  
264 penetration.

265 **Correlations between compliance and efficacy outcomes**

266 In those taking AZD4017, several outcome measures displayed a possible association with  
267 compliance (absolute rho>0.3), including negative associations with 11β-HSD1 activity (skin  
268 activity measured by ELISA and systemic activity measured by urinary [THF+alloTHF]/THE  
269 ratios) and positive associations with TEWL and skin hydration.

270

271 **Safety**

272 *Biopsy and Electrocardiogram (ECG)*

273 Biopsy findings did not raise any clinical concerns, and all passed a physical inspection. No  
274 incidents of infection were observed. Participants did not report any significant pain or  
275 discomfort from the biopsies, which all healed well.

276 No participants remaining in the trial at day 42 (13 with placebo and 14 with AZD4017)  
277 showed clinically meaningful ECG anomalies.

278 *Longitudinal laboratory safety data*

279 With AZD4017 (Table 3) dehydroepiandrosterone sulphate was higher on days 7, 28, 35, and  
280 42; total cholesterol was lower on days 7, 28, and 35; high-density lipoprotein was lower on  
281 day 35, and systolic blood pressure was lower on day 28 (Table 3, Figure 4a-4d).

282 Apart from some small differences which were not considered to be clinically relevant, the  
283 remaining variables did not differ (Table 3, Figures 4e-4i).

284 Although several laboratory findings (with both treatments) were above or below accepted  
285 clinically normal limits, few warranted further investigation or intervention by the study  
286 team, and none resulted in treatment withdrawal.

287 *Adverse events (AE)*

288 37 individual AEs occurred, of which 13 were with placebo and 24 with AZD4017 (Table 4).  
289 When recurring instances of the same AE within a participant were counted as a single AE,  
290 29 unique AEs occurred, of which 16 were with AZD4017 and 13 with placebo. Most AEs  
291 involved the gastrointestinal, nervous, or respiratory systems. 26 AEs were mild, and 3 were  
292 moderate. None of the 29 unique AEs were considered probably or definitely related to the  
293 study drug, 20 were possibly related, and 8 were unlikely to be related. AEs were broadly  
294 balanced across treatment arms, although all 3 moderately severe events occurred with  
295 AZD4017.

296 **Future study power estimation**

297 Based on power calculations from the current trial, we anticipate that 100 to 150 participants  
298 per arm should suffice to detect a difference of 20% or more in comparison with placebo for  
299 all outcome measures.

300 **Feasibility**

301 Our assessment of the study's recruitment rate, proportions meeting each eligibility criterion,  
302 proportion of eligible candidates consenting to take part, and data completeness found that a  
303 future confirmatory trial is feasible.

304 **DISCUSSION**

305 Our double-blind, randomized, placebo-controlled, parallel-group pilot clinical trial provides  
306 preliminary evidence that wounds were smaller and skin integrity was greater in people with  
307 type 2 diabetes with systemic 11 $\beta$ -HSD1 inhibition. This finding potentially represents a  
308 major advance in the development of 11 $\beta$ -HSD1 inhibitors as novel therapies for diabetic  
309 ulcers. Nevertheless, all findings from this pilot study are considered exploratory, which  
310 require confirmation in an adequately powered phase 2 trial.

311 Studies previously demonstrated effective 11 $\beta$ -HSD1 inhibition in mouse skin (13, 16), but  
312 this had not been explored in humans. In this pilot study, data on our primary outcome  
313 measure failed to show 11 $\beta$ -HSD1 inhibition in skin. The absence of skin 11 $\beta$ -HSD1  
314 inhibition was not due to lack of exposure *in situ* because AZD4017 levels in skin correlated  
315 with plasma levels, albeit at lower concentrations. Alternatively, ineffective AZD4017  
316 efficacy *ex vivo* (low target affinity) or insufficient assay sensitivity (as baseline 11 $\beta$ -HSD1  
317 activity was relatively low) may explain this finding. In this situation, the analysis plan  
318 stipulated that differences in secondary outcomes were only to be interpreted if AZD4017  
319 inhibited systemic 11 $\beta$ -HSD1 activity. Indeed, we found AZD4017 reduced  
320 [THF+alloTHF]/THE ratios and elevated dehydroepiandrosterone sulphate. This finding is  
321 consistent with that of other selective 11 $\beta$ -HSD1 inhibitor trials, including AZD4017 (28-32).  
322 Importantly, 11 $\beta$ -HSD2 activity was unaffected by AZD4017 (23, 33).

323 Our secondary outcomes, although exploratory, offer a series of novel insights into the  
324 potential effects of 11 $\beta$ -HSD1 inhibition on skin function. Optical coherence tomography is a  
325 validated method for non-invasive assessment of wound healing (34), and this is the first  
326 application in a randomized controlled trial. Our finding of improved early granulation tissue  
327 healing in day 2 wounds (across all CIs) with only 2 days of AZD4017 treatment is very  
328 promising, especially as overall healing in this cohort was normal, and participants' diabetes  
329 was well managed. Further, this effect was greater after 30 days of treatment, suggesting  
330 improved efficacy with increased AZD4017 exposure.

331 By day 7 after wounding, early granulation tissue remodeling was complete in all participants  
332 and no effect with AZD4017 was detected, potentially because we measured clot depth,  
333 rather than volume. In a subsequent study, we developed a new machine learning method for  
334 automated volumetric quantification of key morphological features of wound healing using  
335 the optical coherence tomography scans from this clinical trial, which further supports our  
336 finding that AZD4017 promotes wound healing (35). These novel pilot human data are  
337 consistent with the known deleterious effects of GC on wound healing (36) and with  
338 preclinical evidence of improved healing by 11 $\beta$ -HSD1 inhibition in animal models of stress,  
339 obesity, GC excess, and aging from our group and others (13, 16-18).

340 We also found that AZD4017 increased epidermal integrity, an improvement comparable to  
341 the greater epidermal integrity of young vs. aged skin (37). This is supported by studies  
342 demonstrating reduced skin integrity after human psychological stress (38) or exogenous GC  
343 treatment (39) and strengthens the basis for further development of AZD4017 to improve  
344 skin function.

345 Provisional evidence of modest impairments in epidermal barrier function and recovery with  
346 AZD4017 was also observed in our study. GCs are known to both impair and promote

347 epidermal barrier function, the former during exogenous GC treatment (39-41) and the latter  
348 during endogenous GC excess (25). Our results are in agreement, showing for the first time  
349 that endogenous cortisol may promote epidermal barrier function via 11 $\beta$ -HSD1.

350 GCs impair healing through multiple mechanisms, for example, by inhibiting keratinocyte re-  
351 epithelialization whilst promoting keratinocyte differentiation (essential for barrier function)  
352 (9), supporting our findings of improved wound healing and impaired barrier function by  
353 AZD4017. Future 11 $\beta$ -HSD1 inhibitor trials should monitor the epidermal barrier,  
354 particularly in participants with compromised function (e.g. atopic dermatitis). Other key  
355 mechanisms of wound healing defect in ageing and diabetes include progenitor (stem) cell  
356 recruitment and angiogenesis (42), both associated with GC excess (43, 44). Abnormal  
357 immune cell function is also implicated in chronic wound etiology e.g. increased neutrophil  
358 extracellular trap formation (45) but the role of GC in this process is unknown. Such detailed  
359 mechanistic studies were beyond the scope of this pilot trial and regulation of these pathways  
360 by 11 $\beta$ -HSD1 remains an important area for future research.

361 Peripheral neuropathy is a serious complication in diabetes but regulation by GC is unknown.  
362 Nerve function was determined by sudomotor analysis, as previously described (27). In our  
363 study, AZD4017 did not affect nerve function overall or in the hands. At the lowest level of  
364 confidence, a modest impairment occurred in the feet. Therefore, future trials should also  
365 monitor nerve function to rule out any adverse effects.

366 We found no significant safety concerns in this small pilot study. Indeed, we found  
367 improvements in cardiovascular risk factors (notably total cholesterol and systolic blood  
368 pressure) in the AZD4017 arm. These improvements are consistent with results from other  
369 11 $\beta$ -HSD1 inhibitor trials (28, 30, 46, 47). Cardiovascular risk factors are a strong predictor  
370 of ulcers, healing, complications, and recurrence (48, 49). Therefore, oral 11 $\beta$ -HSD1

371 inhibitors could also reduce ulcer recurrence but this requires further studies with long-term  
372 11 $\beta$ -HSD1 inhibitor treatment. Concomitant medication use was not formally measured in  
373 this trial but warrants monitoring in these future studies.

374 Our study has several limitations, including the use of biopsy healing rather than ulcers,  
375 which was necessary to ensure AZD4017 was safe in acute wounds and well-managed  
376 diabetes, before application to more severe disease. Importantly however, our approach  
377 enabled the study of wound healing in a standardized manner, where issues such as infection  
378 and ulcer chronicity that would influence healing apply to a lesser extent, thus enabling a  
379 more focused assessment of AZD4017 impact. Although our findings are promising, the  
380 small sample size and lack of inferential testing (consistent with recommendations for pilot  
381 trials) necessitate confirmation in future trials.

382 Together, our findings provide justification for a powered phase 2 clinical trial in people with  
383 diabetic foot ulcers with an established ulcer healing measure as the primary outcome. This  
384 will likely be multicenter, coordinated with routine appointments and with randomization  
385 stratified for variables known to affect 11 $\beta$ -HSD1 function and wound healing (e.g. ulcer size  
386 and duration at presentation). Although requiring confirmation, the exploratory results from  
387 this pilot trial relating to healing, skin integrity, and cardiovascular risk factors for ulcer  
388 recurrence hold promise for 11 $\beta$ -HSD1 as a novel therapeutic target in wound repair.

### 389 **CONFLICT OF INTEREST**

390 AAT reports grants, personal fees, and travel support from Sanofi, grants, personal fees and  
391 educational events grants from Novo Nordisk, travel support from Merck Sharp and Dohme,  
392 personal fees and travel support from Boehringer Ingelheim, personal fees from Lilly,  
393 AstraZeneca, Bristol-Myers Squibb, and Janssen, equipment and travel support from  
394 ResMed, equipment from Philips Resporinics, Impeto Medical, and ANSAR Medical

395 Technologies, grants and non-financial support from Napp, and equipment and support staff  
396 from BHR Pharmaceuticals Ltd. AAT is currently an employee of Novo Nordisk. This work  
397 was performed before AAT becoming a Novo Nordisk employee and Novo Nordisk had no  
398 role in this study. The other authors have declared that no conflict of interest exists.

#### 399 **FUNDING**

400 This work was supported by a Medical Research Council Confidence in Concept Award to  
401 AT (MC\_PC\_15046), NIHR Senior Investigator Award to PMS (NF-SI-0514-10090), NIHR  
402 Leeds Biomedical Research Centre and NIHR Leeds In vitro Diagnostic Evidence Co-  
403 operative.

#### 404 **AUTHOR CONTRIBUTION STATEMENT**

405 **R.A.** conceptualization, design, investigation, resources, supervision, writing – review and  
406 editing; **E.M.A.H.** conceptualization, design, software, formal analysis, data curation,  
407 visualization, writing – review and editing; **K.S.** design, investigation, writing – review and  
408 editing; **F.D.G.** conceptualization, investigation, writing – review and editing; **A.A.** design,  
409 investigation, writing – review and editing; **R.J.F.** design, resources, supervision; **L.W.**  
410 design, resources, supervision; **L.P.** design, resources, supervision; **A.F.** design, resources,  
411 supervision, writing – review and editing; **A.E.T.** design, investigation, writing – review and  
412 editing, **W.A.** design, investigation, writing – review and editing **A.W.M.** conceptualization,  
413 supervision, writing – review and editing; **A.A.T.** conceptualization, writing – review and  
414 editing, **P.M.S.** conceptualization, funding acquisition, writing – review and editing, **D.A.R.**  
415 design, investigation, supervision, writing – review and editing; **A.T.** conceptualization,  
416 design, funding acquisition, investigation, project administration, supervision, validation,  
417 writing - original draft, writing – review and editing. All authors revised the article for  
418 critically important content and approved the final version to be published.

419 **ACKNOWLEDGEMENTS**

420 This work was supported by a Medical Research Council Confidence in Concept Award to  
421 AT (MC\_PC\_15046), NIHR Senior Investigator Award to PMS (NF-SI-0514-10090), NIHR  
422 Leeds Biomedical Research Centre and NIHR Leeds In vitro Diagnostic Evidence Co-  
423 operative.

424 This paper presents independent research supported by the National Institute for Health  
425 Research (NIHR) Leeds Biomedical Research Centre. The views expressed are those of the  
426 authors and not necessarily those of the NIHR or the Department of Health and Social Care.  
427 We thank Deborah Berlyne, Ph.D., for her editorial support.

428 **REFERENCES**

- 429 1. C. K. Sen, G. M. Gordillo, S. Roy, R. Kirsner, L. Lambert, T. K. Hunt, F. Gottrup, G. C. Gurtner,  
430 M. T. Longaker, Human skin wounds: a major and snowballing threat to public health and  
431 the economy. *Wound repair and regeneration : official publication of the Wound Healing  
432 Society [and] the European Tissue Repair Society* **17**, 763-771 (2009).
- 433 2. K. Vowden, P. Vowden, J. Posnett, The resource costs of wound care in Bradford and  
434 Airedale primary care trust in the UK. *Journal of wound care* **18**, 93-94, 96-98, 100 passim  
435 (2009).
- 436 3. N. Hex, C. Bartlett, D. Wright, M. Taylor, D. Varley, Estimating the current and future costs of  
437 Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and  
438 productivity costs. *Diabetic medicine : a journal of the British Diabetic Association* **29**, 855-  
439 862 (2012).
- 440 4. J. R. Sowers, H. R. Lippman, Cushing's syndrome due to ectopic ACTH production: cutaneous  
441 manifestations. *Cutis* **36**, 351-352, 354 (1985).
- 442 5. P. Autio, A. Oikarinen, J. Melkko, J. Risteli, L. Risteli, Systemic glucocorticoids decrease the  
443 synthesis of type I and type III collagen in human skin in vivo, whereas isotretinoin treatment  
444 has little effect. *The British journal of dermatology* **131**, 660-663 (1994).
- 445 6. V. P. Werth, A. M. Kligman, X. Shi, A. Pagnoni, Lack of correlation of skin thickness with bone  
446 density in patients receiving chronic glucocorticoid. *Archives of dermatological research* **290**,  
447 388-393 (1998).
- 448 7. H. C. Korting, A. Unholzer, M. Schafer-Korting, I. Tausch, J. Gassmueller, K. H. Nietsch,  
449 Different skin thinning potential of equipotent medium-strength glucocorticoids. *Skin  
450 pharmacology and applied skin physiology* **15**, 85-91 (2002).
- 451 8. P. Nuutinen, R. Rieki, M. Parikka, T. Salo, P. Autio, J. Risteli, A. Oikarinen, Modulation of  
452 collagen synthesis and mRNA by continuous and intermittent use of topical hydrocortisone  
453 in human skin. *The British journal of dermatology* **148**, 39-45 (2003).
- 454 9. B. Lee, C. Vouthounis, O. Stojadinovic, H. Brem, M. Im, M. Tomic-Canic, From an  
455 enhanceosome to a repressosome: molecular antagonism between glucocorticoids and EGF  
456 leads to inhibition of wound healing. *Journal of molecular biology* **345**, 1083-1097 (2005).

- 457 10. S. Schoepe, H. Schacke, E. May, K. Asadullah, Glucocorticoid therapy-induced skin atrophy. *Experimental dermatology* **15**, 406-420 (2006).
- 458
- 459 11. K. M. Aberg, K. A. Radek, E. H. Choi, D. K. Kim, M. Demerjian, M. Hupe, J. Kerbleski, R. L. Gallo, T. Ganz, T. Mauro, et al., Psychological stress downregulates epidermal antimicrobial peptide expression and increases severity of cutaneous infections in mice. *The Journal of clinical investigation* **117**, 3339-3349 (2007).
- 460
- 461
- 462
- 463 12. S. A. Morgan, E. L. McCabe, L. L. Gathercole, Z. K. Hassan-Smith, D. P. Lerner, I. J. Bujalska, P. M. Stewart, J. W. Tomlinson, G. G. Lavery, 11beta-HSD1 is the major regulator of the tissue-specific effects of circulating glucocorticoid excess. *Proceedings of the National Academy of Sciences of the United States of America* **111**, E2482-2491 (2014).
- 464
- 465
- 466
- 467 13. A. Tigancu, A. A. Tahrani, S. A. Morgan, M. Otranto, A. Desmouliere, L. Abrahams, Z. Hassan-Smith, E. A. Walker, E. H. Rabbitt, M. S. Cooper, et al., 11beta-Hydroxysteroid dehydrogenase blockade prevents age-induced skin structure and function defects. *The Journal of clinical investigation* **123**, 3051-3060 (2013).
- 468
- 469
- 470
- 471 14. A. Tigancu, E. A. Walker, R. S. Hardy, A. E. Mayes, P. M. Stewart, Localization, age- and site-dependent expression, and regulation of 11beta-hydroxysteroid dehydrogenase type 1 in skin. *The Journal of investigative dermatology* **131**, 30-36 (2011).
- 472
- 473
- 474 15. A. Tigancu, M. Hupe, Y. Uchida, T. Mauro, P. M. Elias, W. M. Holleran, Increased glucocorticoid activation during mouse skin wound healing. *The Journal of endocrinology* **221**, 51-61 (2014).
- 475
- 476
- 477 16. A. Tigancu, M. Hupe, Y. Uchida, T. Mauro, P. M. Elias, W. M. Holleran, Topical 11 beta-Hydroxysteroid Dehydrogenase Type 1 Inhibition Corrects Cutaneous Features of Systemic Glucocorticoid Excess in Female Mice. *Endocrinology* **159**, 547-556 (2018).
- 478
- 479
- 480 17. M. Terao, H. Murota, A. Kimura, A. Kato, A. Ishikawa, K. Igawa, E. Miyoshi, I. Katayama, 11beta-Hydroxysteroid dehydrogenase-1 is a novel regulator of skin homeostasis and a candidate target for promoting tissue repair. *PloS one* **6**, e25039 (2011).
- 481
- 482
- 483 18. J. K. Youm, K. Park, Y. Uchida, A. Chan, T. M. Mauro, W. M. Holleran, P. M. Elias, Local blockade of glucocorticoid activation reverses stress- and glucocorticoid-induced delays in cutaneous wound healing. *Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society* **21**, 715-722 (2013).
- 484
- 485
- 486
- 487 19. M. S. Bitar, Glucocorticoid dynamics and impaired wound healing in diabetes mellitus. *The American journal of pathology* **152**, 547-554 (1998).
- 488
- 489 20. A. Steptoe, R. A. Hackett, A. I. Lazzarino, S. Bostock, R. La Marca, L. A. Carvalho, M. Hamer, Disruption of multisystem responses to stress in type 2 diabetes: Investigating the dynamics of allostatic load. *Proceedings of the National Academy of Sciences of the United States of America* **111**, 15693-15698 (2014).
- 490
- 491
- 492
- 493 21. S. A. Julious, Sample size of 12 per group rule of thumb for a pilot study. *Pharm Stat* **4**, 287-291 (2005).
- 494
- 495 22. E. C. Lee, A. L. Whitehead, R. M. Jacques, S. A. Julious, The statistical interpretation of pilot trials: should significance thresholds be reconsidered? *Bmc Med Res Methodol* **14**, (2014).
- 496
- 497 23. M. S. Sagmeister, A. E. Taylor, A. Fenton, N. A. Wall, D. Chanouzas, P. G. Nightingale, C. J. Ferro, W. Arlt, P. Cockwell, R. S. Hardy, et al., Glucocorticoid activation by 11 beta-hydroxysteroid dehydrogenase enzymes in relation to inflammation and glycaemic control in chronic kidney disease: A cross-sectional study. *Clinical endocrinology* **90**, 241-249 (2019).
- 498
- 499
- 500
- 501 24. J. van Smeden, M. Janssens, G. S. Gooris, J. A. Bouwstra, The important role of stratum corneum lipids for the cutaneous barrier function. *Biochim Biophys Acta* **1841**, 295-313 (2014).
- 502
- 503
- 504 25. T. K. Lin, M. Q. Man, J. L. Santiago, T. C. Scharschmidt, M. Hupe, G. Martin-Ezquerria, J. K. Youm, Y. Zhai, C. Trullas, K. R. Feingold, et al., Paradoxical benefits of psychological stress in inflammatory dermatoses models are glucocorticoid mediated. *The Journal of investigative dermatology* **134**, 2890-2897 (2014).
- 505
- 506
- 507

- 508 26. S. Seite, A. Khemis, A. Rougier, J. P. Ortonne, Importance of treatment of skin xerosis in  
509 diabetes. *J Eur Acad Dermatol Venereol* **25**, 607-609 (2011).
- 510 27. A. I. Vinik, M. L. Nevoret, C. Casellini, The New Age of Sudomotor Function Testing: A  
511 Sensitive and Specific Biomarker for Diagnosis, Estimation of Severity, Monitoring  
512 Progression, and Regression in Response to Intervention. *Frontiers in endocrinology* **6**, 94  
513 (2015).
- 514 28. R. S. Hardy, H. Botfield, K. Markey, J. L. Mitchell, Z. Alimajstorovic, C. S. J. Westgate, M.  
515 Sagmeister, R. J. Fairclough, R. S. Ottridge, A. Yiangou, et al., 11betaHSD1 Inhibition with  
516 AZD4017 Improves Lipid Profiles and Lean Muscle Mass in Idiopathic Intracranial  
517 Hypertension. *J Clin Endocrinol Metab* **106**, 174-187 (2021).
- 518 29. D. Schwab, C. Sturm, A. Portron, S. Fuerst-Recktenwald, D. Hainzl, P. Jordan, W. C. Stewart,  
519 M. E. Tepedino, H. DuBiner, Oral administration of the 11beta-hydroxysteroid-  
520 dehydrogenase type 1 inhibitor RO5093151 to patients with glaucoma: an adaptive,  
521 randomised, placebo-controlled clinical study. *BMJ Open Ophthalmol* **1**, e000063 (2017).
- 522 30. P. U. Feig, S. Shah, A. Hermanowski-Vosatka, D. Plotkin, M. S. Springer, S. Donahue, C. Thach,  
523 E. J. Klein, E. Lai, K. D. Kaufman, Effects of an 11beta-hydroxysteroid dehydrogenase type 1  
524 inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome.  
525 *Diabetes, obesity & metabolism* **13**, 498-504 (2011).
- 526 31. T. Heise, L. Morrow, M. Hompesch, H. U. Haring, C. Kapitza, M. Abt, M. Ramsauer, M. C.  
527 Magnone, S. Fuerst-Recktenwald, Safety, efficacy and weight effect of two 11beta-HSD1  
528 inhibitors in metformin-treated patients with type 2 diabetes. *Diabetes, obesity &*  
529 *metabolism* **16**, 1070-1077 (2014).
- 530 32. S. Freude, T. Heise, H. J. Woerle, A. Jungnik, T. Rauch, B. Hamilton, C. Scholch, F. Huang, U.  
531 Graefe-Mody, Safety, pharmacokinetics and pharmacodynamics of BI 135585, a selective  
532 11beta-hydroxysteroid dehydrogenase-1 (HSD1) inhibitor in humans: liver and adipose  
533 tissue 11beta-HSD1 inhibition after acute and multiple administrations over 2 weeks.  
534 *Diabetes Obes Metab* **18**, 483-490 (2016).
- 535 33. M. Palermo, C. H. Shackleton, F. Mantero, P. M. Stewart, Urinary free cortisone and the  
536 assessment of 11 beta-hydroxysteroid dehydrogenase activity in man. *Clin. Endocrinol.*  
537 *(Oxford)* **45**, 605-611 (1996).
- 538 34. N. S. Greaves, B. Benatar, S. Whiteside, T. Alonso-Rasgado, M. Baguneid, A. Bayat, Optical  
539 coherence tomography: a reliable alternative to invasive histological assessment of acute  
540 wound healing in human skin? *The British journal of dermatology* **170**, 840-850 (2014).
- 541 35. Y. Wang, R. Ajjan, A. Freeman, P. Stewart, F. D. Galdo, A. Tiganescu, Volumetric  
542 quantification of wound healing by machine learning and optical coherence tomography in  
543 adults with type 2 diabetes: the GC-SHEALD RCT. *medRxiv*, 2021.2006.2030.21259754  
544 (2021).
- 545 36. E. Harris, A. Tiganescu, S. Tubeuf, S. L. Mackie, The prediction and monitoring of toxicity  
546 associated with long-term systemic glucocorticoid therapy. *Current rheumatology reports*  
547 **17**, 513 (2015).
- 548 37. R. Ghadially, B. E. Brown, S. M. Sequeira-Martin, K. R. Feingold, P. M. Elias, The aged  
549 epidermal permeability barrier. Structural, functional, and lipid biochemical abnormalities in  
550 humans and a senescent murine model. *The Journal of clinical investigation* **95**, 2281-2290  
551 (1995).
- 552 38. S. J. Choe, D. Kim, E. J. Kim, J. S. Ahn, E. J. Choi, E. D. Son, T. R. Lee, E. H. Choi, Psychological  
553 Stress Deteriorates Skin Barrier Function by Activating 11beta-Hydroxysteroid  
554 Dehydrogenase 1 and the HPA Axis. *Sci Rep* **8**, 6334 (2018).
- 555 39. J. S. Kao, J. W. Fluhr, M. Q. Man, A. J. Fowler, J. P. Hachem, D. Crumrine, S. K. Ahn, B. E.  
556 Brown, P. M. Elias, K. R. Feingold, Short-term glucocorticoid treatment compromises both  
557 permeability barrier homeostasis and stratum corneum integrity: inhibition of epidermal

- lipid synthesis accounts for functional abnormalities. *The Journal of investigative dermatology* **120**, 456-464 (2003).
40. L. Kolbe, A. M. Kligman, V. Schreiner, T. Stoudemayer, Corticosteroid-induced atrophy and barrier impairment measured by non-invasive methods in human skin. *Skin research and technology : official journal of International Society for Bioengineering and the Skin* **7**, 73-77 (2001).
41. S. K. Ahn, H. N. Bak, B. D. Park, Y. H. Kim, J. K. Youm, E. H. Choi, S. P. Hong, S. H. Lee, Effects of a multilamellar emulsion on glucocorticoid-induced epidermal atrophy and barrier impairment. *The Journal of dermatology* **33**, 80-90 (2006).
42. G. P. Fadini, M. Albiero, F. Seeger, N. Poncina, L. Menegazzo, A. Angelini, C. Castellani, G. Thiene, C. Agostini, R. Cappellari, et al., Stem cell compartmentalization in diabetes and high cardiovascular risk reveals the role of DPP-4 in diabetic stem cell mobilopathy. *Basic Res Cardiol* **108**, 313 (2013).
43. A. Uto, K. Miyashita, S. Endo, M. Sato, M. Ryuzaki, K. Kinouchi, M. Mitsuishi, S. Meguro, H. Itoh, Transient Dexamethasone Loading Induces Prolonged Hyperglycemia in Male Mice With Histone Acetylation in Dpp-4 Promoter. *Endocrinology* **162**, (2021).
44. E. Carolina, T. Kato, V. C. Khanh, K. Moriguchi, T. Yamashita, K. Takeuchi, H. Hamada, O. Ohneda, Glucocorticoid Impaired the Wound Healing Ability of Endothelial Progenitor Cells by Reducing the Expression of CXCR4 in the PGE2 Pathway. *Front Med (Lausanne)* **5**, 276 (2018).
45. G. P. Fadini, L. Menegazzo, M. Rigato, V. Scattolini, N. Poncina, A. Bruttocao, S. Ciciliot, F. Mammano, C. D. Ciubotaru, E. Brocco, et al., NETosis Delays Diabetic Wound Healing in Mice and Humans. *Diabetes* **65**, 1061-1071 (2016).
46. J. Rosenstock, S. Banarer, V. A. Fonseca, S. E. Inzucchi, W. Sun, W. Yao, G. Hollis, R. Flores, R. Levy, W. V. Williams, et al., The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. *Diabetes care* **33**, 1516-1522 (2010).
47. S. Shah, A. Hermanowski-Vosatka, K. Gibson, R. A. Ruck, G. Jia, J. Zhang, P. M. Hwang, N. W. Ryan, R. B. Langdon, P. U. Feig, Efficacy and safety of the selective 11beta-HSD-1 inhibitors MK-0736 and MK-0916 in overweight and obese patients with hypertension. *Journal of the American Society of Hypertension : JASH* **5**, 166-176 (2011).
48. D. G. Armstrong, A. J. M. Boulton, S. A. Bus, Diabetic Foot Ulcers and Their Recurrence. *N Engl J Med* **376**, 2367-2375 (2017).
49. M. J. Young, J. E. McCardle, L. E. Randall, J. I. Barclay, Improved survival of diabetic foot ulcer patients 1995-2008: possible impact of aggressive cardiovascular risk management. *Diabetes Care* **31**, 2143-2147 (2008).

594

## 595 DATA AVAILABILITY STATEMENT

596 All data associated with this study are available in the main text or the supplementary  
597 materials.

598 **FIGURE LEGENDS**

599 **Figure 1. CONSORT flow diagram.**

600 Progress, from screening to study completion, of participants in the double-blind,  
601 randomized, placebo-controlled pilot trial comparing 35-day oral AZD4017 treatment with  
602 placebo in adults with type 2 diabetes. A total of 300 prospective participants were screened.  
603 Eight of the 36 individuals enrolled in the study were not randomized because they did not  
604 meet eligibility criteria, and 27 of 28 participants who were randomized completed the study.

605 **Figure 2. Efficacy outcome measures.**

606 Population: Full analysis set. (a) Box plots of observed skin 11 $\beta$ -HSD1 activity (percent  
607 conversion [conv] per 24 hours measured by radioassay) (left panel) and adjusted differences  
608 between placebo (PCB) and AZD4017 (AZD) medians at day 28 with CIs estimated in  
609 imputed data (right panel). (b) Box plots of observed urinary [THF+alloTHF]/THE ratio (left  
610 panel), indicative of systemic 11 $\beta$ -HSD1 activity and adjusted differences between medians  
611 at day 35 with CIs estimated in imputed data (right panel). (c) Means and 90% CIs for  
612 observed urinary cortisol/cortisone (F/E) ratio (left panel), indicative of systemic 11 $\beta$ -HSD2  
613 activity and adjusted differences between means at day 35 with CIs estimated in observed  
614 data (right panel). Solid lines indicate no difference.

615 **Figure 3. Skin outcome measures.**

616 Population: Full analysis set. (a-b, d-g) Means and 90% CIs for observed values (left panel)  
617 and adjusted differences between placebo (PCB) and AZD4017 (AZD) means with CIs  
618 estimated in imputed data (right panel). TEWL and integrity readings were log-transformed  
619 before analysis; therefore, geometric means and ratios are provided for these variables. Solid  
620 lines indicate no difference. (c) Representative day 2 biopsy wound healing optical coherence  
621 tomography images (after 2 days of treatment). Maximal early granulation tissue width

622 (arrow) was measured for participants treated with PCB (left panel) or AZD4017 (right  
623 panel). Wide dashes indicate dermal-epidermal junction. e, epidermis; d, dermis, gt,  
624 granulation tissue. Scale bar: 250 $\mu$ m.

625 **Figure 4. Longitudinal laboratory safety data.**

626 Population: Safety set. Means and 90% CIs with placebo (PCB) and AZD4017 (AZD) over  
627 time in cases with data available. ULN, upper limit of normal; LLN, lower limit of normal  
628 (where applicable).

Figure 1




Figure 2








Figure 3


a)





b)





c)





d)





e)



f)




g)




# Figure 4


a)




b)




c)




d)




e)




f)




g)



h)



i)



1 **Table 1. Baseline demographics, primary and secondary efficacy outcomes, and safety**  
 2 **variables.**

3 Population: Full analysis set.

Variable	Summary	Placebo	AZD4017	Total
		n=14	n=14	n=28
<b>Demographics</b>				
Age	Mean (SD), range	60.3 (13.4), 31-84	60.1 (14.5), 28-75	60.2 (13.7), 28-84
Male	n/N (%)	12/14 (86)	10/14 (71)	22/28 (79)
<b>Primary outcome</b>				
Skin 11 $\beta$ -HSD1 activity (% conversion/24 hours)				
Radioassay	Median (Q1, Q3)	15.3 (11.6, 18.4)	10.7 (9.4, 17.4)	13.6 (9.8, 17.9)
ELISA	Median (Q1, Q3)	6.8 (5.5, 15.6)	6.4 (4.2, 8.5)	6.8 (4.8, 10.7)
<b>Secondary outcomes</b>				
Systemic 11 $\beta$ -HSD1 activity				
Urinary [THF+alloTHF]/THE ratio	Median (Q1, Q3)	1.0 (0.8, 1.2)	1.0 (0.8, 1.1)	1.0 (0.8, 1.1)
Cortisol (mcg/24 hours)	Median (Q1, Q3)	68.5 (40.0, 101.0)	75.5 (48.0, 84.0)	74.5 (47.5, 94.0)
Epidermal barrier TEWL (g/h/m <sup>2</sup> )	Log Mean (SD), n	2.1 (0.4), n=14	2.2 (0.3), n=13	2.2 (0.4), n=27
	Geometric Mean	8.2	9.1	8.6
Epidermal integrity (tape strips)	Log mean (SD), n	3.8 (0.4), n=14	3.9 (0.5), n=13	3.9 (0.4), n=27
	Geometric Mean	44.5	50.5	47.5
Epidermal thickness ( $\mu$ m)	Median (Q1, Q3)	62.8 (54.5, 69.2)	65.7 (60.7, 69.3)	63.8 (58.4, 69.3)
Skin hydration (A.U)	Median (Q1, Q3)	40.5 (34.5, 46.2)	40.4 (36.7, 45.5)	40.5 (36.1, 45.8)
Sudomotor nerve function ( $\mu$ S)				
Left hand	Median (Q1, Q3)	54.0 (47.0, 63.0)	57.5 (39.0, 71.0)	56.0 (46.5, 68.5)

Variable	Summary	Placebo	AZD4017	Total
		n=14	n=14	n=28
Right hand	Median (Q1, Q3)	54.0 (47.0, 60.0)	56.5 (41.0, 67.0)	56.0 (45.5, 61.5)
Hands	Median (Q1, Q3)	53.8 (48.0, 60.5)	56.8 (40.0, 70.5)	56.8 (47.3, 65.0)
Left foot	Median (Q1, Q3)	65.5 (46.0, 78.0)	79.0 (63.0, 84.0)	74.5 (57.0, 81.5)
Right foot	Median (Q1, Q3)	69.5 (48.0, 79.0)	77.0 (69.0, 82.0)	74.0 (54.5, 79.0)
Feet	Median (Q1, Q3)	67.5 (44.5, 76.5)	78.0 (64.0, 83.5)	75.0 (55.8, 79.8)
Overall	Median (Q1, Q3)	61.0 (46.8, 67.8)	66.6 (63.3, 71.3)	64.6 (50.3, 69.8)
<b>Safety variables</b>				
Body mass index (kg/m <sup>2</sup> )	Mean (SD)	33.67 (13.47)	35.05 (5.68)	34.36 (10.17)
Waist-hip ratio	Mean (SD)	0.98 (0.08)	1.03 (0.08)	1.01 (0.08)
HbA1c (mmol/mol)	Mean (SD)	72.29 (19.43)	66.00 (14.91)	69.14 (17.29)
<b>Blood pressure (mm Hg)</b>				
Systolic	Mean (SD)	135.71 (21.01)	140.43 (12.02)	138.07 (16.97)
Diastolic	Mean (SD)	83.86 (8.91)	72.64 (9.96)	78.25 (10.89)
<b>Full blood count</b>				
Hemoglobin (g/l)	Mean (SD)	139.21 (14.12)	139.43 (11.35)	139.32 (12.57)
White blood cells (x10 <sup>9</sup> /l)	Mean (SD)	6.46 (2.55)	7.34 (2.04)	6.90 (2.31)
Platelets (x10 <sup>9</sup> /l)	Mean (SD)	218.71 (61.85)	273.14 (81.37)	245.93 (76.15)
Red blood cells (x10 <sup>12</sup> /l)	Mean (SD)	4.84 (0.49)	4.71 (0.48)	4.78 (0.48)
Mean corpuscular volume (fl)	Mean (SD)	88.43 (4.64)	91.21 (6.96)	89.82 (5.98)
Hematocrit (packed cell volume)	Mean (SD)	0.43 (0.04)	0.43 (0.03)	0.43 (0.03)
Mean corpuscular hemoglobin (pg)	Mean (SD)	28.82 (2.09)	29.74 (2.47)	29.28 (2.29)
Corpuscular hemoglobin (g/l)	Mean (SD)	325.57 (10.43)	326.64 (8.29)	326.11 (9.26)

Variable	Summary	Placebo	AZD4017	Total
		n=14	n=14	n=28
Red blood cell distribution width (%)	Mean (SD)	13.88 (0.98)	14.12 (1.10)	14.00 (1.03)
Lipid profile				
High density lipoprotein (mmol/l)	Mean (SD)	1.24 (0.31)	1.19 (0.27)	1.21 (0.29)
Cholesterol (mmol/l)	Mean (SD)	4.36 (1.13)	3.95 (0.75)	4.15 (0.97)
Triglycerides (mmol/l)	Mean (SD)	1.68 (0.74)	2.02 (1.02)	1.85 (0.89)
Liver function				
Albumin (g/l)	Mean (SD)	39.43 (2.56)	39.50 (2.44)	39.46 (2.46)
Bilirubin (umol/l)	Mean (SD)	8.93 (2.97)	8.14 (2.82)	8.54 (2.87)
Alkaline phosphatase (U/l)	Mean (SD)	80.43 (23.76)	85.07 (26.08)	82.75 (24.59)
Alanine aminotransferase (iu/l)	Mean (SD)	24.64 (7.10)	27.43 (10.91)	26.04 (9.14)
Aspartate aminotransferase (iu/l)	Mean (SD)	21.00 (4.95)	22.64 (5.50)	21.82 (5.20)
Gamma-glutamyl transpeptidase (iu/l)	Mean (SD)	41.86 (33.87)	39.29 (29.87)	40.57 (31.37)
Kidney function				
eGFR (ml/min/1.73m <sup>2</sup> )	Mean (SD)	81.86 (9.69)	79.21 (13.59)	80.54 (11.66)
Sodium (mmol/l)	Mean (SD)	138.93 (2.06)	140.71 (5.47)	139.82 (4.15)
Potassium (mmol/l)	Mean (SD)	4.46 (0.33)	4.63 (0.41)	4.55 (0.37)
Urea (mmol/l)	Mean (SD)	6.96 (2.81)	7.25 (2.17)	7.10 (2.47)
Creatinine (umol/l)	Mean (SD)	76.64 (15.36)	76.21 (20.04)	76.43 (17.52)
Adrenal function				
Testosterone (nmol/l)	Mean (SD)	11.10 (6.25)	6.97 (5.48)	9.04 (6.14)
Dehydroepiandrosterone sulphate (umol/l)	Mean (SD)	3.53 (2.19)	2.91 (1.69)	3.22 (1.95)
Thyroid function				

Variable	Summary	Placebo	AZD4017	Total
		n=14	n=14	n=28
Free thyroxine (pmol/l)	Mean (SD)	14.86 (2.20)	15.73 (1.58)	15.30 (1.93)
Thyroid stimulating hormone (mIU/l)	Mean (SD)	1.74 (0.66)	1.72 (0.63)	1.73 (0.64)

Nn, number non-missing; Q1, first quartile; Q3, third quartile.



**Table 2. Primary and secondary efficacy outcomes; adjusted differences.**

Population: Full analysis set. Multiple imputation was used to address missing data. For TEWL, integrity, wound depth and diameter, linear regression was used to estimate CIs around differences between the groups. TEWL and integrity measurements were log-transformed before analysis; differences are expressed as ratios of geometric means between groups (AZD4017:placebo). For the remaining variables, which did not meet assumptions for linear regression, median regression was used. For each variable, the comparison was adjusted for the variable's baseline value (this was not available for wound diameter and depth), age, sex, and baseline HbA1c. All TEWL readings were adjusted using pre-disruption TEWL at baseline. Between-group differences were not calculated for biopsy and plasma AZD4017 because available placebo values did not vary, and all were below the detection limit.

Variable	Observed median (Q1, Q3), n		Estimated median*		Difference*	90% CI
	Placebo	AZD4017	Placebo n=14	AZD4017 n=14		
<b>Primary outcome</b>						
Skin 11 $\beta$ -HSD1 activity (% conversion/24 hours): Day 28						
Radioassay	12.0 (8.9, 14.5), n=13	12.7 (8.8, 15.6), n=14	11.8	12.8	1.1	(-3.4, 5.5)
ELISA	5.6 (1.0, 7.6), n=13	4.3 (3.1, 5.0), n=14	4.9	4.3	-0.5	(-3.8, 2.7)
<b>Secondary outcomes</b>						
Systemic 11 $\beta$ -HSD1 activity: Day 35						
Urinary [THF+alloTHF]/THE ratio	0.89 (0.88, 1.24), n=13	0.10 (0.08, 0.12), n=13	1.00	0.13	-0.87	(-1.04, -0.69)
Cortisol (mcg/24h): Day 35	55.0 (47.0, 120.0), n=13	62.0 (52.0, 73.0), n=13	61.6	66.9	5.3	(-30.2, 40.7)
Epidermal thickness ( $\mu$ m): Day 35	57.5 (55.7, 67.3), n=13	66.3 (60.6, 74.4), n=12	61.2	66.8	5.6	(-4.9, 16.0)

Variable	Observed median (Q1, Q3), n		Estimated median*		Difference*	90% CI
	Placebo	AZD4017	Placebo n=14	AZD4017 n=14		
Skin hydration (A.U): Day 35	40.5 (29.4, 46.0), n=12	45.3 (37.0, 46.5), n=12	38.0	43.7	5.7	(-2.8, 14.1)
Sudomotor (nerve) function (µS): Day 35						
Left hand	58.0 (48.0, 63.0), n=13	64.0 (59.0, 72.0), n=13	55.3	65.7	10.4	(-1.8, 22.6)
Right hand	55.0 (51.0, 60.0), n=13	63.0 (57.0, 69.0), n=13	55.6	60.6	5.0	(-6.7, 16.8)
Hands	57.5 (49.5, 61.0), n=13	63.5 (59.0, 70.5), n=13	55.8	63.0	7.3	(-4.8, 19.3)
Left foot	70.0 (61.0, 76.0), n=13	80.0 (64.0, 82.0), n=13	75.5	68.5	-7.0	(-18.4, 4.3)
Right foot	65.0 (63.0, 75.0), n=13	80.0 (68.0, 82.0), n=13	73.0	68.9	-4.1	(-13.2, 5.1)
Feet	68.5 (62.0, 75.0), n=13	80.0 (66.0, 82.5), n=13	73.8	69.3	-4.5	(-14.5, 5.4)
Overall	59.8 (53.8, 68.0), n=13	70.8 (64.5, 73.0), n=13	65.0	63.7	-1.3	(-9.2, 6.6)
AZD4017 (nmol/l)						
Biopsy: Day 28	<5 (<5, <5), n=13	1570 (876, 2440), n=14				
Plasma: Day 35	<5 (<5, <5), n=7	6490 (2960, 9040), n=12				
	Observed mean (SD), n		Estimated mean *		Difference*	90% CI
	Placebo	AZD4017	Placebo	AZD4017		
Wound healing (mm) after day 0 biopsies						
Diameter: Day 2	1.49 (0.72), n=14	0.98 (0.70), n=14	1.51	0.98	-0.52	(-0.95, -0.10)
Depth: Day 7	0.60 (0.23), n=14	0.59 (0.16), n=14	0.60	0.59	-0.01	(-0.15, 0.13)
Wound healing after day 28 biopsies						
Diameter: Day 30	1.44 (0.70), n=11	0.65 (0.49), n=12	1.35	0.70	-0.65	(-1.15, -0.16)
Depth: Day 35	0.60 (0.17), n=13	0.54 (0.21), n=12	0.59	0.56	-0.03	(-0.16, 0.09)
	Observed mean (SD); geometric mean, n		Estimated geometric mean *		Ratio*	90% CI
	Placebo	AZD4017	Placebo	AZD4017		

Variable	Observed median (Q1, Q3), n		Estimated median*		Difference*	90% CI
	Placebo	AZD4017	Placebo n=14	AZD4017 n=14		
Epidermal barrier TEWL (g/h/m <sup>2</sup> ): Day 35	1.9 (0.4); 7.0, n=13	2.2 (0.5); 8.9, n=12	6.9	9.2	1.33	(0.97, 1.82)
Epidermal integrity (tape strips): Day 28	3.6 (0.6); 37.9, n=13	4.0 (0.4); 55.6, n=14	39.0	55.8	1.43	(1.07, 1.91)
Epidermal barrier recovery TEWL (g/h/m <sup>2</sup> ) after day 0 disruption						
Hour 3	3.6 (0.3); 34.9, n=14	3.4 (0.2); 30.8, n=12	35.1	32.0	0.91	(0.76, 1.09)
Hour 48	3.0 (0.3); 19.8, n=14	3.1 (0.4); 21.3, n=11	20.4	20.6	1.01	(0.79, 1.28)
Hour 168	2.6 (0.3); 13.5, n=13	2.8 (0.7); 16.1, n=13	14.1	15.6	1.11	(0.76, 1.62)
Epidermal barrier recovery TEWL (g/h/m <sup>2</sup> ) after day 28 disruption						
Hour 3	3.2 (0.5); 23.8, n=13	3.4 (0.3); 29.8, n=14	23.0	30.7	1.33	(0.99, 1.79)
Hour 48	2.7 (0.4); 14.4, n=13	2.9 (0.4); 18.2, n=14	14.6	18.4	1.26	(0.94, 1.67)
Hour 168	2.3 (0.4); 10.0, n=13	2.4 (0.4); 10.8, n=12	10.1	10.8	1.07	(0.79, 1.44)

\*Estimated using multiple imputation, adjusted for baseline value (if applicable), age, sex, and baseline HbA1c.

1 **Table 3. Longitudinal laboratory safety variables; adjusted differences.**

2 Population: Safety set. All point estimates and CIs were estimated using linear regression in imputed data (n=14 for placebo, n=14 for  
3 AZD4017).

Variable	Difference* AZD4017-placebo (90% CI)			
	Day 7	Day 28	Day 35	Day 42
Body mass index (kg/m <sup>2</sup> )	N/A	N/A	0.41 (-0.51, 1.34)	N/A
Waist-hip ratio	N/A	N/A	0.02 (-0.01, 0.05)	N/A
HbA1c (mmol/mol)	0.18 (-1.51, 1.88)	2.17 (-0.64, 4.99)	0.72 (-3.64, 5.09)	2.42 (-2.38, 7.22)
Blood pressure (mm Hg)				
Systolic	N/A	N/A	-14.74 (-23.00, -6.47)	0.77 (-6.58, 8.11)
Diastolic	N/A	N/A	-2.43 (-7.67, 2.80)	2.09 (-6.77, 10.95)
Full blood count				
Hemoglobin (g/l)	0.67 (-2.12, 3.45)	-0.98 (-4.13, 2.17)	0.64 (-3.96, 5.24)	2.07 (-1.62, 5.76)
White blood cells (x10 <sup>9</sup> /l)	0.54 (-0.14, 1.22)	-0.40 (-0.87, 0.08)	-0.31 (-0.96, 0.34)	0.33 (-0.41, 1.07)
Platelets (x10 <sup>9</sup> /l)	2.42 (-13.65, 18.50)	13.32 (-9.56, 36.20)	-0.91 (-25.20, 23.37)	1.47 (-16.74, 19.68)
Red blood cells (x10 <sup>12</sup> /l)	-0.05 (-0.17, 0.06)	-0.05 (-0.15, 0.04)	-0.02 (-0.15, 0.12)	0.15 (0.03, 0.26)
Mean corpuscular volume (fl)	0.11 (-1.83, 2.05)	0.52 (-1.49, 2.53)	-0.17 (-2.53, 2.19)	0.16 (-1.42, 1.73)
Hematocrit (packed cell volume)	-0.01 (-0.02, 0.01)	0.00 (-0.01, 0.02)	0.00 (-0.02, 0.02)	0.02 (0.00, 0.03)
Mean corpuscular hemoglobin (pg)	0.41 (0.08, 0.75)	-0.07 (-0.44, 0.31)	0.17 (-0.28, 0.62)	-0.42 (-0.95, 0.10)
Corpuscular hemoglobin (g/l)	4.91 (-1.41, 11.22)	-3.80 (-10.80, 3.21)	1.75 (-4.85, 8.35)	-5.22 (-12.18, 1.74)
Red blood cell distribution width (%)	-0.36 (-0.89, 0.18)	-0.09 (-0.49, 0.31)	0.11 (-0.28, 0.51)	-0.21 (-0.68, 0.26)

Variable	Difference* AZD4017-placebo (90% CI)			
	Day 7	Day 28	Day 35	Day 42
<b>Lipid profile</b>				
High-density lipoprotein (mmol/l)	-0.06 (-0.14, 0.02)	-0.08 (-0.16, 0.00)	-0.13 (-0.21, -0.05)	0.05 (-0.07, 0.16)
Cholesterol (mmol/l)	-0.42 (-0.60, -0.23)	-0.46 (-0.79, -0.12)	-0.51 (-0.87, -0.15)	-0.10 (-0.54, 0.34)
Triglycerides (mmol/l)	-0.14 (-0.67, 0.40)	-0.19 (-0.56, 0.18)	-0.48 (-1.21, 0.24)	0.02 (-0.51, 0.55)
<b>Liver function</b>				
Albumin (g/l)	0.37 (-0.82, 1.55)	-0.37 (-1.82, 1.09)	-0.01 (-1.60, 1.59)	0.40 (-0.59, 1.38)
Bilirubin (umol/l)	0.93 (-1.14, 3.00)	0.60 (-0.89, 2.09)	-0.64 (-3.01, 1.73)	0.35 (-1.17, 1.87)
Alkaline phosphatase (U/l)	-6.00 (-12.44, 0.44)	-12.39 (-20.21, -4.56)	-13.09 (-20.43, -5.75)	-5.65 (-15.25, 3.95)
Alanine aminotransferase (iu/l)	1.16 (-1.84, 4.15)	-1.96 (-4.94, 1.03)	-1.64 (-5.88, 2.61)	0.78 (-3.00, 4.56)
Aspartate aminotransferase (iu/l)	0.46 (-2.29, 3.21)	0.12 (-1.81, 2.05)	-0.04 (-2.52, 2.45)	2.21 (-1.02, 5.44)
Gamma-glutamyl transpeptidase (iu/l)	0.76 (-2.83, 4.35)	-10.28 (-14.96, -5.60)	-11.97 (-22.80, -1.15)	-9.55 (-14.88, -4.22)
<b>Kidney function</b>				
eGFR (ml/min/1.73m <sup>2</sup> )	-3.18 (-8.30, 1.94)	-2.19 (-5.38, 1.01)	0.27 (-4.57, 5.10)	1.62 (-2.77, 6.01)
Sodium (mmol/l)	0.10 (-1.23, 1.44)	0.16 (-0.98, 1.29)	-1.19 (-3.21, 0.82)	-1.25 (-2.42, -0.07)
Potassium (mmol/l)	-0.31 (-0.58, -0.03)	0.18 (-0.06, 0.43)	0.01 (-0.22, 0.25)	-0.04 (-0.31, 0.22)
Urea (mmol/l)	0.13 (-0.79, 1.05)	-0.35 (-1.31, 0.61)	-0.52 (-1.88, 0.83)	0.02 (-1.04, 1.08)
Creatinine (umol/l)	7.43 (0.79, 14.08)	3.43 (-0.98, 7.85)	1.78 (-5.65, 9.22)	-1.58 (-8.24, 5.07)
<b>Adrenal function</b>				
Testosterone (nmol/l)	-0.63 (-2.52, 1.25)	-1.06 (-2.58, 0.45)	-0.40 (-2.66, 1.85)	1.12 (-1.20, 3.45)
Dehydroepiandrosterone sulphate (umol/l)	2.30 (1.52, 3.08)	2.86 (2.09, 3.64)	2.16 (1.29, 3.04)	1.09 (0.43, 1.75)
<b>Thyroid function</b>				
Free thyroxine (pmol/l)	0.50 (-0.63, 1.64)	0.51 (-0.43, 1.44)	0.65 (-0.45, 1.76)	0.79 (0.07, 1.52)

Variable	Difference* AZD4017-placebo (90% CI)			
	Day 7	Day 28	Day 35	Day 42
Thyroid stimulating hormone (mIU/l)	0.10 (-0.22, 0.42)	-0.20 (-0.58, 0.19)	-0.15 (-0.54, 0.23)	-0.04 (-0.46, 0.38)

\*Estimated in imputed data, adjusted for baseline value, age, sex and baseline HbA1c.



1 **Table 4. Adverse event summary.**

2 Population: Safety set.

<b>AEs</b>	<b>PCB (n=14)</b>	<b>AZD (n=14)</b>	<b>All participants (n=28)</b>
Total AEs: n (n per PY)	13 (8.3)	24 (13.8)	37 (11.1)
Unique AE: n (n per PY)	13 (8.3)	16 (9.2)	29 (8.7)
Patients with ≥1 AE: n (%)	8 (57)	10 (71)	18 (64)
Discontinuation due to AE: n (%)	0 (-)	0 (-)	0 (-)
<b>AEs by SOC: total number (unique number*), number of participants (%)</b>			
Gastrointestinal	9 (9), 6 (43)	14 (8), 7 (50)	23 (17), 13 (46)
Infections	0 (0), 0 (-)	1 (1), 1 (7)	1 (1), 1 (4)
Musculoskeletal	0 (0), 0 (-)	1 (1), 1 (7)	1 (1), 1 (4)
Nervous system	1 (1), 1 (7)	6 (4), 4 (29)	7 (5), 5 (18)
Respiratory	2 (2), 1 (7)	2 (2), 1 (7)	4 (4), 2 (7)
Skin	1 (1), 1 (7)	0 (0), 0 (-)	1 (1), 1 (4)
<b>AE severity: n*</b>			
Mild	13	13	26
Moderate	0	3	3
<b>AEs by relation to study drug: n*</b>			
Not related	0	1	1
Unlikely	4	4	8
Possible	9	11	20
<b>SAEs</b>			
Total SAE: n	0	1	1
Patients with >1 SAE: n (%)	0 (-)	1 (7)	1 (4)

\*Recurrent AEs counted once at maximum severity and relatedness reported.

AE, adverse event; PY, patient year; SAE, serious adverse events; SOC, Common Terminology Criteria for Adverse Events system order class

Leeds Institute of Rheumatic and Musculoskeletal Medicine

# Research Protocol

Version 2.0 - 24/10/2018

---

**Study Short Title: GC-SHealD (Glucocorticoids and Skin Healing in Diabetes)**

**Study Full Title: A double-blind, randomized, placebo-controlled phase II pilot trial investigating efficacy, safety and feasibility of 11 $\beta$ -hydroxysteroid dehydrogenase type 1 inhibition by AZD4017 to improve skin function and wound healing in patients with type 2 diabetes**

**Sponsor Name: University of Leeds**

**Sponsor Number: ED17/93260**

**EudraCT Number: 2017-001351-31**

**ISRCTN: 74621291**

---

**Protocol status: FINAL**

**Details of previous amendments**

**Version 1.2 11/07/2017**

---

## **Key contacts**

### **Chief Investigator**

Dr Ramzi Ajjan

Associate Professor and Consultant in Diabetes and Endocrinology

Division of Cardiovascular and Diabetes Research

0113 343 7475

R.Ajjan@leeds.ac.uk

### **Scientific Lead**

Ana Tiganeşcu

Postdoctoral Research Fellow

Leeds Institute of Rheumatic and Musculoskeletal Medicine

0113 34 38336

a.tiganeşcu@leeds.ac.uk

## INVESTIGATOR DECLARATION AND SIGNATURE(S)

GC-SHealD Version 2.0, 24<sup>th</sup> October 2018

### DECLARATION OF PROTOCOL ACCEPTANCE

I confirm that I am fully informed and aware of the requirements of the protocol and agree to conduct the study as set out in this protocol.

Ramzi Ajjan	
Chief Investigator	Date

Ana Tiganescu	
Scientific Lead	Date

Francesco Del Galdo	
Investigator	Date

Abd Tahrani	
Investigator	Date

## Table of Contents

INVESTIGATOR DECLARATION AND SIGNATURE(S) .....	3
ABBREVIATIONS .....	9
PROTOCOL SYNOPSIS .....	11
SCHEMATIC DIAGRAM OF RECRUITMENT, RANDOMIZATION & TREATMENT .....	13
1. INTRODUCTION .....	14
1.1. Background .....	14
1.2. Investigational medicinal product (IMP) .....	15
1.2.1. Investigator brochure (IB) updates .....	15
1.2.2. Summary of product characteristics .....	15
1.2.3. Non IMP(s) .....	15
1.3. Rationale for the proposed study .....	15
2. STUDY AIM AND OBJECTIVES .....	16
2.1. Study aims.....	16
2.2. Primary objective .....	16
2.3. Secondary objectives.....	16
3. STUDY ENDPOINTS .....	16
3.1. Primary endpoint .....	16
3.2. Secondary endpoints.....	16
4. STUDY VARIABLES.....	16
4.1. Primary variable .....	16
4.2. Secondary variables .....	17
5. STUDY DESIGN .....	18
5.1. Study description .....	18
5.2. Study duration .....	18
5.3. Rationale for study design and selection of dose.....	18
6. SELECTION AND WITHDRAWAL OF SUBJECTS .....	21
6.1. Target population.....	21
6.2. Estimated number of eligible participants .....	21
6.3. Eligibility criteria.....	21
6.3.1. Inclusion criteria .....	21
6.3.2. Exclusion criteria .....	21
6.3.3. Exclusions for general safety .....	23

6.3.4. Screen failures.....	23
6.4. Recruitment, consent and randomization processes .....	23
6.4.1. Recruitment .....	23
6.4.2. Consent .....	23
6.4.3. Randomization process .....	24
6.4.4. Definition for the end of the trial.....	24
6.5. Withdrawal criteria .....	24
6.5.1. Patients who withdraw consent .....	25
6.5.2. Managing/replacing patients who withdraw early.....	25
7. STUDY BLINDING .....	25
7.1. Type of blinding .....	25
7.2. Procedure for production and maintenance of blind .....	25
7.3. Breaking the blind in an emergency .....	25
8. STUDY TREATMENTS.....	26
8.1. General information on the products (trial drugs) to be used.....	26
8.2. Frequency and duration of the trial drugs .....	26
8.3. Administration/handling of the trial drugs .....	26
8.3.1. Handling, storage and supply.....	26
8.3.2. Drug accountability .....	26
8.4. Prior and concomitant illnesses.....	27
8.5. Prior and concomitant medications.....	27
8.5.1. Permitted prior medications.....	27
8.5.2. Prohibited prior medications .....	27
8.5.3. Permitted concomitant medications.....	27
8.5.4. Prohibited concomitant medications .....	27
8.5.5. Surgical procedures .....	28
8.6. Special warnings and precaution for use .....	28
8.7. Dose modifications.....	29
8.8. Assessing subject compliance with study treatment(s).....	29
8.9. Withdrawal of treatment .....	29
8.9.1. Subject compliance .....	29
8.9.2. Lack of efficacy .....	29

9. METHODS OF ASSESSMENT .....	29
9.1. Assessment of primary variable (AZD4017 efficacy) .....	29
9.2. Assessment of secondary variables .....	30
9.2.1. Efficacy .....	30
9.2.2. Safety .....	30
9.2.3. Skin function .....	32
9.2.4. Feasibility .....	35
10. STUDY PROCEDURES BY VISIT .....	35
10.1. Summary schedule of study assessments .....	35
10.2. Screening visit (day -7 to -2) SJUH Diabetes Clinic.....	36
10.3. Visit 1 (day 0) SJUH Diabetes Clinic and CAH LMBRU .....	36
10.4. Visit 2 (day 2) at CAH LMBRU .....	37
10.5. Visit 3 (day 7) at CAH LMBRU .....	37
10.6. Visit 4 (day 28) at SJUH Diabetes Clinic .....	37
10.7. Visit 5 (day 30) at CAH LMBRU .....	37
10.8. Visit 6 (day 35) at CAH LMBRU .....	37
10.9. Follow-up visit (day 42 onwards) at SJUH Diabetes Clinic .....	38
10.10. Unscheduled visits.....	38
11. PHARMACOVIGILANCE .....	38
11.1. Defining adverse events .....	38
11.2. Defining serious adverse events .....	39
11.3. AE of special interest.....	39
11.3.1. Pregnancy.....	39
11.4. Defining suspected unexpected serious adverse reactions .....	39
11.5. Exemptions from safety reporting .....	40
11.5.1. Efficacy endpoints and disease progression events.....	40
11.5.2. Other expected events .....	40
11.6. Recording and reporting of AE.....	40
11.6.1. Recording and reporting of all AE .....	40
11.6.2. Sponsor SAE and SUSAR reporting requirements.....	40
11.6.3. AstraZeneca SAE and SUSAR reporting requirements .....	41
11.7. Urgent safety measures .....	42

11.8. Serious breaches of protocol .....	42
11.9. Other breaches of protocol .....	43
11.10. Laboratory measurements .....	43
11.11. Other safety measurements .....	44
11.12. Annual reports .....	44
11.13. End of trial report.....	45
12. STUDY MANAGEMENT AND ADMINISTRATION .....	45
12.1. Training of study site personnel .....	45
12.2. Good clinical practice and regulatory compliance.....	45
12.3. Adherence to protocol .....	46
12.4. Monitoring, audit and inspection .....	46
12.4.1. Procedures for monitoring subject compliance.....	46
12.4.2. Definition of source data .....	46
12.4.3. Source data verification .....	47
12.4.4. Quality assurance .....	47
12.4.5. Trial oversight.....	47
12.4.6. Data monitoring, ethics and trial steering committee.....	47
12.5. Data handling .....	48
12.5.1. CRF completion .....	48
12.5.2. Database entry and reconciliation .....	48
12.5.3. Screening and enrolment logs .....	48
12.6. Archiving and data retention .....	48
12.7. Study suspension, termination and completion.....	49
13. DATA EVALUATION .....	49
13.1. Responsibilities .....	49
13.2. Hypotheses .....	49
13.3. General statistical considerations.....	50
13.4. Planned analyses.....	50
13.4.1. Primary endpoint analysis .....	50
13.4.2. Secondary endpoint analyses .....	51
13.4.3. Skin function .....	52

13.4.4. Feasibility .....	52
13.5. Safety analyses.....	52
13.6. Definition of 'per protocol' set .....	52
13.7. Handling of dropouts and missing data .....	52
13.8. Planned interim analysis and data monitoring.....	52
13.9. Determination of sample size and randomization method .....	53
13.10. Procedure for unblinding the study prior to analysis .....	53
14. ETHICS AND REGULATORY REQUIREMENTS .....	53
14.1. Good Clinical Practice .....	53
14.2. Delegation of Investigator duties.....	54
14.3. Subject information and informed consent .....	54
14.4. Subject confidentiality.....	55
14.5. Subject identification cards .....	55
14.6. Approval of clinical study protocol and amendments .....	55
14.7. Protocol amendments .....	56
14.8. Ongoing information for MHRA/REC .....	56
15. FINANCE AND INSURANCE .....	56
15.1. Indemnity and insurance .....	56
15.2. Financial disclosure .....	56
16. PUBLICATION.....	56
17. REFERENCES .....	58

## ABBREVIATIONS

<b>Abbreviation</b>	<b>Term</b>
11 $\beta$ -HSD(1/2)	11 $\beta$ -hydroxysteroid dehydrogenase (type 1/type 2)
ACTH	Adrenocorticotrophic hormone
AE	Adverse event
ALP	Alkaline phosphatase
ALT	Alanine aminotransferase
AST	Aspartate aminotransferase
BP	Blood pressure
BMI	Body mass index
CBX	Carbenoxolone
CI	Chief Investigator
CK	Creatine kinase
CRF	Case report form
CTCAE	Common Terminology Criteria for Adverse Events
DFU	Diabetic foot ulcer
ECG	Electrocardiogram
ECM	Extracellular matrix
FBC	Full blood count
GC	Glucocorticoid
GC/MS	Gas chromatography/mass spectrometry
GCP	Good clinical practice
GMP	Good manufacturing practice
GP	General practitioner
GR	Glucocorticoid receptor
H6PDH	Hexose-6-phosphate dehydrogenase
HPA	Hypothalamic-pituitary-adrenal
IB	Investigator brochure
ICH	International conference on harmonisation
IMP	Investigational medicinal product
LFT	Liver function test
LIRMM	Leeds Institute of Rheumatic and Musculoskeletal Medicine
LMBRU	Leeds Musculoskeletal Biomedical Research Unit


<b>Abbreviation</b>	<b>Term</b>
MHRA	Medicines and healthcare products regulatory agency
MRI	Magnetic resonance imaging
PIL	Participant Information Leaflet
QA	Quality assurance
REC	Research ethics committee
SAE	Serious adverse event
SD	Standard deviation
SJUH	St James' University Hospital
SUSAR	Suspected unexpected serious adverse reaction
T2DM	Type 2 diabetes mellitus
[THF+alloTHF]/THE	Tetrahydrocortisol to tetrahydrocortisone urinary metabolites
TEWL	Trans-epidermal water loss
TMFTSH	Trial Master File
U+E	Thyroid stimulating hormone
ULN	Urea and electrolytes (kidney function test) Upper limit of normal
WH	Wound healing
WTBB	Wellcome Trust Brenner Building

## PROTOCOL SYNOPSIS

GENERAL INFORMATION	
Short Title	GC-SHealD (Glucocorticoids and Skin Healing in Diabetes)
Full Title	A double-blind, randomized, placebo-controlled phase II pilot trial investigating efficacy, safety and feasibility of 11 $\beta$ -hydroxysteroid dehydrogenase type 1 inhibition by AZD4017 to improve skin function and wound healing in patients with type 2 diabetes
Sponsor	University of Leeds
Sponsor ID	ED17/93260
IRAS No.	215411
EudraCT No.	
MREC No.	
Chief Investigator	Ramzi Ajjan
Co-ordinating Centre	University of Leeds
National / International	Single site
TRIAL INFORMATION	
Phase	Phase II pilot
Indication	Type 2 diabetes mellitus
Design	Placebo-controlled, double-blind, parallel-group, randomised controlled pilot trial
Number of sites	1
Primary Objective	Evaluate AZD4017 efficacy
Secondary Objective(s)	1) Evaluate safety of AZD4017 2) Examine effects of AZD4017 on skin function 3) Assess study feasibility
Primary Endpoint	24 hour 11 $\beta$ -HSD1 activity in skin at baseline and day 28
Secondary Endpoint(s)	Systemic 11 $\beta$ -HSD1 activity at baseline and day 35, AZD4017 detection in skin at day 28 and plasma at day 35, safety variables at baseline and days 7, 28 and 35, urinary cortisol to cortisone metabolite analysis at baseline and day 35, skin function variables at baseline and days 2, 7, 28, 30 and 35 and feasibility measures throughout the study
TRIAL TIMELINES	
Expected start date	Jun 2017

Subject enrolment phase	Jul 2017 to Jan 2018
Follow-up duration	One visit at least 7 days after the last treatment dose
End of Trial Definition	Entry of the last participant's last data item
Expected completion date	Feb 2018
<b>TRIAL SUBJECT INFORMATION</b>	
Number of trial subjects	30
Age group of trial subjects	>18 years old
Inclusion criteria	1) Able and willing to consent 2) T2DM with HbA1c $\leq$ 11% ( $\leq$ 97 mmol/mol) at screening while taking standard therapy at a stable dose for $\geq$ 10 weeks
Exclusion criteria	1) WOCBP, 2) Active leg/foot ulceration, 3) Clinically relevant acute ECG anomalies 4) Uncontrolled hypertension, 5) Endocrine disorder (other than T2DM), including type 1 or secondary diabetes (except treated hypothyroidism), 6) Gilbert's disease, 7) Alanine aminotransferase and/or aspartate aminotransferase and/or alkaline phosphatase $>$ 1.5x ULN, 8) Bilirubin $>$ 1.5x ULN, 9) eGFR $<$ 45 ml/min/m <sup>2</sup> , 10) CK $>$ 2x ULN, 11) Drug abuse within the last year, 12) Any GC treatment within 3 months of screening, 13) Anti-coagulant medication, 14) Probenecid therapy, 15) Medical/surgical procedure or trauma during IMP administration or one week after IMP cessation (excluding skin biopsies), 16) Involvement in trial planning and/or conduct, 17) Participation in other clinical study within 1 month, 18) Deemed inappropriate to participate by the trial team
<b>IMP</b>	
IMP name(s)	AZD4017
IMP mode of administration	400mg oral twice daily
Duration of IMP Treatment	35 days
IMP Supplier(s)	AstraZeneca
Non IMP name(s)	Placebo

## SCHEMATIC DIAGRAM OF RECRUITMENT, RANDOMIZATION & TREATMENT



# 1. INTRODUCTION

## 1.1. Background

Chronic, non-healing wounds e.g. diabetic foot ulcers (DFU) are a common worldwide health problem that have substantial medical and socioeconomic importance and represent a major unmet clinical need [1]. In Europe, 1-1.5% of the population has a problem wound at any one time. The average cost per episode is 6,650€ for leg ulcers and 10,000€ for foot ulcers, accounting for 2-4% of the healthcare budget and likely to escalate with an increasingly elderly and diabetic population [2]. In the Leeds/Bradford region the overall prevalence of wounds is 2.8-3.6 people per 1000 population [3], up to 50% of which are chronically inflamed, non-healing wounds. Costs for wound care in the UK are estimated at £2.03-3.8 million per 100,000 population [4] and diabetes currently accounts for approximately 10% of the total health resource expenditure and is projected to account for around 17% in 2035/2036 [5].

The profound atrophogenic effects of glucocorticoids (GC) on human skin structure and function are well documented, causing decreased collagen content, increased transepidermal water loss (TEWL), dermal and epidermal thinning, telangiectasia, impaired wound healing (WH) and increased infection risk [6-13]. Keratinocytes, melanocytes, fibroblasts and sebocytes play significant roles as GC targets in these processes [11, 14]. These effects arise from GC excess including systemic [7, 8] and topical [10] GC therapy, Cushing's disease [6] and psychological stress [13, 15-17].

The expertise of our group has focused on 11 $\beta$ -hydroxysteroid dehydrogenase (11 $\beta$ -HSD) isozymes which regulate local GC availability in many tissues largely independently of circulating levels [18]. In skin, 11 $\beta$ -HSD1 activates cortisol from cortisone, is expressed in epidermal keratinocytes, hair follicles, sebaceous glands and dermal fibroblasts and is upregulated by GC in a forward-feedback manner [19, 20]. Conversely, 11 $\beta$ -HSD2 converts cortisone to cortisol and, in skin, is predominantly expressed in eccrine (sweat) glands where it functions to protect the mineralocorticoid receptor from inappropriate activation by GC (as with other mineralocorticoid-responsive tissues e.g. kidney) [21]. We recently demonstrated increased 11 $\beta$ -HSD1 activity during the inflammatory phase of mouse skin WH [22] and faster healing in 11 $\beta$ -HSD1-null mice treated with oral corticosterone (active GC in mouse) and topical application of carbenoxolone (CBX), an 11 $\beta$ -HSD non-selective inhibitor (unpublished observations). Strikingly, mice with global deletion of 11 $\beta$ -HSD1 were protected from age-induced dermal atrophy, with improved collagen processing and accelerated WH [19]. Others have also reported accelerated WH by 11 $\beta$ -HSD1 blockade in animal models of diabetes and GC excess [23, 24].

These findings suggest that 11 $\beta$ -HSD1 mediates the effects of circulating GC in skin and drives the cutaneous consequences of GC excess. However, **the role of 11 $\beta$ -HSD1 in regulating skin function in man remains unexplored**, despite evidence that 11 $\beta$ -HSD1 is

upregulated by pro-inflammatory cytokines e.g. IL-1 $\beta$  and TNF- $\alpha$  (abundant in chronic wounds) [25-27] and reports of increased systemic GC levels in patients with type 2 diabetes mellitus (T2DM) [28, 29]. Moreover, pro-inflammatory cytokines and GC synergistically increase 11 $\beta$ -HSD1 expression [30] which may exacerbate GC availability in to further impede WH.

Targeting 11 $\beta$ -HSD1 through selective inhibitors has been a focus of major pharma for the last 5 years. In 2011, 11 $\beta$ -HSD1 was cited as the second most popular therapeutic target for patents filed ([www.thomsonreuters.com/content/science/pdf/ls/iyc2011.pdf](http://www.thomsonreuters.com/content/science/pdf/ls/iyc2011.pdf)), the main target indication being metabolic syndrome to reduce hepatic gluconeogenesis, steatosis and visceral adipogenesis. Proof of concept was established in a number of phase II studies but effect size may prevent progression to phase III [31-34]. Selective 11 $\beta$ -HSD1 inhibitors, such as AZD4017, are now being released for repurposing studies funded through schemes such as the MRC Asset Sharing Initiative. **The ability of systemic 11 $\beta$ -HSD1 inhibitors to target enzyme activity in peripheral tissue (e.g. skin) in man is unknown.**

Our proposed pilot trial will generate efficacy, safety and study feasibility data for the application of selective 11 $\beta$ -HSD1 inhibitors as novel therapies to improve skin function and WH in diabetes. Our skin-specific study variables are a combination of validated disease-related outcomes and **measures previously unexplored in T2DM** that will greatly improve our knowledge of GC metabolism in skin. The potential to accelerate WH in patients with T2DM would contribute to a significant **improvement in patient quality of life and reduction in costs of care.**

## 1.2. Investigational medicinal product (IMP)

### 1.2.1. Investigator brochure (IB) updates

Please refer to the current IB (edition 9 Oct 2016) for more information.

### 1.2.2. Summary of product characteristics

Not applicable

### 1.2.3. Non IMP(s)

A placebo tablet containing microcrystalline cellulose and sodium stearyl fumarate is also available to match the active tablets in size, shape and colour. Matched placebo tablets will be provided by AstraZeneca.

## 1.3. Rationale for the proposed study

The project is well-aligned with the research strategies of the School of Medicine at the University of Leeds and compliments a key platform of the Leeds Institute of Rheumatic and Musculoskeletal Medicine: Regeneration and Repair. This preliminary study aims to investigate efficacy and safety of 11 $\beta$ -HSD1 inhibition on skin function in patients with

T2DM. Study feasibility will also be assessed; if successful, data from this pilot study will inform power calculations for a future trial to investigate the ability of 11 $\beta$ -HSD1 inhibition to promote foot ulcer healing in T2DM.

## 2. STUDY AIM AND OBJECTIVES

### 2.1. Study aims

To evaluate efficacy of oral AZD4017 in skin, determine safety of AZD4017 in patients with T2DM, examine effects of AZD4017 on skin function and assess study feasibility.

### 2.2. Primary objective

Evaluate AZD4017 efficacy

### 2.3. Secondary objectives

- 1) Evaluate safety of AZD4017
- 2) Examine effects of AZD4017 on skin function
- 3) Assess study feasibility

## 3. STUDY ENDPOINTS

### 3.1. Primary endpoint

24 hour 11 $\beta$ -HSD1 activity in skin (efficacy) at baseline and day 28

### 3.2. Secondary endpoints

Systemic 11 $\beta$ -HSD1 activity at baseline and day 35 and AZD4017 quantification in skin at day 28 and plasma at day 35 (to support efficacy), safety variables at baseline and days 7, 28 and 35, blood pressure, blood safety variables, ECG and biopsy inspection at day 42, urinary cortisol to cortisone metabolite analysis at baseline and day 35 (to assess systemic GC levels), skin function variables at baseline and days 2, 7, 28, 30 and 35 and feasibility variables at throughout the study.

## 4. STUDY VARIABLES

### 4.1. Primary variable

#### AZD4017 efficacy

- 24 hour 11 $\beta$ -HSD1 activity in skin

## 4.2. Secondary variables

### AZD4017 efficacy

- 24 hour urinary cortisol to cortisone metabolite ratio
- AZD4017 levels in skin and plasma

### Safety

- Body mass index (BMI)
- Waist-hip ratio
- Blood pressure (BP)
- Blood HbA1c
- Blood lipids
- Full blood count (FBC)
- Liver function test (LFT)
- Estimated glomerular filtration rate (eGFR)
- Kidney function test (U+E)
- Adrenal function (testosterone and dehydroepiandrosterone sulphate)
- Thyroid function
- Adverse event (AE) reporting
- Number of patients discontinuing study therapy due to safety

### T2DM-related skin variables

- Sudomotor function (in each hand or foot, average in hands, average in feet, overall average)
- Skin hydration

### Exploratory skin variables

- Epidermal barrier function
- Epidermal barrier recovery
- Epidermal barrier integrity
- Skin thickness
- WH
- RNA-seq gene expression profiling

### Other secondary variables

- 24 hour urinary free cortisol

### Feasibility

- Data on eligibility (proportion of patients assessed for eligibility deemed to be eligible and for each inclusion/exclusion criterion, proportion of patients eligible)
- Data on recruitment success (recruitment rate per month and week by week)
- Data on consent success (proportion of eligible patients consented)

- Assessment of randomization (evenness of numbers randomised to the two groups and balance of baseline characteristics between the two groups)
- Data on adherence to intervention (number of patients completing diary card, percentage compliance throughout treatment phase and reasons for missed doses)
- Data on retention to trial (number of patients completing final study assessment, reasons for discontinuation and number discontinuing in each case)
- Data on completeness of outcome measure reporting (for each outcome, number of patients with data available at each visit)

## 5. STUDY DESIGN

### 5.1. Study description

This study aims to conduct a double-blind, randomised, parallel group, placebo-controlled phase II pilot trial of 35 days' duration with 400mg oral AZD4017 twice daily (n=15) or placebo (n=15) in patients with T2DM.

Eligible participants will be identified using medical records from the Diabetes Clinic at St. James' University Hospital (SJUH) by the CI or an authorised member of the direct care team. Once identified, patients will be invited to participate in the trial by email and/or post and provided with a Participant Information Leaflet (PIL) and PIL Feedback Form (returnable by self-addressed prepaid envelope).

Patients will be contacted by telephone to confirm willingness to participate and eligibility after 72 hours since sending the PIL.

### 5.2. Study duration

The protocol treatment duration is 35 days with follow-up visit at least 7 days after the last treatment dose.

Skin, plasma, serum and 24 hour urine samples will be stored for future biochemical analyses but storage will not exceed 5 years after the end of the trial. At 5 years after the end of the trial any residual samples will either be destroyed or placed in an approved Research Tissue Bank.

### 5.3. Rationale for study design and selection of dose

#### AZD4017 efficacy

The ability of 11 $\beta$ -HSD1 inhibitors to reduce 11 $\beta$ -HSD1 activity in peripheral tissues has not been determined in man. Our primary variable will therefore evaluate the ability of AZD4017 to inhibit 24 hour 11 $\beta$ -HSD1 activity in skin. In addition to assessment of efficacy, this outcome measure will be used to provide preliminary data on associations between 11 $\beta$ -HSD1 activity levels and skin function variables. To support this outcome measure,

secondary variables will include systemic AZD4017 efficacy by measuring urinary cortisol to cortisone metabolite ratios ([THF+alloTHF]/THE) and pharmacokinetic analyses to confirm AZD4017 levels in plasma and skin biopsies.

### **Safety**

AZD4017 has been studied in healthy human volunteers and is tolerated when given in single doses up to 1500mg and in multiple doses up to 900mg for periods of up to 9 days. A Phase IIa study of 28 days duration has been conducted in patients with raised intraocular pressure; 7 subjects received 200 mg once daily AZD4017 for up to 28 days and 19 subjects received 400 mg twice daily AZD4017 for up to 28 days. The most commonly reported AE in the studies with AZD4017 were gastrointestinal disorders and headache and were of mild to moderate intensity. Previous safety studies in healthy volunteers also reported an increase in ACTH and dehydroepiandrosterone sulfate levels. However, cortisol and testosterone levels were not changed. As the proposed pilot trial is relatively short, we will measure dehydroepiandrosterone sulfate and testosterone. However, blood samples will be stored allowing ACTH and cortisol to be measured in any patient showing evidence of hypothalamic-pituitary-adrenal (HPA) axis activation.

Other safety laboratory analyses showed no clinically relevant changes. No clinically relevant changes or trends were seen in vital signs or in ECG results in previous safety studies.

Although other 11 $\beta$ -HSD1 inhibitors have been trialled in patients with T2DM and were safe and well-tolerated [32, 33], AZD4017 has not been tested in this patient cohort. This preliminary pilot trial will therefore evaluate safety by monitoring validated safety variables of T2DM (e.g. BMI, waist-hip ratio, BP, HbA1c and lipids) and AZD4017 (e.g. FBC, LFT, eGFR, U+E, adrenal and thyroid function). Further information regarding non-clinical data and previous clinical studies can be found in the AZD4017 IB.

Data collected will be used to inform powering and feasibility of a future confirmatory trial.

### **Treatment duration**

The study design is suitable for the time and funding constraints available. The study duration (35 days) is sufficient to detect changes in all T2DM-related skin secondary outcome measures [35-39].

### **Dose**

AZD4017 is a novel orally bioavailable small molecule inhibitor of 11 $\beta$ -HSD1 enzyme activity. It is potent and highly selective *in vitro* and *in vivo*. The half maximal inhibitory concentration (IC<sub>50</sub>) for inhibition of 11 $\beta$ -HSD1 activity (cortisone to cortisol conversion) is 2nM. AZD4017 is selective (> 2000x) for 11 $\beta$ -HSD1 over human recombinant 11 $\beta$ -HSD2 and the closely-homologous enzymes 17 $\beta$ -hydroxysteroid dehydrogenase 1 (17 $\beta$ -HSD1) and 17 $\beta$ -hydroxysteroid dehydrogenase 3 (17 $\beta$ -HSD3) *in vitro*.

The dose to be used in this study is 400mg twice daily. This dose results in a decrease in the urinary ratio of tetrahydrocortisol to tetrahydrocortisone metabolites ([THF+alloTHF]/THE) from 0.99+0.27 to 0.11+0.06 and decreases the generation of plasma prednisolone following oral prednisone by 80%. Pharmacokinetic and pharmacodynamic data from single and multiple ascending dose studies in healthy volunteers suggest that a dose of 400mg twice daily may achieve approximately 90% inhibition of 11 $\beta$ -HSD1 over 24 hours. The safety and tolerability profile of AZD4017 has been studied in animals and in single and multiple ascending dose studies in human volunteers and supports the use of AZD4017 twice daily to 900 mg/day. The 35-day treatment period is considered sufficient to see sustained inhibition of 11 $\beta$ -HSD1 by AZD4017, and therefore this dose and duration is appropriate. Please refer to IB for more information.

### **Other secondary variables**

Additional secondary study variables have been selected to represent a combination of clinically validated disease-related and/or GC-regulated exploratory outcome measures of skin function. Peripheral diabetic neuropathy in diabetes is characterized by a decrease in intra-epidermal nerve fiber density and sudomotor function leading to decreased skin hydration which and an increased risk of DFU [40-47]. Sudomotor function analysis has superseded intra-epidermal nerve fiber density as the “gold standard” for evaluating peripheral diabetic neuropathy and measures sweat gland innervation as a direct indicator of cutaneous C-fiber function [48]. Although the regulation of sudomotor function by GC is poorly understood, skin hydration is known to be reduced by GC treatment [49] and will also be investigated as a secondary study variable. The proposed study will generate novel data on the regulation of DFU risk factors by 11 $\beta$ -HSD1-mediated GC activation in skin.

Previous studies have indicated increased TEWL following treatment with topical GC [50] and acute systemic stress [51]. Conversely, acute systemic stress (physical restraint) decreased TEWL in rodent models of inflammatory diseases [52]. Therefore, we anticipate that limiting local GC reactivation by 11 $\beta$ -HSD1 inhibition may regulate TEWL. Impaired barrier recovery has been reported following systemic GC excess in humans [53] and rodents [54-56]. The number of tapes required to induce a standardized degree of barrier disruption will be used to evaluate barrier integrity, which is also impaired by GC excess [55, 56]. Skin thinning is a frequently reported side-effect of GC excess driven by both dermal and epidermal thinning [8, 9, 12, 57, 58], however, regulation of skin thinning by 11 $\beta$ -HSD1 in man remains unexplored. Impaired WH is a common side-effect of GC excess [11, 59] and 11 $\beta$ -HSD1 has been implicated in mouse WH models by us [19, 22] and others [23, 24]. However, this remains to be investigated in man. Although chronic wounds are a widely reported feature of T2DM, acute WH has not been fully investigated. Moreover, TEWL, barrier recovery, epidermal integrity and skin thickness remain unexplored in T2DM. Our study will provide a new insight into the regulation of these key skin functions by 11 $\beta$ -HSD1 in T2DM. RNA-seq will also be used for transcriptomic profiling of gene expression to identify key pathways involved in 11 $\beta$ -HSD1-mediated regulation of skin function.

Systemic GC levels have been shown to be important in determining peripheral GC exposure by regulating 11 $\beta$ -HSD1 substrate (cortisone) availability [18]. Therefore, systemic GC levels in combination with peripheral 11 $\beta$ -HSD1 activity may affect AZD4017 responsiveness and will also be monitored by measuring 24 hour urinary free cortisol levels.

Study feasibility will be assessed using a range of quantifiable measures including eligibility, recruitment, consent, randomization, adherence, retention and data completeness as in accordance with Consolidated Standards of Reporting Trials guidance [60, 61].

## **6. SELECTION AND WITHDRAWAL OF SUBJECTS**

### **6.1. Target population**

Adults aged 18 years or older, with T2DM

### **6.2. Estimated number of eligible participants**

Current data from the NIHR Yorkshire and Humber Clinical Research Network identified >45,000 patients with T2DM from 11 general practitioner (GP) practices, indicating a large target population pool. Therefore, we estimate a trial invitation requirement of 86 participants of whom an estimated 50% will consent and of whom an estimated 70% will be eligible (using the criteria below) to reach our target of 30 participants (allowing a 20% post-randomization drop-out rate to achieve a total of 24 completers with 12 in each arm).

### **6.3. Eligibility criteria**

#### **6.3.1. Inclusion criteria**

- 1) Able and willing to provide informed consent
- 2) Clinical diagnosis of T2DM with HbA1c <11% (<97 mmol/mol) at screening while taking standard therapy at a stable dose for  $\geq$ 10 weeks

#### **6.3.2. Exclusion criteria**

1) Women of child-bearing potential (WOCBP). Note: WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or is not postmenopausal [defined as amenorrhea  $\geq$  12 consecutive months or women on hormone replacement therapy with documented serum follicle stimulating hormone level >35 mIU/mL].

Additionally, male study participants who are sexually active with a female partner of childbearing potential must be surgically sterilized or agree, along with their partner, to use a highly effective method of birth control (as defined below) from the time of screening until 3 weeks after final dose of study drug (5 drug elimination half-lives plus 2 weeks). Male

study participants must also **not** donate sperm from the time of screening until 3 weeks after final dose of study drug (5 drug elimination half-lives plus 2 weeks).

Highly effective methods of contraception are defined as combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (either oral, intravaginal or transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (either oral [such as Cerazette™], injectable or implantable), intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomized partner or true sexual abstinence: When this is in line with the preferred and usual lifestyle of the subject. [Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods), declaration of abstinence for the duration of a trial, and withdrawal are not acceptable methods of contraception].

2) Active leg/foot ulceration

3) Acute electrocardiogram (ECG) anomalies deemed to be clinically relevant by the CI

4) Systemic hypertension (BP >150/90), on 3 successive measurements at the screening visit (patients with controlled hypertension can be included in the trial) with the first acceptable measurement recorded and either systolic or diastolic BP exceeding these values requiring re-measurement

5) Any endocrine disorder (other than T2DM), including type 1 or secondary diabetes, except treated hypothyroidism with normal thyroid function tests for at least 3 months

6) Suspicion of or known Gilbert's disease

7) Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) and/or alkaline phosphatase (ALP) > 1.5x upper limit of normal (ULN)

8) Bilirubin (total) > 1.5x ULN

9) An eGFR calculated by the Modification of Diet in Renal Disease equation of <45 ml/min/m<sup>2</sup>

10) Creatine kinase (CK) >2 x ULN

11) Participant is, at the time of signing the informed consent, a user of recreational or illicit drugs (including marijuana) or has had a recent history (within the last year) of drug or alcohol abuse or dependence on questioning or clinical history

12) Receiving any topical, systemic (including vaginal/rectal) or inhaled GC treatment at the time of or within 3 months prior to the screening visit

13) Taking any anticoagulant medication (blood thinning e.g. warfarin)

14) Taking probenecid or similar (for gout) at the time of inquiry

15) Any medical/surgical procedure (excluding skin biopsies) or trauma during IMP administration or within one week following the last administration of the IMP as judged by the CI

16) Involved in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)

17) Participated in any other clinical study within 1 calendar month prior to the screening visit (except registry-only participation)

18) Deemed otherwise inappropriate to participate by the trial team

### **6.3.3. Exclusions for general safety**

Not applicable

### **6.3.4. Screen failures**

Participants who sign an Informed Consent Form and fail to meet the inclusion and/or exclusion criteria are defined as screen failures. For all screen failures, the investigator is to maintain a Screening Log that documents the screening number, participant initials, and reason(s) for screen failure. A copy of the log will be retained with the Case Report Form (CRF) and screening will be recorded as pass or fail in the CRF. Screening Log originals will be stored in the TMF.

## **6.4. Recruitment, consent and randomization processes**

### **6.4.1. Recruitment**

Eligible participants will be identified using medical records from the Diabetes Clinic at St. James's University Hospital by the Chief Investigator or an authorized member of the direct care team. Potentially eligible participants will be selected using a computerized search and review of medical records.

A PIL and PIL Feedback Form will be provided by a qualified member of staff who has signed/dated the staff delegation log for suitable candidates to consider. This will include detailed information about the rationale, design and personal implications of the study. Following information provision, patients will be contacted by telephone after 72 hours to ask whether they would be willing to take part in the trial and to check eligibility. This process will be clearly documented into the patient's medical notes.

### **6.4.2. Consent**

Assenting patients will then be invited to attend a screening visit where they will be formally assessed for eligibility and asked to provide written, informed consent. Where English is not the patient's first language every effort will be made to provide a Trust interpreter according to normal Trust procedures. The right of the patient to refuse consent without giving reasons will be respected. The original Informed Consent Form will be filed in the Trial Master File (TMF), with one copy given to the patient and one filed in the hospital notes. Consent pass or fail will also be recorded in the CRF. The written consent will be taken by an

eligible member of staff who has signed/dated the staff delegation log. The process of obtaining written consent will be clearly documented in the patient's medical notes.

A separate Informed Consent Form will be attained prior to the skin biopsy procedure which will be stored with the general Informed Consent Form in the TMF and recorded as pass or fail in the CRF.

#### **6.4.3. Randomization process**

Treatment groups will be allocated on a fully randomised basis. A randomization schedule will be generated by the dedicated trials pharmacy representative who has signed/dated the staff delegation log and is not otherwise associated with this study. Patients will be randomised in a 1:1 treatment allocation ratio to either AZD4017 or placebo. The randomization schedule will be stored in a password protected file accessible only to the dedicated trials pharmacy (the CI and Scientific Lead will be blinded to the randomization process) until all samples have been collected.

#### **6.4.4. Definition for the end of the trial**

The end of the trial will be defined as entry of the last participant's last data item.

### **6.5. Withdrawal criteria**

Participants are at any time free to withdraw from study (IMP and assessments), without prejudice to further treatment (withdrawal of consent) at any point. Such participants will always be asked about the reason(s) and the presence of any AE. Participants are not under obligation to give a reason for withdrawal. If possible, they will be invited to attend a follow-up visit, ideally, at least 7 days after stopping the IMP. They will undergo the follow-up visit safety measurements and be formally discharged by telephone. Any AE will be followed up wherever possible and all remaining IMP should be returned by the participant.

Should the participant need to be withdrawn from the active treatment phase of the study between study visits for safety reasons e.g. serious adverse event (SAE) or laboratory abnormalities, study medication will be stopped immediately. If withdrawn from IMP, participants will be free to complete the remaining protocol if they choose to do so unless deemed clinically unfit by the CI, in which case they will be withdrawn from the remainder of the protocol.

IMP withdrawal criteria are as follows:

- 1) Participant decision. The subject is at any time free to discontinue treatment, without prejudice to further treatment
- 2) The participant has a clinically significant or serious AE that would not be consistent with treatment continuation, as determined by the CI or the participant; including but not limited to hospitalisation or disability, requirement for medical or surgical intervention to prevent

hospitalisation or disability; or abnormalities of liver, muscle or thyroid function that are considered unacceptable by the CI

3) Hepatotoxicity: ALT and/or ALP and/or AST >2.5x ULN or bilirubin >2x ULN. This is in keeping with Common Terminology Criteria for AE (v5.0) Grade 2 recommendations from the National Institute of Health.

4) Renal toxicity: eGFR <45

#### **6.5.1. Patients who withdraw consent**

Unless the participant specifically withdraws consent for their data and samples to be stored, all data and samples that have already been collected from them will continue to be stored as per the original participant consent. This will also apply to participants who are unable to confirm enduring consent due to loss of capacity.

#### **6.5.2. Managing/replacing patients who withdraw early**

Participants who decide to withdraw will be invited to complete a withdrawal form which will be stored in the TMF (although refusal to do so will be respected). Participants who are withdrawn by the CI will be recorded in a Withdrawal Log that documents the enrolment number, participant initials, reason(s) for withdrawal and treatment offered (if applicable). A copy of the log will be retained in the CRF which will also directly capture information on withdrawal outcome (Discontinuation due to Adverse Event or Elective Withdrawal). Withdrawal Log originals will be stored in the TMF. Participants who withdraw or are withdrawn pre-randomization will be classified as screening failures (see section 6.3.4). Participants who withdraw or are withdrawn post-randomization (see section 6.5) will be classified as withdrawals and will not be replaced.

## **7. STUDY BLINDING**

### **7.1. Type of blinding**

Treatment groups will be allocated in a double-blind manner. Participants will be blinded to the treatment they receive (placebo or IMP) throughout all stages of the study. Investigators will also be blinded to the treatment until all samples have been collected and processed. Blinding will be generated by the dedicated trials pharmacy representative who has signed/dated the staff delegation log and is not otherwise associated with this study.

### **7.2. Procedure for production and maintenance of blind**

Blind production and maintenance will be according to dedicated trials pharmacy guidelines.

### **7.3. Breaking the blind in an emergency**

In an emergency (e.g. participant AE) the blind may be broken to determine whether this may be treatment-related. Blinding for previously collected or future treatments will not be compromised.

## 8. STUDY TREATMENTS

### 8.1. General information on the products (trial drugs) to be used

IMP	Dosage form and strength	Manufacturer
AZD4017	Tablets 200 mg	AstraZeneca
Placebo to match AZD4017	Tablets	AstraZeneca

Please refer to the IB for more information.

### 8.2. Frequency and duration of the trial drugs

Participants will be randomised to receive either AZD4017 400mg twice daily (as close to 12 hours apart as possible) or placebo. AZD4017 or placebo will be dosed as 2 tablets orally twice daily for 35 days starting at the baseline visit (Visit 1).

### 8.3. Administration/handling of the trial drugs

The AZD4017 tablets and matching placebo will be supplied to the dedicated trial pharmacy by Almac in bottles of 32, 200mg tablets with a unique kit number (sufficient for 8 days per bottle); 4 bottles will be dispensed at Visit 1 and 1 bottle will be dispensed at Visit 4 (sufficient for 5 days overage per participant). Almac will provide the pharmacy with a kit list to refer to when dispensing for each patient and a set of code breaks for emergency unblinding.

Participants will be instructed to take the AZD4017 or placebo tablets 30min before or at least 2 hours after a meal. In the case of vomiting or diarrhoea after taking the tablets, participants will be instructed not to repeat the dose but to wait for their next scheduled dose.

#### 8.3.1. Handling, storage and supply

Labels will be prepared in accordance with Good Manufacturing Practice (GMP) and local regulatory guidelines. The labels will fulfil GMP Annex 13 requirements for labelling. Label text will be in English. The labels will have a peel-off portion, which will be inserted into the participant's source data verification document at dispensing.

All study medications will be kept in a secure place under appropriate storage conditions. The IMP label on the pack specifies the appropriate storage.

#### 8.3.2. Drug accountability

The IMP provided for this study will be used only as directed in the study protocol. The study personnel will account for all IMP dispensed to and returned from the participants.

AstraZeneca personnel or its representative CTRU will ensure accountability logs are maintained for all study drugs received at the site, unused study drugs and for appropriate destruction. If possible, the study drug will be destroyed locally by the site pharmacy. Certificates of delivery and destruction will be signed and stored in the pharmacy site file.

#### **8.4. Prior and concomitant illnesses**

Participants and their GP will be requested to report any prior or concomitant illness and these will be assessed on an individual basis as to the most appropriate subsequent actions to be taken (if any) based on the exclusion and withdrawal criteria described above.

We do not anticipate that ADZ4017 will adversely affect any prior or concomitant illness.

#### **8.5. Prior and concomitant medications**

We do not anticipate that AZD4017 will adversely affect any prior or concomitant medications; however, certain medications are prohibited as they may interfere with study outcome measures.

##### **8.5.1. Permitted prior medications**

Participants will be allowed to receive any treatment that is judged to be in their best medical interests. Participants and their GP will be requested to report any new treatment and participants may be withdrawn according to exclusion and withdrawal criteria.

##### **8.5.2. Prohibited prior medications**

No specific drug interactions have been reported for AZD4017. However, the following medications are listed in the exclusion criteria as they may interfere with data integrity:

- Any topical, systemic (including vaginal/rectal) or inhaled GC treatment at the time of or within 3 months prior to the screening visit as this may affect 11 $\beta$ -HSD1 activity and secondary outcome measures
- Any anticoagulant medication (blood thinning e.g. warfarin) as this may reduce blood clotting and delay WH
- Probenicid or similar (for gout) as this may be increase AZD4017 excretion

##### **8.5.3. Permitted concomitant medications**

Participants will be allowed to receive any treatment that is judged to be in their best medical interests.

##### **8.5.4. Prohibited concomitant medications**

Please refer to exclusion criteria.

### 8.5.5. Surgical procedures

We do not anticipate that AZD4017 will adversely affect any prior or concomitant surgical procedures but as a precaution patients will be ineligible to participate in the event of any medical/surgical procedure (excluding skin biopsy) or trauma during IMP administration or within one week following the last administration of the IMP as judged by the CI.

### 8.6. Special warnings and precaution for use

AZD4017 has been studied in healthy human volunteers some patient groups and is generally well tolerated.

The most commonly reported AE amongst healthy volunteers were gastrointestinal disorders and headache and were of mild to moderate intensity. Please refer to IB for more information.

In a multiple ascending dose study (see IB for details) 30 healthy male subjects received single doses of AZD4017 followed by repeated doses of 75 mg once daily up to 900 mg twice daily for 9 days. The expected inhibition on 11 $\beta$ -HSD1 enzyme activity in liver measured by prednisolone generation in plasma after an oral prednisone challenge as well as on urinary GC metabolites was observed. An activation of the HPA axis was also indicated as an increase in both adrenocorticotrophic hormone (ACTH) and dehydroepiandrosterone sulphate levels while cortisol and testosterone levels were unchanged. A few subjects had transient increases in ALT and AST at 1-1.5xULN. One subject taking 1200mg once daily experienced an increase in ALT to 3x ULN. In all cases, liver transaminases returned to baseline on withdrawal of study drug. There is **no clear relationship with plasma exposure as the subjects with the highest ALT did not have the highest plasma area under the curve of either AZD4017** or the glucuronic acid metabolite.

In a Phase IIa trial of subjects with raised intraocular pressure, 7 subjects receiving 200mg AZD4017 once daily and 19 subjects receiving 400mg AZD4017 twice daily for up to 28 days, **no deaths or SAE were reported**; in the group receiving AZD4017 400 mg twice daily three subjects had ALT between 1 and 1.5x ULN, four subjects had AST between 1 and 1.5x ULN, two subjects had gamma-glutamyl transferase between 1 and 1.5x ULN and one subject had GGT between 1.5 and 2x ULN. An activation of the HPA-axis was demonstrated by an increase in ACTH and dehydroepiandrosterone sulfate levels. However, cortisol and testosterone levels were unaffected. No AEs associated with these findings were reported. In the clinical studies performed so far no obvious muscle effects have been seen.

Non-clinical data and observations in previous clinical studies with similar and even higher repeated doses of AZD4017 support dose administration according to the proposed clinical study protocol. Further information regarding non-clinical data and previous clinical studies can be found in the AZD4017 IB.

Blood samples will be taken at screening, baseline, days 7, 28, 35 and follow-up to monitor HbA1c, lipids, liver, kidney, thyroid and adrenal function.

## 8.7. Dose modifications

We do not anticipate any requirements for dose modifications.

## 8.8. Assessing subject compliance with study treatment(s)

Participants will be asked to complete a daily Diary Card indicating the time of treatment (at approximately 12h intervals).

The administration of all study medication will be recorded directly into the CRF as the expected number of tablets remaining, the actual number of tablets remaining, the overall percentage compliance  $((140 - (\text{actual number of doses remaining} - \text{expected number of tablets remaining})) / 140) * 100$  and the cumulative percentage compliance  $(1 - ((\text{actual number of tablets remaining} - \text{expected number of tablets remaining}) / (\text{visit day} \times 4))) * 100$  at Visits 2-6. Any missed tablets will be documented in the medical notes, along with reasons for the missed tablets.

Percentage Diary Card completion will also be recorded in the CRF (number of doses recorded divided by the total available number of doses and multiplied by 100) along with a copy of the Diary Card. Diary Card originals will be stored in the TMF.

## 8.9. Withdrawal of treatment

### 8.9.1. Subject compliance

Participants will not be withdrawn on grounds of non-compliance in accordance with recent European Medicines Agency to avoid the presence of unobserved measurements as much as possible.

### 8.9.2. Lack of efficacy

Efficacy will be evaluated after termination of recruitment and a lack of efficacy will therefore not affect participant withdrawal.

## 9. METHODS OF ASSESSMENT

### 9.1. Assessment of primary variable (AZD4017 efficacy)

#### 11 $\beta$ -HSD1 activity in skin

To evaluate efficacy of oral AZD4017 on 24 hour 11 $\beta$ -HSD1 activity in skin, 3mm punch biopsies will be obtained at Visits 1 and 4 from lower outer forearm (midpoint between wrist and elbow) performed under local anaesthetic (e.g. lidocaine). This procedure will be conducted by authorised trial personnel according to the staff delegation log and does not require sutures. Administration of local anaesthetic may involve a momentary stinging sensation after which the procedure is pain-free. 11 $\beta$ -HSD1 activity assays will be conducted by the Scientific Lead within 8h as previously described [19]. To prevent accidental

unblinding, 11 $\beta$ -HSD1 activity samples will be stored frozen until the blind is broken at the end of the trial and will then be batch processed. Approximately 10% of the sample will be used for validation using a cortisol Enzyme Linked Immunosorbent Assay. Raw data (enrolment number, visit number and date) will be copied in its original form to secure server storage and recorded in the CRF as % conversion of cortisone to cortisol per hour.

## 9.2. Assessment of secondary variables

### 9.2.1. Efficacy

#### 9.2.1.1. Global 11 $\beta$ -HSD1 activity

Systemic 11 $\beta$ -HSD1 activity will be inferred from urinary [THF+alloTHF]/THE ratios. These will be measured in 24 hour urine samples at Visits 1 and 6 by liquid chromatography–mass spectrometry. Samples will be taken using commercially available collection containers, frozen in aliquots and stored at -80°C in the WTBB designated storage area before batch shipping for analyses by the Institute of Metabolism and Systems Research (University of Birmingham) at the end of the trial. The original report generated for each sample will be stored in the TMF and recorded in the CRF at the end of the trial.

Measurements will be used to examine associations between participant systemic GC levels and outcome measures of skin function.

#### 9.2.1.2. AZD4017 in plasma and skin

Skin samples will be collected at Visit 4 and blood plasma at visit 6 and stored at -80°C in the WTBB designated storage area before batch shipping for AZD4017 pharmacokinetic analysis by York Bioanalytical Solutions Ltd after the end of the trial. Blood samples will be collected by authorised research nurse support. Shipping contents, collection and delivery will be recorded and stored in the TMF. The original report generated for each sample will be stored in the TMF and recorded in the CRF.

### 9.2.2. Safety

AE-related participant withdrawals (i.e. number of Discontinuations due to Adverse Events) e.g. exceeding hepatic/renal stopping criteria, myocardial infarction or stroke, inpatient hospitalization or any other AE deemed by the clinical care team to require trial withdrawal will be recorded as a Discontinuation due to Adverse Event under withdrawal outcome in the CRF. The following safety measures will also be used to assess AZD4017 safety:

#### 9.2.2.1. Clinical evaluation of biopsy site

Following punch biopsies, participants will be requested to monitor the wound for any excessive adverse reaction (e.g. redness, rash, swelling or pain) and report any concerns to their GP. During Visits 2, 3, 4, 5 and 6, the application site will also be assessed by authorised trial personnel for signs of infection, detailed in the medical notes and recorded directly into the CRF as pass or fail.

#### 9.2.2.2. Body mass index

BMI is an attempt to quantify the amount of tissue mass (muscle, fat, and bone) in an individual, and then categorize that person as underweight, normal weight, overweight, or obese based on that value. BMI is defined as the body weight divided by the square of the body height, and is universally expressed in units of  $\text{kg}/\text{m}^2$ , resulting from mass in kilograms and height in metres. Height will be measured in metres to the nearest centimetre (e.g. 1.63m) and weight will be measured in kilograms to the nearest 100 grams (e.g. 60.2kg). Split values will be rounded up (e.g. 1.625m to 1.63m and 60.15kg to 60.2kg). BMI will be calculated using the formula:  $\text{BMI} = \text{weight (kg)}/\text{height (m}^2\text{)}$  and rounded up to two decimal place (e.g.  $\text{BMI} = 60.2/1.63^2 = 22.66$ ). Commonly accepted BMI ranges are underweight: under 18.5  $\text{kg}/\text{m}^2$ , normal weight: 18.5 to 25, overweight: 25 to 30, obese: over 30. Measurements will be conducted at Visits 1 and 6 by a qualified member of staff who has signed/dated the staff delegation log and weight, height and BMI will be recorded directly into the CRF.

#### 9.2.2.3. Waist-hip ratio

Waist-hip ratio is used in combination with BMI to assess obesity and can be more accurate as BMI can be skewed by muscle mass [62]. The waist-hip ratio is the ratio of the circumference of the waist to that of the hips. This is calculated as waist measurement (to the nearest cm) divided by hip measurement (to the nearest cm). Measurements will be conducted at Visits 1 and 6 by a qualified member of staff who has signed/dated the staff delegation log and waist circumference, hip circumference and waist-hip ratio will be recorded directly into the CRF.

#### 9.2.2.4. Blood pressure

Blood pressure is usually expressed in terms of the systolic (maximum) pressure over diastolic (minimum) pressure and is measured in millimeters of mercury (mm Hg) via a non-invasive sphygmomanometer. Measurements will be conducted at screening, Visits 1, 6 and follow-up by a qualified member of staff who has signed/dated the staff delegation log and recorded directly into the CRF.

#### 9.2.2.5. Blood tests

Blood samples collected at screening, baseline, study Visits 3 (day 7), 4 (day 28), 6 (day 35) and follow-up (day 42 onwards) will be analysed immediately through the Leeds Teaching Hospitals NHS Trust Pathology Service or processed and stored for future research.

Blood samples at each of these visits will evaluate HbA1c (mmol/mol) and lipids [total and high density lipoprotein cholesterol and triglycerides (mmol/l)] for T2DM disease markers and FBC [haemoglobin (g/l), white cells and platelets ( $\times 10^9/\text{l}$ ), red cells ( $\times 10^{12}/\text{l}$ ), mean corpuscular volume (fl), haematocrit (%/100), mean corpuscular haemoglobin (pg), mean corpuscular hemoglobin concentration (g/l) and red blood cell distribution width (%)], LFT

[ALT, AST and gamma-glutamyl transpeptidase (iu/l), ALP (U/l), albumin (g/l) and bilirubin (umol/l)], eGFR (ml/min/1.73m<sup>2</sup>), U+E [sodium, potassium and urea (mmol/l) and creatinine (umol/l)], adrenal [testosterone (nmol/l) and dehydroepiandrosterone sulphate (umol/l)] and thyroid [thyroid stimulating hormone (mIU/l) and free thyroxine (pmol/l)] function (AZD4017 safety markers). CK (iu/l) will also be measured at the screening visit. Samples will be collected by authorised research nurses.

Results will be sent to the CI or authorised delegated personnel for immediate monitoring signature and dating. Signed and dated result reports will be stored with the patient's medical notes for each visit and recorded in the CRF as pass or fail.

Blood will also be taken at baseline and day 35 for separation to serum and plasma and stored at -80°C in the WTBB designated storage area for plasma AZD4017 detection and future studies (up to 5 years). At 5 years after the end of the trial any residual samples will either be destroyed or placed in an approved Research Tissue Bank.

#### 9.2.2.6. Adverse event reporting

Any reported AE will record the following information directly into the CRF at Visits 2, 3, 4, 5 and 6

- Type of AE defined by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 preferred term
- Date of onset
- Severity (defined by CTCAE v5.0)
- Relation to study intervention (definite, probable, possible, unlikely, unrelated)
- Date of resolution

#### 9.2.3. Skin function

##### 9.2.3.1. Sudomotor function

The test is conducted using a Sudoscan device consisting of a simple desktop computer connected to two sets of large surface stainless steel electrodes: two for application of the palms, and two for the soles. The test will be conducted at Visits 1 and 6 and performed by the Scientific Lead at the SJUH Diabetes Centre. The procedure is non-invasive, pain-free and requires approximately 10min.

The patient places both hands and feet simultaneously on the designated electrodes and a painless scanning process ensues over the course of 2–3 min. A low voltage (1-4V) is incrementally applied to the electrodes, with the left and right electrodes serving alternatively as cathode and anode. At voltages <10V, the *stratum corneum* is electrically insulating; the sweat glands, however, consist of a cellular bilayer and therefore can transmit electrically charged ions to the electrodes through the skin's surface. The current of chloride ions generated is quantified and reflects C-fiber innervation. This chloride ion current is reported as electrochemical skin conductance measured in microSiemens (µS)

[48]. The results will be recorded directly into the CRF. Raw data on the Sudoscan device (including enrolment number, visit number and date) will be copied in its original form to secure server storage.

#### 9.2.3.2. Skin hydration

*Stratum corneum* hydration will be measured using a Corneometer CM 825 device. The device measures the change in the dielectric constant due to skin surface hydration changing the capacitance of a precision capacitor and can detect even slight changes in hydration (reported in arbitrary units).

The measurement will be taken at Visits 1 and 6 with a small portable probe that is applied to the skin, is non-invasive and pain-free. The test requires approximately 5min and will be conducted by the Scientific Lead. The results will be recorded in the CRF and stored as image files in a temporary folder (including enrolment number, visit number and date) on the secure (encrypted) laptop used for the measurements before transfer to a secure server.

#### 9.2.3.3. Epidermal barrier function

TEWL is a validated measure of skin epidermal permeability barrier function.

Evaporation of water from the skin occurs as part of normal skin metabolism. As barrier function is disrupted, water loss increases. The Tewameter TM 300 probe measures the density gradient of the water evaporation from the skin by two pairs of sensors (temperature and relative humidity) inside a hollow cylinder. The open chamber measurement method is the only method to assess the TEWL continuously without influencing its microenvironment. A microprocessor analyses the values and expresses the evaporation rate in g/h/m<sup>2</sup>.

The procedure requires 5min to perform, is non-invasive, pain-free and will be conducted by the Scientific Lead at Visits 1, 2, 3, 4, 5 and 6. The results will be recorded in the CRF and stored as image files in a temporary folder (including enrolment number, visit number and date) on the secure (encrypted) laptop used for the measurements before transfer to a secure server.

#### 9.2.3.4. Epidermal barrier recovery

In addition to resting TEWL, epidermal function can be assessed by measuring TEWL recovery over time following barrier disruption by repeated tape stripping.

Following the initial TEWL measurement, adhesive patches (D-Squame tapes) will be used to gently remove the *stratum corneum* layers to a pre-specified TEWL rate from the lower inner forearm at Visits 1 and 4. Recovery of TEWL at this location will be evaluated by repeated TEWL readings at 3 hour, 48 hour and 7 days post-disruption at Visits 1, 2, 3, 4, 5 and 6.

This procedure will be conducted by the Scientific Lead and may cause a temporary mild discomfort or transient irritation which should subside within a few hours. The results will be recorded in the CRF and stored as image files in a temporary folder (including enrolment number, visit number and date) on the secure (encrypted) laptop used for the measurements before transfer to a secure server.

#### **9.2.3.5. Epidermal barrier integrity**

The number of tapes required is an indication of *stratum corneum* integrity. Tapes will be stored at -80°C in the WTBB designated storage area for future molecular biology studies. The results will be recorded directly in the CRF.

#### **9.2.3.6. Skin thickness**

Epidermal thickness will be evaluated by OCT at Visits 1 and 6 according to the manufacturer's instructions. Image files (including enrolment number, visit number and date) will be stored on the OCT machine until the end of the trial. They will then be transferred to a secure server, compiled, analysed and values for skin thickness entered into the CRF.

#### **9.2.3.7. Wound healing**

Both biopsies from visit 1 and two biopsies from visit 3 will be imaged by OCT at Visits 2, 3, 5 and 6. Recent studies suggest OCT may be a useful tool to evaluate wound re-epithelialization [63]. This imaging modality is already being utilised by our department [64]. OCT uses light to capture sub-micrometer resolution, three-dimensional images from within biological tissue (e.g. skin). The method is based on low-coherence interferometry, typically employing near-infrared light. The use of relatively long wavelength light allows it to penetrate 1-2mm into the tissue. In addition to wound diameter, collected images capture information on vascularization which may be used for future studies.

The procedure takes approximately 2min using a small probe applied to the skin, is non-invasive, pain-free and will be conducted by the Scientific Lead or delegated authorised personnel. Image files (including enrolment number, visit number and date) will be stored on the OCT machine until the end of the trial. They will then be transferred to a secure server, compiled, analysed and values for wound diameter entered into the CRF.

#### **9.2.3.8. RNA-seq gene expression profiling**

Freshly snap-frozen 3mm skin biopsies collected at Visit 1 and 4 will be used to examine differences in mRNA expression by RNA-seq between baseline measurement and following 35 days of AZD4017. Skin samples will be stored -80°C in the WTBB designated storage area until all samples have been collected prior to processing for RNA extraction and RNA-seq. Lists of expressed and differentially expressed genes will be stored on a secure sever (including enrolment number and visit number). Genes and pathways found to be regulated

by AZD4017 will be quantified by qPCR and the data (including enrolment number and visit number) will be stored on a secure server.

#### 9.2.4. Feasibility

Data for powering of secondary variables and feasibility of a future confirmatory trial will be captured on the CRF. Data on eligibility, recruitment, consent, randomization, adherence, retention and data completeness will be captured through a range of sources including eligibility, enrolment, screening and withdrawal logs, Informed Consent Forms, pharmacy records and diary cards (stored in the TMF) to enable assessment of future confirmatory trial feasibility.

## 10. STUDY PROCEDURES BY VISIT

### 10.1. Summary schedule of study assessments

Table 1. Summary schedule of study assessments

Assessment (day)	Screening (-7 to -2)	Visit 1 (0)	Visit 2 (2)	Visit 3 (7)	Visit 4 (28)	Visit 5 (30)	Visit 6 (35)	Follow-up (>42)
Eligibility	X							
Informed consent*	X	X			X			
ECG	X							X
BMI, BP, waist-hip ratio	BP only	X					X	BP only
Blood tests**	X	X		X	X		X	X
24 hour urine collection		X					X	
Skin hydration		X					X	
Barrier function		X	X	X	X	X	X	
Barrier recovery		X	X	X	X	X	X	
Skin integrity		X			X			
Sudomotor test		X					X	
Biobank serum and plasma		X					X	
Randomization		X						
Tablet supply		X			X			
11 $\beta$ -HSD1 activity (biopsy)		X			X			
RNA-seq		X			X			

(biopsy)								
Skin thickness		X					X	
AE monitoring			X	X	X	X	X	X
Evaluation of biopsy site			X	X	X	X	X	X
Wound healing			X	X		X	X	
Compliance monitoring			X	X	X	X	X	
AZD4017 in plasma and skin (biopsy)***							X	

\* Informed consent will also be obtained prior to each biopsy

\*\* HbA1c, lipids, FBC, LFT, eGFR, U+E, adrenal and thyroid function (CK will also be analysed at screening). For further detail see section 9.2.2.5

\*\*\* Active (AZD4017) arm only after unblinding at the end of the trial

## 10.2. Screening visit (day -7 to -2) SJUH Diabetes Clinic

Patients invited to participate in the trial will be contacted by telephone after 72 hours and asked to confirm willingness to enrol, eligibility and identify a suitable study schedule. Two to seven days before the baseline visit (Visit 1), eligibility will be confirmed at screening by a medically qualified doctor and will be recorded in both the medical notes and CRF. Written informed consent will be obtained before testing for other exclusion criteria (clinically relevant acute ECG anomalies, hypertension and blood analyses). Potential participants will also be supplied with 24 hour urine collection devices. If all screening criteria are met, potential participants will be contacted by telephone when the results are ready to confirm enrolment and arrange a visit schedule.

## 10.3. Visit 1 (day 0) SJUH Diabetes Clinic and CAH LMBRU

Participants will return 24 hour urine samples for storage until processing. Participants will be asked if anything has changed since the previous visit.

**Baseline measures** will be conducted as follows: 1) BMI, BP, waist-hip ratio 2) skin hydration 3) epidermal barrier function and integrity 4) sudomotor function 5) blood samples for HbA1c, lipids, FBC, LFT, eGFR, U+E, thyroid and adrenal function and serum/plasma biobank storage 6) Randomization to 400mg oral AZD4017 twice daily or placebo 7) collection of IMP from pharmacy 8) obtain biopsy informed consent 9) 2 x 3mm biopsies for 11 $\beta$ -HSD1 activity RNA-seq 10) 3 hour barrier recovery time-point 11) skin thickness 12) payment

Pre-paid transport between SJUH and CAH for the skin thickness measurement will be arranged by a member of the trial team.

**10.4. Visit 2 (day 2) at CAH LMBRU**

We will monitor the biopsy site and participants will be asked if anything has changed since the previous visit and if they have experienced any AE. Measures will be conducted as follows: 1) epidermal barrier function 2) 48 hour barrier recovery time-point 3) biopsy site inspection and wound imaging by optical coherence tomography (OCT) 4) compliance monitoring 5) payment

**10.5. Visit 3 (day 7) at CAH LMBRU**

We will monitor the biopsy site and participants will be asked if anything has changed since the previous visit and if they have experienced any AE. Measures will be conducted as follows: 1) epidermal barrier function 2) 7 day barrier recovery time-point 3) blood samples for HbA1c, lipids, FBC, LFT, eGFR, U+E, thyroid and adrenal function 4) biopsy site inspection and wound imaging by OCT 5) compliance monitoring 6) payment

**10.6. Visit 4 (day 28) at SJUH Diabetes Clinic**

We will monitor the biopsy site and participants will be asked if anything has changed since the previous visit and if they have experienced any AE. Biopsy sites will be inspected and measures will be conducted as follows 1) epidermal barrier function and integrity 2) blood samples for HbA1c, lipids, FBC, LFT, eGFR, U+E, thyroid and adrenal function 3) collection of IMP from pharmacy 4) obtain biopsy informed consent 5) 3 x 3mm biopsies for 11 $\beta$ -HSD1 activity, RNA-seq and AZD4017 quantification 6) 3 hour barrier recovery time-point 7) compliance monitoring 8) payment

**10.7. Visit 5 (day 30) at CAH LMBRU**

We will monitor the biopsy site and participants will be asked if anything has changed since the previous visit and if they have experienced any AE. Measures will be conducted as follows: 1) epidermal barrier function 2) 48 hour barrier recovery time-point 3) biopsy site inspection and wound imaging by OCT 4) participants will be supplied with 24 hour urine collection devices 5) compliance monitoring 6) payment

**10.8. Visit 6 (day 35) at CAH LMBRU**

We will monitor the biopsy site and participants will return 24 hour urine samples for storage until processing. Participants will be asked if anything has changed since the previous visit and if they have experienced any AE. Measures will be conducted as follows: 1) BMI, BP, waist-hip ratio 2) skin hydration 3) epidermal barrier function 4) 7 day barrier recovery time-point 5) sudomotor function 6) blood samples for HbA1c, lipids, FBC, LFT, U+E, thyroid and adrenal function, serum/plasma biobank storage and AZD4017 quantification 7) remaining tablets and diary cards will be returned to the pharmacy 8) wound imaging by OCT 9) skin thickness 10) payment

Blood tests results from all visits will be sent to the CI or authorised delegated personnel for immediate consultation, signature and dating. Signed and dated blood reports will be stored in the medical notes and recorded in the CRF as pass or fail.

### **10.9. Follow-up visit (day 42 onwards) at SJUH Diabetes Clinic**

The follow-up visit will take place at least 7 days following cessation of trial treatments (day 42 onwards). At the follow-up visits, all biopsy sites will undergo clinical evaluation for signs of infection. ECG, BP and AE will be recorded. Blood samples will be collected for HbA1c, lipids, FBC, LFT, U+E, thyroid and adrenal function. Measurements will be conducted by a qualified member of staff who has signed/dated the staff delegation log and recorded directly into the CRF (ECG will be recorded in the CRF as pass or fail with original reports stored in the medical notes). Participants will be contacted by telephone to confirm follow-up findings and to be discharged from the trial (this will be recorded in the CRF). Dates of screening visits and Visits 1-6 will also be recorded directly into the CRF.

### **10.10. Unscheduled visits**

Presently, there is no information regarding overdose of AZD4017 in man and there is no known antidote for AZD4017. If an overdose is suspected any ongoing administration of AZD4017 should be stopped and the subject should be monitored closely and treated symptomatically. To determine the level of AZD4017 a blood sample must be drawn as soon as possible in proximity to the event. In addition, the time and extent of overdose must be ascertained. Since activation of the HPA-axis is a suspected pharmacological effect of excessive levels of AZD4017, blood sampling for testosterone and dehydroepiandrosterone sulfate should be carried out.

Test findings will be recorded in the CRF and participants may be withdrawn from the study.

## **11. PHARMACOVIGILANCE**

### **11.1. Defining adverse events**

An AE is any untoward medical occurrence in a patient during or following administration of an investigational product and which does not necessarily have a causal relationship with treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporarily associated with the use of the trial drugs, whether or not considered related to the trial drugs.

For the purposes of this study, an AE can include an undesirable medical condition occurring at any time between the Baseline and Completion Visits. As this is a blinded trial, AE will be assessed for expectedness and causal relationship assuming that the participant has been receiving AZD4017.

## 11.2. Defining serious adverse events

A SAE is an AE which is defined as serious, i.e. that it:

- Results in death. Death may occur as a result of the basic disease process. Nevertheless, all deaths occurring within 7 days of the last administration of the study agent must be treated as SAEs and reported as such. All deaths which may be considered as related to the trial agent, regardless of the interval, must be treated as a SAE and reported as such
- Is life-threatening
- Requires inpatient (overnight) hospitalization or prolongation of an existing hospitalization
- Results in a persistent or significant disability or incapacity
- Additionally, important medical events that may not result in death, be life-threatening, or require hospitalization may be considered SAE when, based on appropriate medical judgment, they may jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition
- Any other significant clinical event, not falling into any of the criteria above, but which in the opinion of the CI requires reporting

**Other Reportable Information:** Certain information, although not considered an SAE, must be recorded, reported, and followed up as indicated for an SAE. This includes the following:

- Overdose of IMP as specified in this protocol, with or without an AE
- Inadvertent or accidental exposure to IMP, with or without an AE

## 11.3. AE of special interest

### 11.3.1. Pregnancy

WOCP are excluded from this study. Should a pregnancy still occur, study medication will be discontinued immediately and the pregnancy reported to the University of Leeds and to AstraZeneca.

Pregnancy is considered a form of SAE. If a pregnancy is confirmed, use of the IMP must be discontinued immediately. Both maternal and paternal exposures are considered other reportable information. For exposure involving the female partner of a male subject, the necessary information must be collected from the subject, while respecting the confidentiality of the partner. All pregnancies will be followed up until birth.

## 11.4. Defining suspected unexpected serious adverse reactions

A Suspected Unexpected Serious Adverse Reaction (SUSAR) is a SAE suspected to have a reasonable causal relationship to the IMP where the nature or severity of the reaction is inconsistent with the available product information (mainly referring to the IB). All SAE

assigned by the CI or delegated clinician as both *suspected* to be related to the trial drugs and *unexpected* are subject to expedited reporting.

### **11.5. Exemptions from safety reporting**

Not applicable

#### **11.5.1. Efficacy endpoints and disease progression events**

Not applicable

#### **11.5.2. Other expected events**

Not applicable

### **11.6. Recording and reporting of AE**

#### **11.6.1. Recording and reporting of all AE**

Determination of AE will be based on the signs or symptoms detected during the physical examination and on clinical evaluation of the subject, and will be assessed and recorded at every visit. Signs and symptoms must be recorded using standard medical terminology. Subjects considered incapable of giving consent would not be considered for this study.

AE and SAE will be monitored from the first dose of protocol treatment to 7 days after the last dose of treatment with a protocol IMP. The Scientific Lead must instruct the subject to report AE and SAE during this time period.

During the time period specified above, the Scientific Lead will:

- Record all AE and SAE on source documents
- Record all AE and SAE in the CRF for subjects who are not screen failures
- Report all SAE on a 'CTT21 Serious Adverse Event Form'. Instructions on where to send this form will be provided by the Sponsor

The Scientific Lead must follow up on all AE and SAE until the events have subsided, returned to baseline, or, in case of permanent impairment, until the condition has stabilized. The Sponsor will maintain detailed records of all AE and SAE reported by the Scientific Lead in accordance with Good Clinical Practice (GCP – section 14.1) and applicable local regulations.

#### **11.6.2. Sponsor SAE and SUSAR reporting requirements**

All SAE assigned by the Scientific Lead as both suspected to be related to protocol treatment and unexpected will be reviewed by the CI. The CI or other qualified and delegated individual may declare a SAE a SUSAR. In the absence of the CI the event will be reported as a SUSAR. If upon receipt of follow-up information the causality relation is changed, this information will be submitted to the MHRA as part of the SUSAR follow-up reporting

procedures. All Investigators will refer to the IB when determining whether a SAE is expected.

All SAE, other information reportable as SAE and follow-up information must be reported to the Sponsor within 24 hours of the research team becoming aware of them, by emailing a completed 'CTT21 Serious Adverse Event Form' to the email address [leedsth-tr.sponsorqa@nhs.net](mailto:leedsth-tr.sponsorqa@nhs.net). The Sponsor will confirm, by phone or e-mail, that the email was received. SUSAR are subject to expedited reporting to the Research Ethics Committee (REC) and Medicines and Healthcare products Regulatory Agency (MHRA).

Identifiable patient data, other than linked anonymised data required by the SAE form, must not be included when reporting SAE and SUSAR.

The Sponsor<sup>1</sup> then will inform the MHRA<sup>2,3</sup> via the MHRA eSUSAR web portal and the Main REC<sup>2,3</sup> of SUSAR within the required expedited reporting timescales.

1. All SUSAR must be reported to the Sponsor QA office using the email address [leedsth-tr.sponsorqa@nhs.net](mailto:leedsth-tr.sponsorqa@nhs.net) within 24 hours of the event being reported to the CI (or their research team)
2. SUSAR must be reported to the REC/MHRA within 7 calendar days of the CI (or their research team) being informed of the event, if they result in Death or are deemed to be life-threatening. Follow-up information must be reported within 8 calendar days
3. Any SUSAR not resulting in death or deemed to be life-threatening must be reported to the REC/MHRA within 15 calendar days of the CI (or their research team) being informed of the event. Follow-up information must be reported within 8 calendar days

SUSAR will be reported in accordance with the requirements and provisions of the applicable national laws. They will all be signed off by the CI or, in their absence, by a delegated individual.

### **11.6.3. AstraZeneca SAE and SUSAR reporting requirements**

The Sponsor will:

- Report unblinded SUSAR to AstraZeneca as individual case reports as they occur
- Report blinded listings of SAE and Suspected Serious Adverse Reactions to AstraZeneca on a quarterly basis
- Inform AstraZeneca within 24 hours of knowledge of the event of any emerging safety data or actions that the Sponsor is considering as a result of a safety signal with the IMP. This includes but is not limited to:
  1. Urgent safety measures to be implemented in the study
  2. Safety amendments to protocol/patient information and informed consent

3. Open reports from Independent Data Monitoring Committees excluding confidential reports to and meeting minutes

4. Interactions with Regulatory Authorities / Ethics Committees

5. Inform AstraZeneca on an ongoing basis of any new safety trends or signals observed during routine safety surveillance activities

- Report SUSAR / SAE through the AstraZeneca Contract Research Organization Kinapse (astrazeneca@kinapse.com)

- Include the following essential information in SUSAR, Suspected Serious Adverse Reactions and SAE reports provided to AstraZeneca (initial and follow-up):

1. AstraZeneca Reference number

2. Sponsor trial number

3. Centre number

4. Patient trial number

5. Year of birth or age

6. Sex

7. IMP dose, start and stop date

8. AE onset and stop date

9. Event term as reported by the investigator (and/or the CTCAE v5.0 term and grade)

10. Investigator's assessment of seriousness (International Council for Harmonisation definitions)

11. Investigator's assessment of causality

12. SAE Outcome

### **11.7. Urgent safety measures**

If the research team becomes aware of information affecting the risk/benefit balance of the trial they may take immediate action to ensure patient safety. Urgent safety measures deemed necessary must be reported immediately by telephone to the MHRA (in conjunction with the Sponsor) and to the Main REC for the trial, and must be followed within three days by notice in writing setting out the reasons for the urgent safety measures and the plan for further action. The REC co-ordinator will acknowledge within 30 days.

### **11.8. Serious breaches of protocol**

A serious breach is a breach which is likely to effect to a significant degree either:

- The safety or physical or mental integrity of the subjects of the trial

- The scientific value of the trial

Serious breaches of GCP, the trial protocol and the Clinical Trial Authorisation will be reported to the Sponsor QA office within 24 hours from the time the research team becomes aware of the incident. A member of the research team must complete form 'CTT20: UoL/LTHT CTIMP Protocol Deviations, Violations and Potential GCP Breaches' and email it to [leedsth-tr.sponsorqa@nhs.net](mailto:leedsth-tr.sponsorqa@nhs.net).

### **11.9. Other breaches of protocol**

Although minor non-compliances from the protocol do not need to be reported to the MHRA as a serious breach, only the Sponsor QA office are permitted to make this assessment. A member of the research team must complete form 'CTT20: UoL/LTHT CTIMP Protocol Deviations, Violations and Potential GCP Breaches' and email it to [leedsth-tr.sponsorqa@nhs.net](mailto:leedsth-tr.sponsorqa@nhs.net) within 24 hours of discovery.

If the research team have any doubt or uncertainty if what they have identified is a suspected serious breach, it must be discussed with the Sponsor QA office without delay, in accordance with Sponsor QA guidance and Standard Operating Procedure.

### **11.10. Laboratory measurements**

The laboratory staff will have access to a laboratory manual which will provide detailed descriptions of collection, preparation and labelling requirements for all laboratory samples for the study.

#### **Blood**

A maximum of 70 ml of blood will be collected at each study visit. The blood will be drawn into a combination of tubes, according to the planned experiments. After collection, blood samples will be analysed immediately or processed for serum and plasma and stored at -80°C in freezers at the WTBB SJUH for future biomarker and pharmacokinetic analyses, respectively.

Sample labels containing appropriate identification information will be provided.

The blood measurements to be collected in this study include T2DM-specific (HbA1c and lipids) and AZD4017-related (FBC, LFT, eGFR, U+E, thyroid and adrenal function) safety measures as presented in Table 2.

#### **Urine**

24 hour urine samples will be collected by the participant and brought in to appropriate study visits (see section 10). Samples will be aliquoted and stored at -80°C in the WTBB SJUH.

#### **Skin biopsies**

For 11 $\beta$ -HSD1 activity: sample will be placed in 1ml assay media and stored at room temperature until all participants for that day have been processed. Samples will be assayed overnight by incubating at 37°C with 200nM cortisone and ~1500cpm of [3H] cortisone. After 24 hours, tissue will be weighed and destroyed and media will be stored frozen. At the end of the trial, samples will be thawed to RT (an aliquot of 50 $\mu$ l will be retained for cortisol Enzyme Linked Immunosorbent Assay following manufacturer's recommendation) and steroids will be extracted from the media by vortexing with 3ml dichloromethane. The aqueous layer will be aspirated and the dichloromethane evaporated under air at 60°C. Dried steroids will be resuspended in 40 $\mu$ l dichloromethane, spotted onto aluminium-silica plates with 2 $\mu$ l 10mM cortisone/cortisol standards and separated by thin layer chromatography in a 186:14ml chloroform: ethanol mobile phase for 90min. Steroids are visualised under UV, marked, excised and extracted in scintillation fluid overnight. Following detection by scintillation, the % conversion of cortisol from cortisone is calculated and expressed as pmol/mg tissue/h. In the event of radioassay failure, Enzyme Linked Immunosorbent Assay data will be used for the calculation.

For RNA-seq: sample will be snap-frozen and stored at -80°C in freezers at the WTBB SJUH until batch processing to RNA after all samples have been collected.

Table 2. Summary of laboratory measurements. For more details please consult Section 9.2.2.5 and the IB

Measurement (day)	Screening (-7 to -2)	Visit 1 (0)	Visit 2 (2)	Visit 3 (7)	Visit 4 (28)	Visit 5 (30)	Visit 6 (35)	Follow-up (>42)
Blood HbA1c, lipids, FBC, LFT, eGFR, U+E, adrenal and thyroid (and CK at screening)	X	X		X	X		X	X
Blood plasma for AZD4017 detection					X			
Blood serum and plasma for biobank (2 each)		X					X	
24 hour urine samples		X					X	
Skin biopsies		X			X			

### 11.11. Other safety measurements

Not applicable

### 11.12. Annual reports

An annual report describing the general progress and any relevant safety data related to the trial must be submitted to the Main REC, MHRA and the Sponsor on the anniversary of the Clinical Trial Authorisation being granted. The annual report will follow the format of a Developmental Safety Update Report. A template and guidance for the completion of this report is available from the Sponsor office. The CI must review and sign/date the report. Any findings in the Developmental Safety Update Report that are inconsistent with the IB should be communicated to AstraZeneca during report production but at the latest in parallel to the report being sent to the regulatory authorities. The production of any Developmental Safety Update Report with no new safety concerns should be confirmed in writing to the AstraZeneca operational representative.

### **11.13. End of trial report**

A declaration of end of trial form must be submitted to the MHRA within 90 days of the end of the trial (or 15 days for a premature termination). Upon completing the trial, as defined in section 6.4.4, an end of trial report must be submitted to the MHRA within one year of the end of the trial by the Sponsor or Sponsor-delegated individual. A copy of this end of trial report will also be supplied to all support departments involved in the study, for example pharmacy and or radiology. The CI must review and sign/date the report. AstraZeneca require an unblinded listing of SAE and Suspected Serious Adverse Reactions to enable unblinding of these events on the AZ safety database. For convenience and completeness SUSAR should also be included and easily identifiable. This will be provided to AstraZeneca at 'clean file' (when all study queries have been answered and the database is locked) at the following time points:

1. At primary analysis
2. After last patient has completed study treatment

For all safety reporting communications with AstraZeneca the AstraZeneca reference number ESR-16-12321 and IMP name should be included in email headers and emails should be sent in an encrypted file e.g. WinZip.

## **12. STUDY MANAGEMENT AND ADMINISTRATION**

### **12.1. Training of study site personnel**

All Investigators will have completed GCP training within 2 years prior to study commencement. All procedures included in this study are already conducted at the Leeds sites as part of other on-going studies. Staff contributing to the study will be invited to a launch meeting to be briefed on the study background, objectives, eligibility criteria, procedures and safety protocols.

### **12.2. Good clinical practice and regulatory compliance**

This clinical trial, which involves the use of an IMP has been designed and will be run in accordance with the Principles of GCP and the current regulatory requirements, as detailed in the Medicines for Human Use (Clinical Trials) Regulations 2004 (UK S.I. 2004/1031) and any subsequent amendments of the clinical trial regulations.

### **12.3. Adherence to protocol**

The Investigators will not deviate from the protocol. In medical emergencies, the CI may use his medical judgment and may remove a study participant from immediate hazard before notifying the Sponsor, the MHRA and the REC in writing regarding the type of emergency and the course of action taken.

### **12.4. Monitoring, audit and inspection**

The Sponsor reserves the right to audit any site involved in the trial and authorisation for this is given via the study contract or agreement. A site may be audited, by LIRMM, an independent contractor working for LIRMM or may be subject to inspection by the MHRA in order to ensure compliance with International Conference on Harmonisation (ICH)-GCP, and the Scientific Lead will allow direct access to trial documentation.

#### **12.4.1. Procedures for monitoring subject compliance**

The administration of all study medication (including IMP) will be recorded in the appropriate sections of the CRF.

The administration of all study medication will be recorded directly into the CRF as the expected number of tablets remaining, the actual number of tablets remaining, the overall percentage compliance  $((140 - (\text{actual number of doses remaining} - \text{expected number of tablets remaining})) / 140) * 100$  and the cumulative percentage compliance  $(1 - ((\text{actual number of tablets remaining} - \text{expected number of tablets remaining}) / (\text{visit day} \times 4))) * 100$  at Visits 2-6. Any missed tablets will be documented in the medical notes, along with reasons for the missed tablets.

Percentage Diary Card completion will also be recorded in the CRF (number of doses recorded divided by the total available number of doses and multiplied by 100) along with a copy of the Diary Card. Diary Card originals will be stored in the TMF.

#### **12.4.2. Definition of source data**

Source documents are original records in which raw data are first recorded. These may include, e.g. hospital/clinic/general practitioner records, charts, diaries, laboratory results, printouts, pharmacy records, care records, ECG or other printouts. Source documents will be kept in a secure, limited access area.

Some data will be recorded directly in the CRF and will not appear in a source document as defined in the Source Data Location Sheet (e.g. BMI, BP, waist-hip ratio).

Source documents that are computer-generated and stored electronically will if possible/practical be printed for review by the monitor. Once printed, these copies will be signed and dated by the Scientific Lead or CI where appropriate and become a permanent part of the subject's source documents.

The Scientific Lead will authorize the monitor to compare the content of the print out and the data stored in the computer to ensure all data are consistent. If electronically stored and impractical to print, each timely review of the electronically-stored data will be annotated in the patient's notes.

#### **12.4.3. Source data verification**

Source data verification ensures accuracy and credibility of the data obtained. During monitoring, reported data are reviewed with regard to being accurate, complete, and verifiable from source documents (e.g. subject files, recordings from automated instruments, ECG tracings, laboratory notes). All data reported on the CRF will be supported by source documents, unless otherwise specified in section 12.4.2. Data Verification and will be carried out by the Scientific Lead and members of the study team who will check the CRF for completeness and clarity, and crosscheck them with source documents.

#### **12.4.4. Quality assurance**

Investigators will promptly notify the Sponsor Quality Assurance Office of the following within the required timeframe:

- Serious breaches of GCP
- Urgent safety measures
- Protocol violations
- Any amendments to the trial
- Any changes the Clinical Trial Risk Assessment (form A).
- Any other issues as stated in the study contract or agreement

#### **12.4.5. Trial oversight**

#### **12.4.6. Data monitoring, ethics and trial steering committee**

Independent oversight of the study will be conducted by the Independent Data Monitoring, Ethics and Trial Steering Committee. Amongst its members will be an independent chair, a lay individual (from the Leeds Musculoskeletal Biomedical Research Unit Public and Patient Advocacy Group), a clinician who is independent of the study research team, and a representative of the LIRMM study management group. They are expected to meet at least quarterly. A copy of the Independent Data Monitoring, Ethics and Trial Steering Committee minutes will be forwarded to the Sponsor QA office for review.

The daily running of the trial will be co-ordinated by Dr Tiganescu who will lead the Trial Management Group (also comprising of Dr Ajjan, Dr Del Galdo and Dr Tahrani).

## 12.5. Data handling

### 12.5.1. CRF completion

The research team is responsible for prompt reporting of accurate, complete, and legible data in the CRFs and in all required reports. Any change or correction to the paper CRF will be dated, initialled, and explained (if necessary) and will not obscure the original entry. Use of correction fluid is not permitted. The Scientific Lead will maintain a list of personnel authorized to enter data into the CRF. Detailed instructions will be provided in the CRF Instructions.

### 12.5.2. Database entry and reconciliation

CRF/external electronic data will be captured on an electronic spreadsheet, accessible only to the CI and delegated personnel and stored on a secure server with regular backups. Periodic manual reviews will be conducted to check for discrepancies and to ensure consistency with CRF/external electronic data. Upon completion, the database will be locked for editing and subjected to final data inspection as recommended by the Data Management Committee before analysis.

### 12.5.3. Screening and enrolment logs

Subject's Screening will be recorded in the Subject Screening Log.

The Scientific Lead will keep a list containing all subjects enrolled into the study. This list remains with the Scientific Lead and is used for unambiguous identification of each subject. The list contains the subject identification number, full name, date informed consent signed and the hospital number or National Health Security number, if applicable.

The subject's consent and enrolment in the study must be recorded in the subject's medical record. These data will identify the study and document the dates of the subject's participation.

## 12.6. Archiving and data retention

In line with the principles of GCP/UK Clinical Trial Regulations, at the end of the trial, essential documents will be securely archived at each participating centre for a minimum of 15 years. However, because of international regulatory requirements, the Sponsor may request retention for a longer period. Arrangements for confidential destruction will then be made. **If a patient withdraws consent for their data to be used, it will be confidentially destroyed immediately.** No records/study documentation/data may be destroyed without first obtaining written permission from the Sponsor.

Essential documents include (this list is not exhaustive):

- Signed informed consent documents for all subjects
- Subject identification code list\*, screening and enrolment log

- Record of all communications between the CI, the REC and the Sponsor
- Composition of the REC, and the Sponsor (or other applicable statement as described in section 14.6).
- List of sub-Investigators and other appropriately qualified persons to whom the Scientific Lead/CI has delegated significant trial-related duties, together with their roles in the study and their signatures
- Copies of CRF and documentation of corrections for all subjects
- Investigational product accountability records
- Record of any body fluids or tissue samples retained
- All other source documents (subject medical records, hospital records, laboratory records, etc.)
- All other documents as listed in section 8 of the ICH E6 Guideline for GCP (Essential Documents for the Conduct of a Clinical Trial)

\*European Union legislation requires this list to be maintained for a minimum of 15 years.

Normally, these records will be held in the Scientific Lead's archives. If the Scientific Lead is unable to meet this obligation, he or she must ask the Sponsor for permission to make alternative arrangements. Details of these arrangements will be documented.

## **12.7. Study suspension, termination and completion**

Suspension or termination of the study may occur at any time for any reason, following discussion between the Investigators and the Sponsor. In the case of early study termination the Sponsor or Sponsor-delegated individual will be responsible for completing a premature end of study report to the MHRA and the REC within 15 days. Upon study completion, the Sponsor or Sponsor-delegated individual will be responsible for sending the Declaration of the End of a Clinical Trial to the MHRA within 90 days. The Sponsor or Sponsor-delegated individual will be responsible for providing the end of trial report to the MHRA within 1 year of the end of the trial.

## **13. DATA EVALUATION**

### **13.1. Responsibilities**

Data analysis, report preparation and study dissemination will be conducted by the Scientific Lead and other delegated authorised personnel.

### **13.2. Hypotheses**

In this pilot study, analysis will be descriptive throughout and hence no specific inferential hypotheses are being formally tested. We seek preliminary descriptive evidence that:

- Oral AZD4017 inhibits 11 $\beta$ -HSD1 activity in skin
- AZD4017 is safe and well-tolerated in patient with T2DM

- Oral AZD4017 regulates the skin function outcome measures described in this study
- Systemic GC levels and skin 11 $\beta$ -HSD1 activity, independently or in combination correlate with the skin function outcome measures described in this study

### 13.3. General statistical considerations

Unless otherwise specified, the last valid measurement before study medication administration will be utilized as the baseline value. In general, summary statistics [n (number of available measurements), arithmetic mean, standard deviation, median, minimum, and maximum] for quantitative variables and absolute and relative frequency tables for qualitative data will be presented.

Wherever possible the trial will be reported in accordance with the recommendations of the Consolidated Standards of Reporting Trials statement.

An initial blind review of the data will be completed prior to locking the database to identify patients to be excluded from per-protocol analysis.

### 13.4. Planned analyses

#### 13.4.1. Primary endpoint analysis

Skin 11 $\beta$ -HSD1 activity will be summarized descriptively in each treatment group at each time-point; the primary analysis will be on an intention-to-treat basis, will all patients included, as randomised. This will be supplemented by a per-protocol analysis that includes patients whose compliance with protocol is deemed satisfactory. Unadjusted and adjusted summaries (adjusted for gender, age and baseline HbA1c) for absolute values and changes from baseline will be presented; between-group differences in absolute values and changes from baseline will be presented together with 90% confidence intervals – deemed acceptable for pilot studies [65]. Adjusted summaries will be obtained via a linear regression model which mirrors analysis of covariance. Where necessary, transformations to a normal distribution will be performed. Preliminary proof-of-concept will be considered to have been achieved if adjusted mean 11 $\beta$ -HSD1 activity in skin at 28 days is lower in the active treatment arm compared to the placebo arm. Estimated sample sizes for future trials will be produced based on the pooled standard deviations from both treatment arms for the following outcomes: 11 $\beta$ -HSD1 activity in skin (at baseline and 28 days), sudomotor function, skin hydration, epidermal barrier function (at baseline and 35 days), integrity (at baseline and 28 days) and recovery (at baseline and 28 days – 3 hour, 2 day and 7 day), skin thickness (at baseline and 35 days) and wound healing (at baseline and 28 days – 2 day and 7 day). Sample sizes for a range of plausible and clinically-meaningful between-group differences will be presented, assuming analysis of covariance controlling for baseline values would be used. Correlation (Pearson's  $r$ ) between baseline and follow-up values will be estimated in the combined treatment groups to aid in the sample size estimates. If the

correlation between the measurements at the two time-points is  $\rho$ , ANCOVA comparing groups of  $(1-\rho^2)n$  subjects has the same power as a t-test comparing groups of  $n$  subjects.

### **13.4.2. Secondary endpoint analyses**

#### **13.4.2.1. Efficacy**

Systemic 11 $\beta$ -HSD1 activity and skin function analyses will be conducted as for the primary endpoint (above). The strength of association between skin AZD4017 at day 28 concentration and plasma AZD4017 at day 35 in the active treatment arm will be assessed using Pearson's product moment correlation coefficient; for severely skewed variables for which a suitable transformation cannot be found, Spearman rank correlation will be used. For all correlation analyses, absolute correlation coefficients with a value of  $r(\rho) \geq 0.3$  will be considered preliminary evidence of substantive association.

#### **13.4.2.2. Safety**

Safety analyses will be conducted in all patients who received any study treatment, according to treatment received. Continuous safety variables (BMI, waist-hip ratio, BP, HbA1c levels, lipids, FBC, LFT, eGFR, U+E, adrenal and thyroid function test) will be summarized descriptively by patient group at each timepoint. Unadjusted and adjusted summaries (adjusted for gender, age and baseline HbA1c) for absolute values and changes from baseline will be presented; between-group differences in absolute values and changes from baseline will be presented together with 90% confidence intervals. Adjusted summaries will be obtained via a linear regression model which mirrors analysis of covariance. Where necessary, transformations to a normal distribution will be performed. Where applicable, numbers of patients in each group whose values exceeded ULN (or were below the lower limit of normal) during the trial will be presented, corrected for exposure by 100 patient years.

Line listings of all AEs will be provided in the end of trial report. The frequency of all AE during the study period will be presented for each treatment group separately within classes of AEs defined by CTCAE preferred term. The data will be displayed as number of subjects experiencing the AE, percentage of subjects, and number of AE. AE will also be summarized by severity and relation to IMP. For recurrent AEs, the most severe occurrence will be recorded per AE per patient. AE data will also be corrected for exposure by 100 patient-years. For expected AEs the recorded rates will be compared against the rates outlined in the IB.

In addition to the above, the proportions of patients who passed the overall assessment of blood safety will be summarised using absolute and relative frequencies at each visit, in all patients and by treatment group at days 0, 7, 28, 35 & 42.

No inferential testing will be conducted; safety will be assessed in terms of the clinical relevance of the AEs reported and of any observed differences between groups.

### **13.4.3. Skin function**

The strengths of associations among systemic GC level, skin 11 $\beta$ -HSD1 activity and skin outcome measures will be assessed using Pearson's product moment correlation or, where a bivariate association needs to adjust for a third variable, partial correlation. For severely skewed variables for which a suitable transformation cannot be found, Spearman rank correlation will be used.

### **13.4.4. Feasibility**

Feasibility variables will be summarised descriptively in all patients. They will be interpreted in terms of whether sufficient data were obtained to determine feasibility and if so, whether the data obtained indicate that a larger phase II trial is feasible and what adjustments to protocol, if any, may be needed.

## **13.5. Safety analyses**

See section 13.4.2.2

## **13.6. Definition of 'per protocol' set**

In addition to an intention-to-treat analysis including all patients, a supplemental 'per protocol' analysis (including only those who adhered to the treatment regimen of the programme they were allocated, did not violate the trial protocol in any substantial way, and have data available) will be performed. Prior to unblinding of the study, patients will be allocated to or excluded from the 'per protocol' set by a panel including the clinical project manager, trial statistician, and other appropriate clinical study team members.

## **13.7. Handling of dropouts and missing data**

The level of missing data is one of the feasibility endpoints of this trial. Effective means of imputation such as multiple imputation may prove impractical if the sample size is too small for the imputation model to converge successfully. If multiple imputation cannot be performed, available case analysis will be used, supplemented by last-observation-carried forward single imputation as a sensitivity analysis. Multiple imputation by chained equations will be attempted, using multiple regression as the imputation model. If multiple imputation is viable, both available case and LOCF will be performed as sensitivity analyses.

## **13.8. Planned interim analysis and data monitoring**

In this small study with short follow-up no formal interim efficacy analysis is planned. Data monitoring will be carried out during the trial by the study management team and the sponsor (see section 12.4). Interim safety monitoring will be conducted by the study Data Management and Ethics Committee. The DMEC independent statistician will obtain the randomisation list from pharmacy and will code this as treatment A or B before passing to the trial statistician. The trial statistician will produce both open (blinded) and closed

(unblinded) reports for the DMEC, the latter using the treatment codes. Only safety data values will be presented by treatment group; data completeness will be summarised for all secondary variables and for biopsy success. Feasibility data will also be presented. The primary outcome will not be available for interim analysis as this will not be calculated until after the final patient completes follow-up. The trial statistician will not be present when closed reports are discussed by the DMEC with knowledge of the codebreak, which will be supplied to committee members by the DMEC independent statistician. The DMEC will examine at least one set of interim safety data after the first 8 patients have completed the trial up to day 35 (or have been withdrawn); timings of subsequent analyses will be informed by the findings of the first analysis.

There will be a blind review of the data after the last patient has completed follow-up.

### **13.9. Determination of sample size and randomization method**

Sample size is small as this is a preliminary pilot study and the first use in this patient group. Published rules of thumb for pilot studies recommend a sample size of 12 participants per arm completing the protocol [66]. To ensure this minimum number complete the protocol we will randomise 15 per arm to allow for 20% drop-out.

### **13.10. Procedure for unblinding the study prior to analysis**

The final database is not to be locked or unblinded until a review of the data has been completed, the per protocol sample identified, and the statistical analysis plan has been finalised. The dates of each of these milestones will be recorded in the study documentation prior to the full unblinding of the data.

## **14. ETHICS AND REGULATORY REQUIREMENTS**

### **14.1. Good Clinical Practice**

This study will be conducted in accordance with applicable laws and regulations including, but not limited to, the ICH Guideline for GCP and the recommendations guiding ethical research involving human subjects adopted by the 18th World Medical Assembly, Helsinki, Finland, 1964, amended at the 48<sup>th</sup> General Assembly, Somerset West Republic of South Africa, October 1996. The REC and MHRA must review and approve the protocol and Informed Consent Form before any subjects are enrolled. Before any protocol-required procedures are performed, the subject must sign and date the REC-approved Informed Consent Form. The right of a patient to refuse participation without giving reasons must be respected. The patient must remain free to withdraw at any time from the study without giving reasons and without prejudicing his/her further treatment. The study will be submitted to and approved by a Main REC and the appropriate regulatory authorities prior to entering patients into the study.

## 14.2. Delegation of Investigator duties

The Investigators will ensure that all persons assisting with the trial are adequately qualified and informed about the protocol, any amendments to the protocol, the study treatments, and their trial-related duties and functions.

The Scientific Lead will maintain a delegation log of co-Investigators and other appropriately qualified persons to whom he or she has delegated significant trial-related duties.

## 14.3. Subject information and informed consent

Before being enrolled in the clinical study, subjects must consent to participate after the nature, scope, and possible consequences of the clinical study have been explained in a form understandable to them.

A PIL that includes information about the study will be prepared and given to the subject at least 24 hours prior to the screening visit. This document will contain all the elements required by the ICH E6 Guideline for GCP and any additional elements required by local regulations. The document must be translated (by an independent interpreter) into a language understandable to the subject and must specify who informed the subject. Where required by local law, the person who informs the subject must be a physician.

During verification of eligibility, patients will be given the opportunity to ask questions and the nature and objectives of the study will be explained. A research nurse may help in this process but the study doctor is responsible for the General Informed Consent discussions at the Screening Visit. The Skin Biopsy Informed Consent at Visits 1 and 4 can be received by a qualified member of staff who has signed/dated the staff delegation log (i.e. study doctor or research nurse).

After reading the informed consent document, the subject must give consent in writing. The subject's consent must be confirmed at the time of consent by the personally dated signature of the subject and by the personally dated signature of the person conducting the informed consent discussions, (i.e. the study doctor for General Informed Consent or qualified research nurse for Skin Biopsy Informed Consent).

The original signed Informed Consent Form will be retained in the TMF. Other copies of the consent form are required:

- One copy will be kept in the patient's clinical notes
- One copy will be given to the patient

Consent is an ongoing process and will be reassessed at each study visit.

The Scientific Lead will not undertake any measures specifically required only for the clinical study until valid consent has been obtained.

The CI must inform the subject's GP about the subject's participation in the trial if the subject has a GP and if the subject agrees to the GP being informed.

#### **14.4. Subject confidentiality**

Only the subject enrolment number will be recorded in the CRF, and if the subject name appears on any other document (e.g. laboratory report), it must be obliterated on the copy of the document to be supplied to anyone outside the clinical care team. The subjects will be informed that representatives of the Sponsor, REC or regulatory authorities may inspect their medical records to verify the information collected, and that all personal information made available for inspection will be handled in strictest confidence.

All information collected during the course of the trial will be kept strictly confidential.

Information will be held securely on paper and electronically.

The Diabetes Clinic at SJUH and LMBRU at CAH will comply with all aspects of the Data Protection Act 1998.

The Scientific Lead will maintain a personal subject identification list (subject numbers with the corresponding subject names) to enable records to be identified.

#### **14.5. Subject identification cards**

All patients who receive at least one dose of study medication will be issued with identification cards which state the name of the IMP and an indication of the possibility that the patient may be receiving placebo or control treatment, in addition to details of whom to contact in the event of an emergency.

#### **14.6. Approval of clinical study protocol and amendments**

Before the start of the study, the clinical study protocol, informed consent document, and any other appropriate documents will be submitted to the REC, the MHRA and the Sponsor with a cover letter or a form listing the documents submitted, their dates of issue, and the site (or region or area of jurisdiction, as applicable) for which approval is sought. If applicable, the documents will also be submitted to the authorities, in accordance with local legal requirements.

Investigational products can only be supplied to the Sponsor after documentation on all ethical and legal requirements for starting the study has been received by the product provider.

Before the first subject is enrolled in the study, all ethical and legal requirements must be met, including approval of the study by the NHS, the Sponsor Research and Development department, the REC and the MHRA.

Amendments must be evaluated to determine whether formal approval must be sought and whether the informed consent document should be revised, thus all protocol amendments and administrative changes must first be discussed with and approved by the Sponsor before being submitted to the REC and the MHRA, in accordance with legal requirements.

The Scientific Lead must keep a record of all communication with the REC, the MHRA, and the Sponsor. This also applies to any communication between the Scientific Lead and the authorities.

#### **14.7. Protocol amendments**

Requests for any amendments to the study must be sent to the Sponsor by the Scientific Lead. The Sponsor will determine whether said amendments are substantial or non-substantial prior to their submission to the appropriate bodies for approval. Patients will be re-consented to the study if the amendments affect the information they have received, patient safety, or if the change alters the type or quality of the data collected for the study. Patients will only be re-consented AFTER an amendment has been fully approved.

#### **14.8. Ongoing information for MHRA/REC**

Unless otherwise instructed by the MHRA, REC and the Sponsor, the Scientific Lead must submit to the MHRA, REC and the Sponsor:

- Information on SUSAR from the CI's site, as soon as possible and within 24 hours (one business day) of the research team becoming aware of them
- Expedited safety reports, as soon as possible
- Annual reports on the progress of the study
- The Declaration of the End of a Trial form

### **15. FINANCE AND INSURANCE**

#### **15.1. Indemnity and insurance**

The University of Leeds is able to provide insurance to cover for liabilities and prospective liabilities arising from negligent harm. In certain circumstances we provide insurance cover for claims arising from non-negligent harm. Clinical negligence indemnification will rest with the participating NHS Trust or Trusts under standard NHS arrangements.

Further details of liability and insurance provisions for this study are given in separate agreements.

#### **15.2. Financial disclosure**

None of the Investigators or members of the research team have any financial involvement with the sponsorship or funding bodies or will receive personal benefits, incentives or payment over and above normal salary.

### **16. PUBLICATION**

According to the GC-SHealD Research Collaboration Agreement with AstraZeneca, the University of Leeds and its employees, students and agents shall be entitled to publish the results of, or make presentations related to, this study to the extent that such publications or presentations are consistent with academic standards, are not false or misleading, and are not for commercial purposes, subject to the following:

The University of Leeds shall provide, or shall ensure that the Scientific Lead provides, AstraZeneca with copies of any materials relating to the study, study data or the developed technologies that it either intends to publish (or submit for publication, including, but not limited to, materials to be posted on clinical trial registries) or make any presentations relating to, at least forty five days in advance of publication, submission or presentation.

## 17. REFERENCES

1. Sen, C.K., et al., *Human skin wounds: a major and snowballing threat to public health and the economy*. *Wound Repair Regen*, 2009. **17**(6): p. 763-71.
2. Gottrup, F., et al., *Outcomes in controlled and comparative studies on non-healing wounds: recommendations to improve the quality of evidence in wound management*. *J Wound Care*, 2010. **19**(6): p. 237-68.
3. Vowden, K.R. and P. Vowden, *A survey of wound care provision within one English health care district*. *J Tissue Viability*, 2009. **18**(1): p. 2-6.
4. Vowden, K., P. Vowden, and J. Posnett, *The resource costs of wound care in Bradford and Airedale primary care trust in the UK*. *J Wound Care*, 2009. **18**(3): p. 93-4, 96-8, 100 passim.
5. Hex, N., et al., *Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs*. *Diabet Med*, 2012. **29**(7): p. 855-62.
6. Sowers, J.R. and H.R. Lippman, *Cushing's syndrome due to ectopic ACTH production: cutaneous manifestations*. *Cutis*, 1985. **36**(4): p. 351-2, 354.
7. Autio, P., et al., *Systemic glucocorticoids decrease the synthesis of type I and type III collagen in human skin in vivo, whereas isotretinoin treatment has little effect*. *Br J Dermatol*, 1994. **131**(5): p. 660-3.
8. Werth, V.P., et al., *Lack of correlation of skin thickness with bone density in patients receiving chronic glucocorticoid*. *Arch Dermatol Res*, 1998. **290**(7): p. 388-93.
9. Korting, H.C., et al., *Different skin thinning potential of equipotent medium-strength glucocorticoids*. *Skin Pharmacol Appl Skin Physiol*, 2002. **15**(2): p. 85-91.
10. Nuutinen, P., et al., *Modulation of collagen synthesis and mRNA by continuous and intermittent use of topical hydrocortisone in human skin*. *Br J Dermatol*, 2003. **148**(1): p. 39-45.

11. Lee, B., et al., *From an enhanceosome to a repressosome: molecular antagonism between glucocorticoids and EGF leads to inhibition of wound healing*. J Mol Biol, 2005. **345**(5): p. 1083-97.
12. Schoepe, S., et al., *Glucocorticoid therapy-induced skin atrophy*. Exp Dermatol, 2006. **15**(6): p. 406-20.
13. Aberg, K.M., et al., *Psychological stress downregulates epidermal antimicrobial peptide expression and increases severity of cutaneous infections in mice*. J Clin Invest, 2007. **117**(11): p. 3339-49.
14. Lee, S.E., et al., *11beta-hydroxysteroid dehydrogenase type 1 is expressed in human sebaceous glands and regulates glucocorticoid-induced lipid synthesis and toll-like receptor 2 expression in SZ95 sebocytes*. Br J Dermatol, 2013. **168**(1): p. 47-55.
15. Albuquerque, R.G., et al., *Could adult female acne be associated with modern life?* Arch Dermatol Res, 2014. **306**(8): p. 683-8.
16. Roy, S., et al., *Wound site neutrophil transcriptome in response to psychological stress in young men*. Gene Expr, 2005. **12**(4-6): p. 273-87.
17. Marucha, P.T., J.K. Kiecolt-Glaser, and M. Favagehi, *Mucosal wound healing is impaired by examination stress*. Psychosom Med, 1998. **60**(3): p. 362-5.
18. Morgan, S.A., et al., *11beta-HSD1 is the major regulator of the tissue-specific effects of circulating glucocorticoid excess*. Proc Natl Acad Sci U S A, 2014. **111**(24): p. E2482-91.
19. Tiganescu, A., et al., *11beta-Hydroxysteroid dehydrogenase blockade prevents age-induced skin structure and function defects*. J Clin Invest, 2013. **123**(7): p. 3051-60.
20. Tiganescu, A., et al., *Localization, age- and site-dependent expression, and regulation of 11beta-hydroxysteroid dehydrogenase type 1 in skin*. J Invest Dermatol, 2011. **131**(1): p. 30-6.

21. Hirasawa, G., et al., *Colocalization of 11 beta-hydroxysteroid dehydrogenase type II and mineralocorticoid receptor in human epithelia*. J Clin Endocrinol Metab, 1997. **82**(11): p. 3859-63.
22. Tiganeşcu, A., et al., *Increased glucocorticoid activation during mouse skin wound healing*. J Endocrinol, 2014. **221**(1): p. 51-61.
23. Terao, M., et al., *11beta-Hydroxysteroid dehydrogenase-1 is a novel regulator of skin homeostasis and a candidate target for promoting tissue repair*. PLoS One, 2011. **6**(9): p. e25039.
24. Youm, J.K., et al., *Local blockade of glucocorticoid activation reverses stress- and glucocorticoid-induced delays in cutaneous wound healing*. Wound Repair Regen, 2013. **21**(5): p. 715-22.
25. Chapman, K.E., et al., *Changing glucocorticoid action: 11beta-hydroxysteroid dehydrogenase type 1 in acute and chronic inflammation*. J Steroid Biochem Mol Biol, 2013. **137**: p. 82-92.
26. Itoi, S., et al., *11beta-Hydroxysteroid dehydrogenase 1 contributes to the pro-inflammatory response of keratinocytes*. Biochem Biophys Res Commun, 2013. **440**(2): p. 265-70.
27. Ignatova, I.D., et al., *Tumor necrosis factor-alpha upregulates 11beta-hydroxysteroid dehydrogenase type 1 expression by CCAAT/enhancer binding protein-beta in HepG2 cells*. Am J Physiol Endocrinol Metab, 2009. **296**(2): p. E367-77.
28. Bitar, M.S., *Glucocorticoid dynamics and impaired wound healing in diabetes mellitus*. Am J Pathol, 1998. **152**(2): p. 547-54.
29. Steptoe, A., et al., *Disruption of multisystem responses to stress in type 2 diabetes: Investigating the dynamics of allostatic load*. Proc Natl Acad Sci U S A, 2014. **111**(44): p. 15693-8.
30. Kaur, K., et al., *Synergistic induction of local glucocorticoid generation by inflammatory cytokines and glucocorticoids: implications for inflammation associated bone loss*. Ann Rheum Dis, 2010. **69**(6): p. 1185-90.
31. Gathercole, L.L., et al., *11beta-Hydroxysteroid dehydrogenase 1: translational and therapeutic aspects*. Endocr Rev, 2013. **34**(4): p. 525-55.

32. Rosenstock, J., et al., *The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy.* Diabetes Care, 2010. **33**(7): p. 1516-22.
33. Feig, P.U., et al., *Effects of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome.* Diabetes Obes Metab, 2011. **13**(6): p. 498-504.
34. Shah, S., et al., *Efficacy and safety of the selective 11beta-HSD-1 inhibitors MK-0736 and MK-0916 in overweight and obese patients with hypertension.* J Am Soc Hypertens, 2011. **5**(3): p. 166-76.
35. Syngle, A., et al., *Minocycline improves peripheral and autonomic neuropathy in type 2 diabetes: MIND study.* Neurol Sci, 2014. **35**(7): p. 1067-73.
36. Roh, N.K., et al., *A Split-Face Study of the Effects of a Stabilized Hyaluronic Acid-Based Gel of Nonanimal Origin for Facial Skin Rejuvenation Using a Stamp-Type Multineedle Injector: A Randomized Clinical Trial.* Plast Reconstr Surg, 2016. **137**(3): p. 809-16.
37. Wanitphakdeedecha, R., S. Eimpunth, and W. Manuskiatti, *The effects of mucopolysaccharide polysulphate on hydration and elasticity of human skin.* Dermatol Res Pract, 2011. **2011**: p. 807906.
38. Kennedy, W.R., et al., *A randomized, controlled, open-label study of the long-term effects of NGX-4010, a high-concentration capsaicin patch, on epidermal nerve fiber density and sensory function in healthy volunteers.* J Pain, 2010. **11**(6): p. 579-87.
39. Gibbons, C.H., N. Wang, and R. Freeman, *Capsaicin induces degeneration of cutaneous autonomic nerve fibers.* Ann Neurol, 2010. **68**(6): p. 888-98.
40. Boyd, A.L., et al., *Topiramate improves neurovascular function, epidermal nerve fiber morphology, and metabolism in patients*

- with type 2 diabetes mellitus. Diabetes Metab Syndr Obes, 2010. 3: p. 431-7.*
41. Casellini, C.M., et al., *Sudoscans, a noninvasive tool for detecting diabetic small fiber neuropathy and autonomic dysfunction. Diabetes Technol Ther, 2013. 15(11): p. 948-53.*
  42. Seite, S., et al., *Importance of treatment of skin xerosis in diabetes. J Eur Acad Dermatol Venereol, 2011. 25(5): p. 607-9.*
  43. Tahrani, A.A., et al., *Cutaneous structural and biochemical correlates of foot complications in high-risk diabetes. Diabetes Care, 2012. 35(9): p. 1913-8.*
  44. Dinh, T., et al., *Mechanisms involved in the development and healing of diabetic foot ulceration. Diabetes, 2012. 61(11): p. 2937-47.*
  45. Jiang, Y., et al., *A cohort study of diabetic patients and diabetic foot ulceration patients in China. Wound Repair Regen, 2015. 23(2): p. 222-30.*
  46. Gershater, M.A., et al., *Complexity of factors related to outcome of neuropathic and neuroischaemic/ischaemic diabetic foot ulcers: a cohort study. Diabetologia, 2009. 52(3): p. 398-407.*
  47. Prompers, L., et al., *Prediction of outcome in individuals with diabetic foot ulcers: focus on the differences between individuals with and without peripheral arterial disease. The EURODIAB Study. Diabetologia, 2008. 51(5): p. 747-55.*
  48. Vinik, A.I., M.L. Nevoret, and C. Casellini, *The New Age of Sudomotor Function Testing: A Sensitive and Specific Biomarker for Diagnosis, Estimation of Severity, Monitoring Progression, and Regression in Response to Intervention. Front Endocrinol (Lausanne), 2015. 6: p. 94.*
  49. Kim, H.J., et al., *Pseudoceramide-containing physiological lipid mixture reduces adverse effects of topical steroids. Allergy Asthma Immunol Res, 2011. 3(2): p. 96-102.*
  50. Sheu, H.M., et al., *Depletion of stratum corneum intercellular lipid lamellae and barrier function abnormalities after long-*

- term topical corticosteroids.* Br J Dermatol, 1997. **136**(6): p. 884-90.
51. Altemus, M., et al., *Stress-induced changes in skin barrier function in healthy women.* J Invest Dermatol, 2001. **117**(2): p. 309-17.
  52. Lin, T.K., et al., *Paradoxical benefits of psychological stress in inflammatory dermatoses models are glucocorticoid mediated.* J Invest Dermatol, 2014. **134**(12): p. 2890-7.
  53. Kao, J.S., et al., *Short-term glucocorticoid treatment compromises both permeability barrier homeostasis and stratum corneum integrity: inhibition of epidermal lipid synthesis accounts for functional abnormalities.* J Invest Dermatol, 2003. **120**(3): p. 456-64.
  54. Denda, M., et al., *Stress alters cutaneous permeability barrier homeostasis.* Am J Physiol Regul Integr Comp Physiol, 2000. **278**(2): p. R367-72.
  55. Hong, S.P., et al., *Topical calcitriol restores the impairment of epidermal permeability and antimicrobial barriers induced by corticosteroids.* Br J Dermatol, 2010. **162**(6): p. 1251-60.
  56. Choi, E.H., et al., *Mechanisms by which psychologic stress alters cutaneous permeability barrier homeostasis and stratum corneum integrity.* J Invest Dermatol, 2005. **124**(3): p. 587-95.
  57. Kolbe, L., et al., *Corticosteroid-induced atrophy and barrier impairment measured by non-invasive methods in human skin.* Skin Res Technol, 2001. **7**(2): p. 73-7.
  58. Aschoff, R., et al., *Evaluation of the atrophogenic potential of hydrocortisone 1% cream and pimecrolimus 1% cream in uninvolved forehead skin of patients with atopic dermatitis using optical coherence tomography.* Exp Dermatol, 2011. **20**(10): p. 832-6.
  59. Holmes, C.J., et al., *Dynamic Role of Host Stress Responses in Modulating the Cutaneous Microbiome: Implications for Wound Healing and Infection.* Adv Wound Care (New Rochelle), 2015. **4**(1): p. 24-37.

60. Bugge, C., et al., *A process for Decision-making after Pilot and feasibility Trials (ADePT): development following a feasibility study of a complex intervention for pelvic organ prolapse*. *Trials*, 2013. **14**: p. 353.
61. Eldridge, S.M., et al., *CONSORT 2010 statement: extension to randomised pilot and feasibility trials*. *BMJ*, 2016. **355**: p. i5239.
62. Price, G.M., et al., *Weight, shape, and mortality risk in older persons: elevated waist-hip ratio, not high body mass index, is associated with a greater risk of death*. *Am J Clin Nutr*, 2006. **84**(2): p. 449-60.
63. Greaves, N.S., et al., *Optical coherence tomography: a reliable alternative to invasive histological assessment of acute wound healing in human skin?* *Br J Dermatol*, 2014. **170**(4): p. 840-50.
64. Abignano, G., et al., *Virtual skin biopsy by optical coherence tomography: the first quantitative imaging biomarker for scleroderma*. *Ann Rheum Dis*, 2013. **72**(11): p. 1845-51.
65. Lee, E.C., et al., *The statistical interpretation of pilot trials: should significance thresholds be reconsidered?* *Bmc Medical Research Methodology*, 2014. **14**.
66. Julious, S.A., *Sample size of 12 per group rule of thumb for a pilot study*. *Pharmaceutical Statistics*, 2005. **4**(4): p. 287-291.

## Supplementary S3 – Statistical Methods

### 1.1 Primary outcome analysis

For the primary variable (24-hour 11 $\beta$ -HSD1 activity in skin at day 28), unadjusted and adjusted summaries (adjusted for gender, age, baseline 11 $\beta$ -HSD1 activity, and baseline HbA1c) for final values and changes from baseline are presented. Between-group differences in final values and changes from baseline are presented with two-sided 90% CIs, supplemented with CIs ranging from 75% to 95% in 5% increments as prespecified in the statistical analysis plan (SAP). Adjusted differences favoring the intervention arm (i.e., if 11 $\beta$ -HSD1 activity is lower) were considered preliminary evidence of efficacy.

Because model residuals were not normally distributed and a suitable data transformation could not be found, quantile (median) regression was used to obtain adjusted summaries and CIs, as prespecified in the SAP.

The primary analysis was on an intention-to-treat basis, with all patients included, as randomized. Analysis was conducted in the full analysis set using multiple imputation by chained equations to address missing data. Five-nearest-neighbor predictive mean matching was used for all variables; for each outcome, the imputation model included the repeated observations of the outcome, treatment assignment, age, sex, baseline HbA1c, and overall IMP compliance. Variables that correlated with the outcome or the likelihood of missingness and variables that had fewer missing values at a given time point were also included. Twenty datasets were imputed; inspection of Monte Carlo errors indicated that 20 were sufficient. Estimates were combined according to Rubin's rules. Sensitivity analyses using available case and last observation carried forward were also performed. A planned sensitivity analysis in the per-protocol set was not performed (see Section 1.7 below).

## **1.2 Secondary outcome analysis**

The secondary endpoints, systemic 11 $\beta$ -HSD1 activity and skin function, and continuous clinical laboratory safety variables were analyzed in the same ways as the primary endpoints. Adjusted summaries were obtained using a linear regression model that mirrored the analysis of covariance approach for wound healing and laboratory safety variables. For all other variables, visual inspection of linear regression model residuals indicated that they were not normally distributed. For TEWL and epidermal integrity, log-transformation was performed before linear regression. For the remaining outcomes, for which log-transformation did not render normally-distributed linear regression model residuals, quantile (median) regression was used.

Planned supplementary analyses used linear mixed modelling to allow the precise timing of measurements to be included as a covariate where relevant and to account for any differences in timings between groups. Likelihood ratio tests supported the inclusion of non-linear (quadratic) terms for change over time and supported allowance of changes over time to vary between patients.

The standalone SAP pre-specified that in the event that there was not proof-of-concept for the primary outcome, effects on secondary outcomes would be interpreted with reference to the measured effects on systemic, as opposed to skin, 11 $\beta$ -HSD1 activity. If both showed a potential difference between groups, this would be considered preliminary evidence of efficacy. However, without evidence of a substantive difference in 11 $\beta$ -HSD1 activity either systemically or in the skin, any apparent substantive differences in secondary outcomes were to be interpreted with caution.

## **1.3 Additional pre-planned analyses**

Correlations between plasma AZD4017 concentration at day 35 and skin AZD4017 concentration at day 28 and between AZD4017 compliance and efficacy outcomes in the active treatment arm were estimated using Spearman rank correlation.

We measured the strengths of associations between skin 11 $\beta$ -HSD1 activity and skin outcome measures while controlling for systemic GC level using partial correlation after rank transformation. Correlation coefficients were transformed using Fisher's z transformation before averaging across multiple imputed datasets. For all correlation analyses, absolute correlation coefficients with a value of  $r(\rho)$  greater than 0.3 were considered preliminary evidence of substantive association.

The numbers of patients with clinical laboratory values below, within, or above normal ranges before the intervention and at each post-intervention time point were tabulated for each test for the safety population by treatment group. The proportions of patients who passed the overall assessment of blood safety at days 0, 7, 28, 35, 42 were summarized.

For AEs, summaries of incidence rates (frequencies and percentages), intensity, and relationship to study drug of individual AEs by system organ class and preferred term are presented.

Feasibility variables were summarized descriptively.

Estimates of sample sizes for future trials were based on the pooled SDs from both treatment arms for the following outcomes: 11 $\beta$ -HSD1 activity in skin (at 28 days); sudomotor function, skin hydration, epidermal barrier function, integrity (at 28 days), and recovery (TEWL at 3 hours, 2 days, and 7 days after disruption by repeat tape stripping at 28 days); skin thickness (at 35 days); and WH (maximal early granulation tissue width at 2 days and maximal blood clot depth at 7 days after biopsy at 28 days).

#### **1.4 Changes in the Conduct of the Study or Planned Analyses**

### ***Recruitment halted early***

Study recruitment was intended to continue until a total of 30 participants had been randomized to ensure recruitment of at least 12 per group, as recommended for pilot studies, with a 20% dropout rate. The recruitment period was extended twice. At the end of the second extension, 28 patients had been recruited, and the dropout rate, at less than 5%, was lower than expected. Therefore, we decided to halt recruitment rather than extend it further, which would have increased the risk of delaying the reporting of the trial results and the planning of future trials based on these results. This decision was made without reference to the primary outcome measure, whose results had not yet been processed, and before the breaking of the blind.

### ***Primary outcome unit of measurement***

After the completion of the study and final database lock, the primary outcome was found to have been calculated as percent conversion per *24 hours*, rather than *per hour* as stipulated in the protocol. As this difference in scale affected all values equally and did not affect the conclusions, the sponsor and investigators agreed that the values would not be changed and would be reported as percent conversion per 24 hours.

### ***Validation of primary outcome by ELISA***

In a protocol amendment, validation of the radioimmunoassay method of measuring 11 $\beta$ -HSD1 activity in the skin by a cortisol ELISA was added. This addition was made before the processing of the biopsy samples and the breaking of the blind.

### ***Measurement of wound depth instead of diameter at days 7 and 35***

At 2 days after wounding, maximal early granulation tissue width (a marker of early healing) was prespecified as the standardized indicator of wound diameter. However, the tissue width had reduced to zero in all patients by 7 days after wounding. Therefore, maximal clot depth (a

marker of later healing that was absent at 2 days after wounding) was substituted as the standardized indicator of healing at this time point

### ***Per-protocol analysis***

Only one participant who had withdrawn from follow-up due to work commitments after day 7 was excluded from the per-protocol dataset. Because the per-protocol analysis of each outcome was designed to include only participants in the per-protocol population who had data available for that outcome, the per-protocol analysis was essentially identical to the planned available case sensitivity analysis.

### ***Additional sensitivity analysis of multiply imputed data***

An additional planned sensitivity analysis that would have increased or decreased imputed values in multiples of the baseline SD in the observed data was not performed because of the low level of missing data.

## **1.5 Analysis populations**

### ***Safety population***

The safety population or safety set includes all participants who received any amount of the planned study medication.

### ***Efficacy population***

The efficacy population or full analysis set includes all participants who were randomized and received at least one dose of the planned study medication.

### ***Per-protocol efficacy population***

The per-protocol efficacy population includes all participants in the efficacy population, except for those who met the following criteria:

- Receipt of prohibited prior, concomitant, or prior and concomitant medications
- Failure to meet inclusion or exclusion criteria (i.e., those who entered the study in error)
- Overall compliance with study treatment during the trial less than 80%
- No receipt of study treatment to which they were assigned through randomization
- Withdrawal from study treatment for any reason

For each primary and secondary variable, at each visit, only participants in the per protocol population with data available were to be included in the per protocol analysis.

**Table S1: Full descriptive data for primary and secondary efficacy variables in the full analysis set**

Variable	Summary	Placebo n=14	AZD4017 n=14
<b>Baseline</b>			
11bHSD1 activity radioassay (percent conversion per 24 hours): Day 0	Mean (SD)	15.84 (6.80)	13.73 (6.02)
	Median (Q1, Q3)	15.25 (11.60, 18.40)	10.70 (9.40, 17.40)
	Minimum, maximum	5.20, 29.30	7.80, 25.70
	Nn	14	14
11bHSD1 activity ELISA (percent conversion per 24 hours): Day 0	Mean (SD)	11.04 (8.06)	6.56 (3.38)
	Median (Q1, Q3)	6.80 (5.50, 15.60)	6.45 (4.20, 8.50)
	Minimum, maximum	3.00, 26.90	1.40, 13.60
	Nn	14	14
Sudomotor function Left Hand ( $\mu$ S): Day 0	Mean (SD)	54.14 (15.04)	56.43 (17.49)
	Median (Q1, Q3)	54.00 (47.00, 63.00)	57.50 (39.00, 71.00)
	Minimum, maximum	18.00, 75.00	30.00, 81.00
	Nn	14	14
Sudomotor function Right Hand ( $\mu$ S): Day 0	Mean (SD)	51.43 (15.91)	54.29 (16.99)
	Median (Q1, Q3)	54.00 (47.00, 60.00)	56.50 (41.00, 67.00)
	Minimum, maximum	16.00, 73.00	22.00, 80.00
	Nn	14	14
Sudomotor function Hands ( $\mu$ S): Day 0	Mean (SD)	52.79 (15.20)	55.36 (17.13)
	Median (Q1, Q3)	53.75 (48.00, 60.50)	56.75 (40.00, 70.50)
	Minimum, maximum	17.00, 74.00	26.00, 80.50

Variable	Summary	Placebo	AZD4017
		n=14	n=14
	Nn	14	14
Sudomotor function Left Foot ( $\mu$ S): Day 0	Mean (SD)	63.29 (17.18)	73.93 (15.62)
	Median (Q1, Q3)	65.50 (46.00, 78.00)	79.00 (63.00, 84.00)
	Minimum, maximum	38.00, 87.00	34.00, 92.00
	Nn	14	14
Sudomotor function Right Foot ( $\mu$ S): Day 0	Mean (SD)	63.57 (18.00)	71.36 (18.94)
	Median (Q1, Q3)	69.50 (48.00, 79.00)	77.00 (69.00, 82.00)
	Minimum, maximum	37.00, 87.00	14.00, 88.00
	Nn	14	14
Sudomotor function Feet ( $\mu$ S): Day 0	Mean (SD)	63.43 (17.49)	72.64 (17.08)
	Median (Q1, Q3)	67.50 (44.50, 76.50)	78.00 (64.00, 83.50)
	Minimum, maximum	37.50, 87.00	24.00, 90.00
	Nn	14	14
Sudomotor function overall ( $\mu$ S): Day 0	Mean (SD)	58.11 (14.71)	64.00 (15.11)
	Median (Q1, Q3)	61.00 (46.75, 67.75)	66.63 (63.25, 71.25)
	Minimum, maximum	27.25, 80.00	25.00, 84.00
	Nn	14	14
Skin hydration (A.U): Day 0	Mean (SD)	40.88 (7.79)	40.79 (9.19)
	Median (Q1, Q3)	40.47 (34.50, 46.18)	40.35 (36.68, 45.51)
	Minimum, maximum	27.17, 54.06	20.58, 58.68
	Nn	14	14
Epidermal thickness ( $\mu$ m): Day 0	Mean (SD)	61.30 (10.53)	65.96 (9.81)

<b>Variable</b>	<b>Summary</b>	<b>Placebo n=14</b>	<b>AZD4017 n=14</b>
	Median (Q1, Q3)	62.76 (54.51, 69.22)	65.70 (60.74, 69.32)
	Minimum, maximum	37.18, 77.57	44.08, 86.48
	Nn	14	14
Cortisol (mcg/24 hours): Day 0	Mean (SD)	81.50 (49.27)	70.50 (22.24)
	Median (Q1, Q3)	68.50 (40.00, 101.00)	75.50 (48.00, 84.00)
	Minimum, maximum	25.00, 202.00	39.00, 116.00
	Nn	14	14
Urinary [THF+alloTHF]/THE ratio: Day 0	Mean (SD)	1.06 (0.38)	0.91 (0.22)
	Median (Q1, Q3)	0.96 (0.81, 1.23)	0.97 (0.80, 1.06)
	Minimum, maximum	0.50, 1.99	0.45, 1.24
	Nn	14	14
Hour 0 TEWL (Set 1, Day 0)	Mean (SD)	8.96 (3.94)	9.61 (3.73)
	Geometric mean	8.24	9.05
	Median (Q1, Q3)	8.55 (5.10, 10.70)	8.90 (6.80, 11.30)
	Minimum, maximum	4.70, 17.60	5.50, 19.30
	Nn	14	13
Number of tapes required for barrier disruption: Day 0	Mean (SD)	47.14 (15.21)	55.54 (26.52)
	Geometric mean	44.49	50.48
	Median (Q1, Q3)	49.50 (33.00, 60.00)	51.00 (42.00, 58.00)
	Minimum, maximum	19.00, 66.00	22.00, 116.00
	Nn	14	13
<b>Follow-up</b>			

<b>Variable</b>	<b>Summary</b>	<b>Placebo n=14</b>	<b>AZD4017 n=14</b>
11bHSD1 activity radioassay (% conv/24hrs): Day 28	Mean (SD)	12.38 (4.51)	12.58 (5.64)
	Median (Q1, Q3)	12.00 (8.90, 14.50)	12.70 (8.80, 15.60)
	Minimum, maximum	7.10, 23.40	3.40, 21.70
	Nn	13	14
11bHSD1 activity ELISA (% conv/24hrs): Day 28	Mean (SD)	15.27 (37.27)	3.81 (1.78)
	Median (Q1, Q3)	5.60 (1.00, 7.60)	4.30 (3.10, 5.00)
	Minimum, maximum	0.80, 138.70	0.72, 6.50
	Nn	13	14
Sudomotor function Left Hand (μS): Day 35	Mean (SD)	56.46 (11.12)	62.85 (14.35)
	Median (Q1, Q3)	58.00 (48.00, 63.00)	64.00 (59.00, 72.00)
	Minimum, maximum	39.00, 73.00	28.00, 81.00
	Nn	13	13
Sudomotor function Right Hand (μS): Day 35	Mean (SD)	54.08 (13.32)	59.92 (14.79)
	Median (Q1, Q3)	55.00 (51.00, 60.00)	63.00 (57.00, 69.00)
	Minimum, maximum	29.00, 74.00	23.00, 77.00
	Nn	13	13
Sudomotor function Hands (μS): Day 35	Mean (SD)	55.27 (11.97)	61.38 (14.43)
	Median (Q1, Q3)	57.50 (49.50, 61.00)	63.50 (59.00, 70.50)
	Minimum, maximum	35.50, 71.50	25.50, 79.00
	Nn	13	13
Sudomotor function Left Foot (μS): Day 35	Mean (SD)	68.69 (10.91)	70.92 (18.61)
	Median (Q1, Q3)	70.00 (61.00, 76.00)	80.00 (64.00, 82.00)

Variable	Summary	Placebo	AZD4017
		n=14	n=14
	Minimum, maximum	49.00, 85.00	23.00, 88.00
	Nn	13	13
Sudomotor function Right Foot (μS): Day 35	Mean (SD)	69.31 (9.87)	70.31 (21.44)
	Median (Q1, Q3)	65.00 (63.00, 75.00)	80.00 (68.00, 82.00)
	Minimum, maximum	51.00, 85.00	10.00, 85.00
	Nn	13	13
Sudomotor function Feet (μS): Day 35	Mean (SD)	69.00 (10.19)	70.62 (19.92)
	Median (Q1, Q3)	68.50 (62.00, 75.00)	80.00 (66.00, 82.50)
	Minimum, maximum	50.00, 85.00	16.50, 84.50
	Nn	13	13
Sudomotor function Overall (μS): Day 35	Mean (SD)	62.13 (10.01)	66.00 (15.12)
	Median (Q1, Q3)	59.75 (53.75, 68.00)	70.75 (64.50, 73.00)
	Minimum, maximum	49.25, 77.50	21.00, 78.75
	Nn	13	13
Skin hydration (A.U): Day 35	Mean (SD)	38.19 (9.69)	44.82 (10.10)
	Median (Q1, Q3)	40.52 (29.40, 46.04)	45.28 (37.02, 46.53)
	Minimum, maximum	23.74, 52.86	30.53, 69.72
	Nn	12	12
Epidermal thickness (μm): Day 35	Mean (SD)	61.72 (8.35)	66.07 (10.49)
	Median (Q1, Q3)	57.54 (55.69, 67.30)	66.29 (60.57, 74.37)
	Minimum, maximum	51.32, 77.40	49.13, 82.95
	Nn	13	12

<b>Variable</b>	<b>Summary</b>	<b>Placebo n=14</b>	<b>AZD4017 n=14</b>
Cortisol (mcg/24 hours): Day 35	Mean (SD)	81.62 (44.49)	64.08 (22.04)
	Median (Q1, Q3)	55.00 (47.00, 120.00)	62.00 (52.00, 73.00)
	Minimum, maximum	29.00, 164.00	34.00, 124.00
	Nn	13	13
Urinary [THF+alloTHF]/THE ratio: Day 35	Mean (SD)	1.08 (0.36)	0.10 (0.03)
	Median (Q1, Q3)	0.89 (0.88, 1.24)	0.10 (0.08, 0.12)
	Minimum, maximum	0.75, 2.07	0.04, 0.16
	Nn	13	13
Wound gap diameter (mm): Day 2	Mean (SD)	1.49 (0.72)	0.98 (0.70)
	Median (Q1, Q3)	1.64 (1.05, 2.02)	0.88 (0.52, 1.29)
	Minimum, maximum	0.00, 2.51	0.00, 2.42
	Nn	14	14
Wound depth (mm): Day 7	Mean (SD)	0.60 (0.23)	0.59 (0.16)
	Median (Q1, Q3)	0.66 (0.57, 0.77)	0.59 (0.57, 0.68)
	Minimum, maximum	0.00, 0.82	0.27, 0.86
	Nn	14	14
Wound gap diameter (mm): Day 30	Mean (SD)	1.44 (0.70)	0.65 (0.49)
	Median (Q1, Q3)	1.41 (1.14, 1.98)	0.81 (0.25, 0.98)
	Minimum, maximum	0.00, 2.44	0.00, 1.43
	Nn	11	12
Wound depth (mm): Day 35	Mean (SD)	0.60 (0.17)	0.54 (0.21)
	Median (Q1, Q3)	0.63 (0.55, 0.67)	0.54 (0.47, 0.63)

<b>Variable</b>	<b>Summary</b>	<b>Placebo n=14</b>	<b>AZD4017 n=14</b>
	Minimum, maximum	0.27, 0.90	0.19, 0.94
	Nn	13	12
Biopsy AZD4017: Day 28	Mean (SD)	<5.00 (0.00)	1685.07 (914.43)
	Geometric mean	<5.00	1442.44
	Median (Q1, Q3)	<5.00 (<5.00, <5.00)	1570.00 (876.00, 2440.00)
	Minimum, maximum	<5.00, <5.00	443.00, 3310.00
	Nn	13	14
Plasma AZD4017: Day 35	Mean (SD)	<5.00 (0.00)	6992.50 (5303.82)
	Geometric mean	<5.00	5281.66
	Median (Q1, Q3)	<5.00 (<5.00, <5.00)	6490.00 (2960.00, 9040.00)
	Minimum, maximum	<5.00, <5.00	1180.00, 19400.00
	Nn	7	12
Hour 3 TEWL (Set 1; Day 0)	Mean (SD)	36.03 (9.66)	31.68 (8.00)
	Geometric mean	34.94	30.84
	Median (Q1, Q3)	32.50 (29.30, 43.20)	31.50 (26.10, 35.50)
	Minimum, maximum	26.30, 53.80	22.60, 50.70
	Nn	14	12
Hour 48 TEWL (Set 1; Day 2)	Mean (SD)	20.53 (5.64)	22.98 (10.04)
	Geometric mean	19.79	21.29
	Median (Q1, Q3)	19.90 (16.10, 26.00)	21.40 (15.40, 25.80)
	Minimum, maximum	12.40, 29.80	11.40, 47.80
	Nn	14	11

<b>Variable</b>	<b>Summary</b>	<b>Placebo n=14</b>	<b>AZD4017 n=14</b>
Hour 168 TEWL (Set 1; Day 7)	Mean (SD)	13.95 (3.52)	21.22 (18.23)
	Geometric mean	13.55	16.06
	Median (Q1, Q3)	14.90 (11.10, 15.90)	14.50 (9.40, 24.70)
	Minimum, maximum	9.00, 21.10	6.90, 60.60
	Nn	13	13
Hour 3 TEWL (Set 2; Day 28)	Mean (SD)	26.35 (11.63)	31.17 (9.81)
	Geometric mean	23.77	29.83
	Median (Q1, Q3)	27.80 (19.50, 28.60)	32.80 (21.40, 37.40)
	Minimum, maximum	9.00, 52.10	18.70, 54.90
	Nn	13	14
Hour 48 TEWL (Set 2; Day 30)	Mean (SD)	15.65 (5.99)	19.64 (9.12)
	Geometric mean	14.43	18.21
	Median (Q1, Q3)	15.30 (13.20, 19.50)	16.80 (14.90, 19.60)
	Minimum, maximum	6.50, 25.30	11.70, 40.50
	Nn	13	14
Hour 168 TEWL (Set 2; Day 35)	Mean (SD)	10.72 (4.01)	11.72 (4.83)
	Geometric mean	10.02	10.84
	Median (Q1, Q3)	10.50 (8.20, 12.40)	10.40 (8.80, 15.10)
	Minimum, maximum	4.70, 18.20	4.90, 20.40
	Nn	13	12
Hour 0 TEWL (Set 3; Day 35)	Mean (SD)	7.45 (2.82)	9.78 (4.35)
	Geometric mean	6.99	8.87

<b>Variable</b>	<b>Summary</b>	<b>Placebo n=14</b>	<b>AZD4017 n=14</b>
	Median (Q1, Q3)	7.00 (5.40, 9.10)	9.70 (7.70, 12.50)
	Minimum, maximum	3.60, 14.10	4.40, 18.30
	Nn	13	12
Number of tapes required for barrier disruption: Day 28	Mean (SD)	42.85 (19.79)	60.14 (25.72)
	Geometric mean	37.88	55.55
	Median (Q1, Q3)	40.00 (25.00, 54.00)	55.00 (41.00, 70.00)
	Minimum, maximum	11.00, 77.00	30.00, 120.00
	Nn	13	14

Nn, number non-missing; Q1, first quartile; Q3, third quartile.

**Table S2: Full descriptive data for laboratory safety variables in the safety set**

Variable	Summary	Day 0		Day 7		Day 28		Day 35		Day 42	
		Placebo	AZD4017	Placebo	AZD4017	Placebo	AZD4017	Placebo	AZD4017	Placebo	AZD4017
		n=14	n=14	n=14	n=14	n=14	n=14	n=14	n=14	n=14	n=14
Body mass index (kg/m <sup>2</sup> )	Mean (SD)	33.67 (13.47)	35.05 (5.68)					34.07 (14.56)	35.71 (6.43)		
	Median	31.02	34.54					31.35	35.06		
	(Q1, Q3)	(26.52, 33.57)	(30.65, 39.08)					(26.51, 32.93)	(31.38, 38.61)		
	Minimum, maximum	22.59, 75.64	27.04, 46.54					22.85, 77.85	27.35, 51.80		
	Nn	14	14					13	13		
Waist-hip ratio	Mean (SD)	0.98 (0.08)	1.03 (0.08)					0.98 (0.07)	1.02 (0.07)		
	Median	0.98	1.03					0.98	1.01		
	(Q1, Q3)	(0.92, 1.05)	(0.95, 1.10)					(0.91, 1.04)	(0.97, 1.07)		
	Minimum, maximum	0.85, 1.13	0.92, 1.17					0.89, 1.09	0.92, 1.16		
	Nn	14	14					13	13		
Systolic blood pressure (mm Hg)	Mean (SD)	135.71 (21.01)	140.43 (12.02)					143.54 (12.07)	128.62 (11.23)	136.92 (13.12)	137.50 (10.97)
	Median	136.00	140.00					148.00	126.00	137.00	140.00
	(Q1, Q3)	(120.00, 145.00)	(131.00, 150.00)					(140.00, 152.00)	(123.00, 134.00)	(128.00, 146.00)	(129.00, 146.00)
	Minimum, maximum	101.00, 174.00	120.00, 162.00					121.00, 159.00	106.00, 154.00	118.00, 158.00	113.00, 150.00
	Nn	14	14					13	13	13	14
Diastolic blood pressure (mm Hg)	Mean (SD)	83.86 (8.91)	72.64 (9.96)					79.62 (7.11)	73.69 (7.88)	80.00 (10.04)	79.29 (11.36)
	Median	83.00	74.00					80.00	73.00	80.00	77.00

Variable	Summary	Day 0		Day 7		Day 28		Day 35		Day 42	
		Placebo	AZD4017								
		n=14									
	(Q1, Q3)	(77.00, 90.00)	(63.00, 84.00)					(75.00, 84.00)	(70.00, 78.00)	(77.00, 86.00)	(71.00, 89.00)
	Minimum, maximum	68.00, 99.00	60.00, 86.00					67.00, 92.00	61.00, 91.00	59.00, 94.00	60.00, 103.00
	Nn	14	14					13	13	13	14
HbA1c (mmol/mol)	Mean (SD)	72.29 (19.43)	66.00 (14.91)	73.77 (18.09)	64.31 (14.60)	68.92 (17.09)	66.00 (15.66)	70.00 (20.10)	63.67 (16.27)	68.46 (17.76)	65.43 (16.31)
	Median	72.00	64.00	71.00	63.00	67.00	69.00	71.00	68.00	69.00	68.00
	(Q1, Q3)	(54.00, 90.00)	(59.00, 82.00)	(56.00, 90.00)	(57.00, 71.00)	(55.00, 85.00)	(54.00, 81.00)	(49.00, 86.00)	(52.00, 77.00)	(55.00, 81.00)	(53.00, 78.00)
	Minimum, maximum	46.00, 100.00	42.00, 86.00	49.00, 98.00	41.00, 85.00	46.00, 98.00	42.00, 87.00	45.00, 108.00	42.00, 86.00	44.00, 109.00	42.00, 90.00
	Nn	14	14	13	13	13	14	11	12	13	14
High density lipoprotein (mmol/l)	Mean (SD)	1.24 (0.31)	1.19 (0.27)	1.16 (0.29)	1.05 (0.25)	1.22 (0.30)	1.11 (0.25)	1.19 (0.30)	0.98 (0.26)	1.18 (0.36)	1.22 (0.28)
	Median	1.20	1.20	1.10	1.10	1.10	1.10	1.10	0.90	1.20	1.30
	(Q1, Q3)	(1.00, 1.30)	(0.90, 1.40)	(0.90, 1.30)	(0.80, 1.20)	(1.10, 1.30)	(0.80, 1.30)	(1.10, 1.20)	(0.80, 1.10)	(1.00, 1.20)	(0.90, 1.40)
	Minimum, maximum	0.90, 2.00	0.70, 1.60	0.80, 1.80	0.70, 1.40	0.90, 1.90	0.70, 1.40	0.90, 1.90	0.60, 1.40	0.50, 1.80	0.80, 1.70
	Nn	14	14	14	14	13	14	12	12	12	13
Cholesterol (mmol/l)	Mean (SD)	4.36 (1.13)	3.95 (0.75)	4.31 (1.00)	3.59 (0.64)	4.15 (0.91)	3.54 (0.59)	4.17 (0.88)	3.44 (0.64)	4.06 (1.01)	3.81 (0.61)
	Median	4.40	3.90	4.30	3.40	4.10	3.40	4.10	3.40	4.20	3.80
	(Q1, Q3)	(3.60, 4.60)	(3.40, 4.40)	(3.40, 4.50)	(3.20, 4.20)	(3.70, 4.50)	(3.20, 3.70)	(3.80, 4.60)	(3.00, 3.70)	(3.70, 4.40)	(3.40, 4.20)
	Minimum, maximum	3.10, 7.50	2.60, 5.50	3.10, 6.70	2.60, 4.90	2.70, 6.30	2.60, 4.90	2.80, 6.20	2.70, 4.80	2.00, 6.00	2.80, 5.10
	Nn	14	14	14	14	13	14	12	12	12	13
Triglycerides (mmol/l)	Mean (SD)	1.68 (0.74)	2.02 (1.02)	2.11 (0.70)	2.39 (1.58)	1.80 (0.86)	1.71 (0.75)	2.23 (1.02)	2.38 (2.22)	1.63 (0.78)	1.89 (1.31)
	Median	1.60	1.50	2.00	2.00	1.50	1.60	2.00	1.80	1.70	1.60

Variable	Summary	Day 0		Day 7		Day 28		Day 35		Day 42	
		Placebo	AZD4017								
		n=14									
	(Q1, Q3)	(1.10, 1.90)	(1.40, 2.50)	(1.70, 2.70)	(1.70, 2.30)	(1.20, 2.00)	(1.00, 2.00)	(1.60, 2.80)	(1.40, 2.10)	(1.00, 1.90)	(1.20, 2.00)
	Minimum, maximum	1.10, 3.90	1.10, 4.70	0.70, 3.30	1.10, 7.10	1.00, 3.70	1.00, 3.40	0.80, 3.90	0.90, 8.90	0.70, 3.20	0.80, 6.00
	Nn	14	14	14	14	13	14	12	12	12	13
Hemoglobin (g/l)	Mean (SD)	139.21 (14.12)	139.43 (11.35)	136.07 (13.04)	137.43 (10.80)	137.46 (10.11)	138.36 (10.58)	134.42 (12.91)	136.31 (11.50)	135.31 (13.19)	139.86 (13.42)
	Median	138.00	139.00	136.00	135.00	138.00	136.00	133.00	134.00	139.00	140.00
	(Q1, Q3)	(130.00, 146.00)	(130.00, 145.00)	(126.00, 145.00)	(131.00, 144.00)	(132.00, 145.00)	(134.00, 144.00)	(126.00, 144.00)	(129.00, 140.00)	(130.00, 145.00)	(131.00, 145.00)
	Minimum, maximum	112.00, 168.00	121.00, 162.00	115.00, 161.00	122.00, 163.00	113.00, 153.00	124.00, 164.00	110.00, 155.00	122.00, 162.00	106.00, 151.00	117.00, 162.00
	Nn	14	14	14	14	13	14	12	13	13	14
White blood cells (x10 <sup>9</sup> /l)	Mean (SD)	6.46 (2.55)	7.34 (2.04)	6.71 (1.83)	7.97 (2.12)	6.54 (2.11)	6.72 (1.57)	6.69 (1.96)	7.04 (1.94)	6.51 (1.97)	7.66 (2.18)
	Median	6.62	7.36	6.19	8.40	6.44	6.63	7.01	7.09	6.42	7.69
	(Q1, Q3)	(4.59, 8.33)	(6.09, 8.74)	(5.41, 8.00)	(6.47, 9.54)	(5.81, 7.48)	(6.05, 7.43)	(5.06, 7.78)	(5.85, 8.59)	(5.73, 6.82)	(7.00, 8.68)
	Minimum, maximum	2.13, 11.62	3.21, 11.27	4.11, 10.35	3.83, 10.91	2.33, 10.21	3.30, 9.34	3.42, 10.49	3.58, 9.90	3.19, 10.24	3.65, 12.00
	Nn	14	14	14	14	13	14	12	13	13	14
Platelets (x10 <sup>9</sup> /l)	Mean (SD)	218.71 (61.85)	273.14 (81.37)	219.36 (64.89)	275.29 (81.60)	222.69 (59.57)	288.57 (99.85)	215.92 (66.59)	272.69 (85.96)	221.77 (60.01)	281.43 (92.00)
	Median	204.00	264.00	214.00	264.00	190.00	286.00	204.00	260.00	203.00	270.00
	(Q1, Q3)	(171.00, 259.00)	(232.00, 335.00)	(171.00, 264.00)	(223.00, 317.00)	(180.00, 262.00)	(221.00, 331.00)	(171.00, 212.00)	(245.00, 285.00)	(170.00, 254.00)	(205.00, 349.00)
	Minimum, maximum	149.00, 352.00	117.00, 402.00	146.00, 381.00	130.00, 428.00	146.00, 325.00	124.00, 476.00	149.00, 365.00	136.00, 442.00	155.00, 357.00	133.00, 446.00
	Nn	14	14	14	14	13	14	12	13	13	14
Red blood cells (x10 <sup>12</sup> /l)	Mean (SD)	4.84 (0.49)	4.71 (0.48)	4.75 (0.54)	4.59 (0.45)	4.77 (0.39)	4.68 (0.47)	4.66 (0.47)	4.57 (0.44)	4.68 (0.49)	4.77 (0.53)

Variable	Summary	Day 0		Day 7		Day 28		Day 35		Day 42	
		Placebo	AZD4017								
		n=14									
	Median	4.80	4.65	4.79	4.54	4.70	4.65	4.65	4.58	4.55	4.76
	(Q1, Q3)	(4.46, 5.17)	(4.56, 5.05)	(4.27, 5.11)	(4.39, 4.87)	(4.52, 4.89)	(4.44, 4.78)	(4.25, 5.01)	(4.38, 4.81)	(4.41, 4.98)	(4.59, 4.92)
	Minimum, maximum	4.13, 5.78	3.59, 5.68	3.93, 5.66	3.57, 5.53	4.24, 5.62	3.74, 5.60	4.01, 5.42	3.57, 5.43	3.96, 5.53	3.62, 5.97
	Nn	14	14	14	14	13	14	12	13	13	14
Mean corpuscular volume (fl)	Mean (SD)	88.43 (4.64)	91.21 (6.96)	89.71 (4.39)	92.14 (6.77)	88.15 (5.41)	91.21 (6.82)	90.00 (6.30)	92.23 (6.73)	88.08 (4.57)	90.50 (6.10)
	Median	88.00	91.00	90.00	93.00	87.00	91.00	91.00	94.00	88.00	91.00
	(Q1, Q3)	(87.00, 91.00)	(86.00, 95.00)	(89.00, 92.00)	(88.00, 95.00)	(86.00, 92.00)	(84.00, 97.00)	(86.00, 93.00)	(89.00, 95.00)	(85.00, 92.00)	(84.00, 95.00)
	Minimum, maximum	79.00, 97.00	80.00, 107.00	80.00, 98.00	81.00, 105.00	79.00, 98.00	82.00, 105.00	76.00, 99.00	80.00, 104.00	80.00, 96.00	81.00, 101.00
	Nn	14	14	14	14	13	14	12	13	13	14
Hematocrit (packed cell volume)	Mean (SD)	0.43 (0.04)	0.43 (0.03)	0.43 (0.04)	0.42 (0.03)	0.42 (0.03)	0.43 (0.03)	0.42 (0.04)	0.42 (0.04)	0.41 (0.03)	0.43 (0.04)
	Median	0.42	0.43	0.42	0.41	0.41	0.42	0.42	0.41	0.40	0.43
	(Q1, Q3)	(0.40, 0.46)	(0.41, 0.45)	(0.38, 0.46)	(0.40, 0.43)	(0.40, 0.43)	(0.40, 0.45)	(0.39, 0.45)	(0.40, 0.43)	(0.39, 0.45)	(0.40, 0.45)
	Minimum, maximum	0.37, 0.50	0.37, 0.48	0.37, 0.50	0.37, 0.49	0.37, 0.48	0.38, 0.50	0.35, 0.48	0.37, 0.49	0.36, 0.47	0.36, 0.50
	Nn	14	14	14	14	13	14	12	13	13	14
Mean corpuscular hemoglobin (pg)	Mean (SD)	28.82 (2.09)	29.74 (2.47)	28.79 (1.99)	30.13 (2.50)	28.91 (2.07)	29.68 (2.12)	28.93 (2.14)	29.96 (2.56)	28.98 (2.34)	29.42 (2.15)
	Median	28.70	30.00	28.80	30.10	29.60	30.00	29.10	30.10	29.10	29.70
	(Q1, Q3)	(27.70, 29.90)	(27.30, 31.50)	(27.60, 29.90)	(27.70, 32.00)	(27.70, 29.90)	(28.20, 31.10)	(28.00, 30.10)	(27.70, 31.30)	(28.10, 30.70)	(27.70, 30.90)
	Minimum, maximum	23.70, 31.80	25.60, 34.50	24.60, 32.30	26.40, 35.00	24.00, 32.00	26.10, 33.40	23.70, 32.40	26.40, 34.50	23.60, 32.80	26.20, 33.10

Variable	Summary	Day 0		Day 7		Day 28		Day 35		Day 42	
		Placebo	AZD4017								
		n=14									
	Nn	14	14	14	14	13	14	12	13	13	14
Corpuscular hemoglobin concentration (g/l)	Mean (SD)	325.57 (10.43)	326.64 (8.29)	321.07 (11.87)	326.93 (9.03)	328.62 (13.61)	325.79 (7.76)	322.08 (11.20)	325.08 (8.65)	328.85 (15.56)	324.86 (6.69)
	Median	328.00	328.00	321.00	327.00	333.00	326.00	324.00	329.00	333.00	326.00
	(Q1, Q3)	(322.00, 334.00)	(320.00, 332.00)	(311.00, 327.00)	(316.00, 334.00)	(319.00, 337.00)	(321.00, 328.00)	(311.00, 330.00)	(320.00, 330.00)	(320.00, 338.00)	(318.00, 330.00)
	Minimum, maximum	302.00, 337.00	315.00, 345.00	307.00, 343.00	314.00, 344.00	306.00, 347.00	314.00, 344.00	303.00, 337.00	306.00, 334.00	294.00, 350.00	315.00, 336.00
	Nn	14	14	14	14	13	14	12	13	13	14
Red blood cell distribution width (%)	Mean (SD)	13.88 (0.98)	14.12 (1.10)	14.43 (1.29)	14.27 (1.12)	14.02 (0.87)	14.08 (0.82)	14.23 (1.01)	14.44 (0.88)	13.80 (0.98)	13.74 (1.04)
	Median	13.90	13.90	14.50	13.90	13.90	14.00	14.30	14.20	13.90	13.60
	(Q1, Q3)	(13.10, 14.50)	(13.20, 15.30)	(13.90, 14.80)	(13.70, 14.70)	(13.60, 14.30)	(13.80, 14.60)	(13.50, 14.40)	(14.00, 14.90)	(13.10, 14.10)	(13.40, 14.40)
	Minimum, maximum	12.40, 16.00	12.70, 15.80	12.70, 17.70	12.90, 16.80	12.50, 16.00	12.00, 15.30	13.20, 16.60	12.70, 15.90	12.50, 16.30	11.70, 15.70
	Nn	14	14	14	14	13	14	12	13	13	14
Albumin (g/l)	Mean (SD)	39.43 (2.56)	39.50 (2.44)	39.50 (2.53)	40.14 (3.23)	38.85 (2.48)	38.71 (2.89)	39.67 (2.27)	40.00 (3.00)	38.15 (1.95)	38.69 (2.18)
	Median	39.00	40.00	40.00	40.00	39.00	39.00	40.00	39.00	38.00	39.00
	(Q1, Q3)	(38.00, 41.00)	(38.00, 41.00)	(38.00, 41.00)	(38.00, 42.00)	(37.00, 41.00)	(37.00, 40.00)	(38.00, 41.00)	(38.00, 41.00)	(37.00, 40.00)	(36.00, 40.00)
	Minimum, maximum	35.00, 44.00	36.00, 44.00	35.00, 44.00	36.00, 49.00	34.00, 42.00	35.00, 46.00	36.00, 44.00	37.00, 46.00	35.00, 42.00	36.00, 42.00
	Nn	14	14	14	14	13	14	12	13	13	13
Bilirubin (umol/l)	Mean (SD)	8.93 (2.97)	8.14 (2.82)	8.36 (2.17)	8.64 (5.53)	9.69 (3.35)	9.86 (4.49)	8.92 (5.55)	8.54 (3.80)	8.31 (2.14)	8.38 (2.66)
	Median	9.00	8.00	9.00	7.00	10.00	9.00	7.00	8.00	8.00	8.00

Variable	Summary	Day 0		Day 7		Day 28		Day 35		Day 42	
		Placebo	AZD4017	Placebo	AZD4017	Placebo	AZD4017	Placebo	AZD4017	Placebo	AZD4017
		n=14	n=14	n=14	n=14	n=14	n=14	n=14	n=14	n=14	n=14
	(Q1, Q3)	(6.00, 12.00)	(6.00, 9.00)	(7.00, 10.00)	(6.00, 8.00)	(7.00, 11.00)	(7.00, 12.00)	(6.00, 9.00)	(7.00, 10.00)	(7.00, 11.00)	(7.00, 10.00)
	Minimum, maximum	5.00, 14.00	4.00, 14.00	4.00, 12.00	4.00, 24.00	5.00, 16.00	5.00, 22.00	4.00, 24.00	4.00, 19.00	5.00, 11.00	5.00, 13.00
	Nn	14	14	14	14	13	14	12	13	13	13
Alkaline phosphatase	Mean (SD)	80.43 (23.76)	85.07 (26.08)	80.86 (27.04)	80.14 (26.38)	77.31 (21.55)	68.93 (23.03)	79.58 (21.21)	66.15 (21.10)	76.85 (25.66)	78.62 (30.06)
	(U/l)										
	Median	77.00	88.00	72.00	79.00	72.00	70.00	76.00	69.00	69.00	79.00
	(Q1, Q3)	(65.00, 95.00)	(64.00, 106.00)	(66.00, 96.00)	(57.00, 102.00)	(64.00, 86.00)	(55.00, 80.00)	(71.00, 86.00)	(55.00, 75.00)	(65.00, 77.00)	(61.00, 91.00)
	Minimum, maximum	50.00, 145.00	37.00, 123.00	49.00, 147.00	38.00, 122.00	51.00, 129.00	29.00, 114.00	47.00, 130.00	27.00, 100.00	50.00, 145.00	33.00, 152.00
	Nn	14	14	14	14	13	14	12	13	13	13
Alanine aminotransferase	Mean (SD)	24.64 (7.10)	27.43 (10.91)	22.93 (6.83)	26.14 (9.72)	22.69 (6.59)	23.07 (9.39)	21.67 (6.36)	21.15 (10.36)	21.15 (6.40)	24.31 (10.86)
	(iu/l)										
	Median	25.00	25.00	23.00	25.00	20.00	22.00	21.00	18.00	19.00	22.00
	(Q1, Q3)	(19.00, 31.00)	(20.00, 33.00)	(19.00, 30.00)	(21.00, 27.00)	(19.00, 28.00)	(16.00, 30.00)	(18.00, 25.00)	(15.00, 23.00)	(18.00, 24.00)	(15.00, 29.00)
	Minimum, maximum	15.00, 36.00	15.00, 51.00	12.00, 34.00	14.00, 53.00	12.00, 33.00	11.00, 41.00	14.00, 33.00	10.00, 46.00	12.00, 34.00	13.00, 45.00
	Nn	14	14	14	14	13	14	12	13	13	13
Aspartate	Mean (SD)	21.00 (4.95)	22.64 (5.50)	21.07 (5.93)	22.36 (3.99)	20.77 (4.17)	21.36 (2.68)	20.92 (3.85)	20.67 (2.93)	19.00 (5.70)	22.18 (3.76)
	aminotransferase (iu/l)										
	Median	21.00	22.00	20.00	22.00	21.00	21.00	20.00	21.00	20.00	22.00
	(Q1, Q3)	(19.00, 22.00)	(19.00, 26.00)	(17.00, 24.00)	(19.00, 24.00)	(19.00, 23.00)	(19.00, 23.00)	(19.00, 21.00)	(19.00, 23.00)	(16.00, 20.00)	(21.00, 23.00)
	Minimum, maximum	14.00, 32.00	14.00, 36.00	14.00, 36.00	18.00, 30.00	14.00, 28.00	18.00, 27.00	15.00, 30.00	16.00, 25.00	12.00, 34.00	15.00, 30.00
	Nn	14	14	14	14	13	14	12	12	12	11

Variable	Summary	Day 0		Day 7		Day 28		Day 35		Day 42	
		Placebo	AZD4017								
		n=14									
Gamma-glutamyl transpeptidase (iu/l)	Mean (SD)	41.86 (33.87)	39.29 (29.87)	39.71 (32.51)	37.71 (30.94)	42.46 (31.59)	29.86 (21.31)	43.67 (36.88)	23.92 (15.94)	41.23 (33.38)	29.23 (20.66)
	Median	37.00	29.00	37.00	22.00	34.00	21.00	41.00	19.00	40.00	24.00
	(Q1, Q3)	(21.00, 45.00)	(21.00, 43.00)	(19.00, 46.00)	(20.00, 46.00)	(22.00, 58.00)	(17.00, 33.00)	(19.00, 47.00)	(15.00, 24.00)	(22.00, 42.00)	(18.00, 35.00)
	Minimum, maximum	13.00, 145.00	16.00, 127.00	12.00, 143.00	13.00, 129.00	16.00, 133.00	14.00, 94.00	15.00, 147.00	10.00, 71.00	15.00, 143.00	6.00, 89.00
	Nn	14	14	14	14	13	14	12	13	13	13
eGFR (ml/min/1.73 m <sup>2</sup> )	Mean (SD)	81.86 (9.69)	79.21 (13.59)	77.50 (12.37)	71.50 (15.24)	79.77 (11.13)	75.14 (14.09)	76.83 (15.91)	73.31 (16.69)	77.46 (11.60)	76.21 (14.73)
	Median	87.00	85.00	78.00	70.00	83.00	72.00	78.00	69.00	78.00	77.00
	(Q1, Q3)	(76.00, 90.00)	(70.00, 90.00)	(67.00, 90.00)	(55.00, 88.00)	(71.00, 90.00)	(67.00, 90.00)	(73.00, 90.00)	(62.00, 90.00)	(67.00, 90.00)	(69.00, 90.00)
	Minimum, maximum	61.00, 90.00	54.00, 90.00	55.00, 90.00	47.00, 90.00	58.00, 90.00	51.00, 90.00	39.00, 90.00	47.00, 90.00	59.00, 90.00	42.00, 90.00
	Nn	14	14	14	14	13	14	12	13	13	14
Sodium (mmol/l)	Mean (SD)	138.93 (2.06)	140.71 (5.47)	139.29 (2.30)	140.00 (2.48)	138.15 (1.82)	138.79 (2.15)	140.25 (3.47)	139.31 (1.89)	138.92 (2.02)	138.00 (2.15)
	Median	139.00	140.00	139.00	140.00	138.00	139.00	140.00	139.00	139.00	138.00
	(Q1, Q3)	(137.00, 140.00)	(137.00, 142.00)	(138.00, 142.00)	(139.00, 141.00)	(137.00, 139.00)	(137.00, 140.00)	(138.00, 142.00)	(138.00, 140.00)	(138.00, 140.00)	(137.00, 139.00)
	Minimum, maximum	136.00, 143.00	136.00, 158.00	135.00, 143.00	136.00, 144.00	135.00, 141.00	134.00, 142.00	136.00, 148.00	136.00, 143.00	135.00, 142.00	134.00, 142.00
	Nn	14	14	14	14	13	14	12	13	13	14
Potassium (mmol/l)	Mean (SD)	4.46 (0.33)	4.63 (0.41)	4.79 (0.55)	4.59 (0.37)	4.49 (0.31)	4.74 (0.41)	4.48 (0.43)	4.52 (0.28)	4.65 (0.45)	4.63 (0.33)
	Median	4.40	4.60	4.70	4.60	4.60	4.70	4.50	4.50	4.70	4.70
	(Q1, Q3)	(4.20, 4.70)	(4.40, 4.80)	(4.50, 5.00)	(4.30, 4.90)	(4.40, 4.70)	(4.40, 5.10)	(4.30, 4.80)	(4.30, 4.60)	(4.20, 4.90)	(4.60, 4.70)
	Minimum, maximum	3.90, 5.10	3.90, 5.50	3.70, 5.70	4.10, 5.30	3.80, 4.90	4.20, 5.40	3.50, 5.00	4.20, 5.10	3.90, 5.50	4.10, 5.10

Variable	Summary	Day 0		Day 7		Day 28		Day 35		Day 42	
		Placebo	AZD4017	Placebo	AZD4017	Placebo	AZD4017	Placebo	AZD4017	Placebo	AZD4017
		n=14	n=14	n=14	n=14	n=14	n=14	n=14	n=14	n=14	n=14
	Nn	14	14	14	14	13	14	12	13	13	12
Urea (mmol/l)	Mean (SD)	6.96 (2.81)	7.25 (2.17)	6.91 (2.72)	7.24 (1.89)	6.79 (3.85)	6.56 (1.80)	7.67 (5.13)	7.60 (2.72)	7.07 (2.98)	7.57 (2.72)
	Median	6.70	6.40	6.40	6.60	5.80	6.60	6.30	8.50	6.80	7.30
	(Q1, Q3)	(5.20, 7.30)	(5.90, 8.70)	(5.10, 8.90)	(5.60, 9.20)	(4.90, 6.80)	(5.30, 7.90)	(5.80, 7.40)	(5.60, 9.30)	(5.50, 7.30)	(6.10, 8.30)
	Minimum, maximum	3.90, 14.90	3.90, 11.00	2.60, 12.30	4.90, 10.60	3.10, 18.60	3.80, 9.50	2.70, 23.10	3.70, 13.30	3.00, 14.70	3.90, 15.40
	Nn	14	14	14	14	13	14	12	13	13	14
Creatinine (umol/l)	Mean (SD)	76.64 (15.36)	76.21 (20.04)	82.36 (17.90)	88.57 (22.57)	79.08 (16.81)	80.93 (19.07)	84.42 (24.67)	84.69 (21.53)	82.08 (16.96)	79.93 (17.93)
	Median	77.00	76.00	82.00	84.00	81.00	75.00	81.00	74.00	82.00	75.00
	(Q1, Q3)	(66.00, 88.00)	(60.00, 94.00)	(70.00, 97.00)	(71.00, 102.00)	(69.00, 93.00)	(67.00, 93.00)	(70.00, 87.00)	(72.00, 101.00)	(66.00, 96.00)	(70.00, 95.00)
	Minimum, maximum	49.00, 101.00	51.00, 115.00	55.00, 114.00	61.00, 129.00	55.00, 106.00	54.00, 120.00	55.00, 148.00	59.00, 125.00	59.00, 110.00	56.00, 111.00
	Nn	14	14	14	14	13	14	12	13	13	14
Testosterone (nmol/l)	Mean (SD)	11.10 (6.25)	6.97 (5.48)	10.34 (7.47)	6.43 (4.94)	11.72 (6.75)	6.46 (5.01)	10.17 (7.94)	6.03 (5.08)	10.12 (6.47)	7.66 (6.43)
	Median	10.10	8.00	10.70	7.00	11.50	6.70	9.30	5.00	9.70	8.10
	(Q1, Q3)	(8.00, 16.80)	(0.80, 11.40)	(6.20, 13.70)	(1.40, 9.90)	(8.50, 14.70)	(1.00, 10.30)	(8.00, 10.60)	(1.00, 10.00)	(6.90, 13.80)	(0.70, 12.30)
	Minimum, maximum	0.60, 22.00	0.40, 15.00	0.50, 27.50	0.70, 14.90	0.60, 27.20	0.80, 14.20	0.50, 31.50	0.60, 13.50	0.40, 25.00	0.60, 18.30
	Nn	14	14	14	14	12	14	12	13	13	14
Dehydroepiandrosterone sulphate (umol/l)	Mean (SD)	3.53 (2.19)	2.91 (1.69)	3.56 (2.36)	4.91 (3.53)	3.03 (1.86)	5.35 (2.76)	3.49 (1.90)	5.03 (3.22)	2.82 (1.70)	3.55 (2.16)
	Median	2.90	2.50	3.60	3.50	3.20	5.30	3.80	4.60	2.70	3.40
	(Q1, Q3)	(1.00, 5.00)	(1.90, 3.40)	(1.00, 5.30)	(2.90, 5.50)	(1.20, 4.60)	(3.40, 6.70)	(2.30, 4.90)	(2.90, 5.40)	(1.10, 3.40)	(2.00, 4.30)
	Minimum, maximum	1.00, 7.30	1.00, 7.90	1.00, 8.00	1.00, 14.70	1.00, 6.20	1.50, 11.60	1.00, 6.40	1.60, 12.60	1.00, 6.30	1.10, 9.70

Variable	Summary	Day 0		Day 7		Day 28		Day 35		Day 42	
		Placebo	AZD4017								
		n=14									
	Nn	14	14	14	14	13	14	12	13	13	14
Free thyroxine (pmol/l)	Mean (SD)	14.86 (2.20)	15.73 (1.58)	14.63 (1.72)	15.70 (2.53)	14.66 (1.61)	15.72 (1.92)	14.46 (1.43)	15.39 (1.98)	13.94 (1.47)	15.10 (1.49)
	Median	15.20	15.20	14.70	15.50	14.60	16.20	14.60	14.80	14.00	15.10
	(Q1, Q3)	(13.10, 16.40)	(14.80, 16.50)	(13.20, 15.30)	(13.90, 16.80)	(13.40, 15.60)	(14.30, 17.30)	(13.50, 14.90)	(14.40, 17.60)	(12.60, 15.00)	(13.80, 16.10)
	Minimum, maximum	11.20, 18.80	14.00, 20.00	12.10, 18.50	12.20, 21.50	12.60, 17.30	13.10, 19.00	12.70, 17.90	12.30, 18.40	12.10, 16.60	13.00, 18.80
	Nn	14	14	14	13	12	12	12	13	13	14
Thyroid-stimulating hormone (mIU/l)	Mean (SD)	1.74 (0.66)	1.72 (0.63)	1.68 (0.56)	1.88 (0.76)	1.91 (0.84)	1.76 (0.81)	1.76 (0.75)	1.72 (0.64)	1.79 (0.71)	1.76 (0.93)
	Median	1.40	1.60	1.60	1.70	1.70	1.60	1.60	1.60	1.70	1.60
	(Q1, Q3)	(1.30, 2.40)	(1.20, 2.10)	(1.30, 2.00)	(1.30, 2.00)	(1.20, 2.40)	(1.30, 2.10)	(1.20, 2.00)	(1.50, 1.90)	(1.30, 2.10)	(1.40, 2.10)
	Minimum, maximum	0.78, 2.80	0.94, 3.30	0.95, 2.90	0.97, 3.70	1.10, 3.50	0.68, 3.70	0.98, 3.40	0.62, 3.10	0.81, 3.00	0.51, 3.90
	Nn	14	14	14	13	12	12	12	13	13	14

**Table S3: Study treatment (placebo or AZD4017) compliance in the full analysis set**

Definition	Summary	Day 2		Day 7		Day 28		Day 30		Day 35	
		Placebo	AZD4017	Placebo	AZD4017	Placebo	AZD4017	Placebo	AZD4017	Placebo	AZD4017
		n=14	n=14	n=14	n=14	n=14	n=14	n=14	n=14	n=14	n=14
Percent	Mean (SD)	>99 (1)	>99 (1)	99 (1)	99 (2)	99 (3)	98 (2)	97 (6)	99 (2)	98 (5)	98 (2)
	Median (Q1, Q3)	100 (100, 100)	100 (100, 100)	100 (99, 100)	100 (98, 100)	99 (98, 100)	99 (97, 100)	99 (98, 100)	99 (98, 100)	100 (98, 100)	99 (97, 100)
	Minimum, maximum	97, 101	98, 100	96, 101	94, 101	91, 101	94, 100	81, 101	94, 101	84, 101	93, 101
	Nn	13	10	13	14	12	13	13	11	12	14
Cumulative percent	Mean (SD)	95 (17)	96 (12)	97 (7)	96 (10)	98 (3)	98 (2)	97 (6)	98 (2)	98 (5)	98 (2)
	Median (Q1, Q3)	100 (100, 100)	100 (100, 100)	100 (96, 100)	100 (89, 100)	99 (97, 100)	98 (96, 100)	99 (98, 100)	98 (98, 100)	100 (98, 100)	99 (97, 100)
	Minimum, maximum	50, 125	63, 100	79, 107	71, 107	89, 102	93, 100	78, 102	93, 101	84, 101	93, 101
	Nn	13	10	13	14	12	13	13	11	12	14

Nn, number non-missing; Q1, first quartile; Q3, third quartile.

**Table S4: Primary and secondary efficacy outcomes; unadjusted differences in final values between treatment groups in the full analysis set**

Multiple imputation was used to address missing data. For TEWL, integrity, wound depth and diameter, linear regression was used to estimate CIs around differences between the groups. TEWL and integrity measurements were log-transformed before analysis; differences are expressed as ratios of geometric means (AZD4017:placebo). For the remaining variables, which did not meet assumptions for linear regression, median regression was used.

Variable	Median*		Difference*	Confidence interval*				
	Placebo	AZD4017		75%	80%	85%	90%	95%
	n=14	n=14						
11bHSD1 activity radioassay (percent conversion per 24 hours): Day 28	12.18	12.70	0.52	(-2.85, 3.90)	(-3.25, 4.30)	(-3.73, 4.78)	(-4.37, 5.42)	(-5.38, 6.43)
11bHSD1 activity ELISA (percent conversion per 24 hours): Day 28	5.84	4.30	-1.54	(-3.58, 0.49)	(-3.82, 0.73)	(-4.12, 1.03)	(-4.50, 1.41)	(-5.12, 2.03)
Sudomotor function Left Hand (µS): Day 35	58.00	63.15	5.15	(-2.52, 12.82)	(-3.42, 13.72)	(-4.52, 14.82)	(-5.98, 16.28)	(-8.28, 18.58)
Sudomotor function Right Hand (µS): Day 35	54.80	62.60	7.80	(0.35, 15.25)	(-0.53, 16.13)	(-1.60, 17.20)	(-3.02, 18.62)	(-5.26, 20.86)
Sudomotor function Hands (µS): Day 35	57.02	62.80	5.78	(-2.14, 13.69)	(-3.08, 14.63)	(-4.22, 15.77)	(-5.73, 17.28)	(-8.11, 19.66)
Sudomotor function Left Foot (µS): Day 35	69.40	76.20	6.80	(-1.72, 15.32)	(-2.73, 16.33)	(-3.95, 17.55)	(-5.57, 19.17)	(-8.13, 21.73)
Sudomotor function Right Foot (µS): Day 35	70.10	79.05	8.95	(0.86, 17.04)	(-0.10, 18.00)	(-1.27, 19.17)	(-2.82, 20.72)	(-5.27, 23.17)
Sudomotor function Feet (µS): Day 35	69.95	79.53	9.57	(1.75, 17.40)	(0.83, 18.32)	(-0.29, 19.44)	(-1.78, 20.93)	(-4.12, 23.27)
Sudomotor function Overall (µS): Day 35	62.48	70.58	8.10	(1.07, 15.13)	(0.24, 15.96)	(-0.77, 16.97)	(-2.11, 18.31)	(-4.22, 20.42)
Skin hydration (A.U): Day 35	40.17	45.39	5.22	(-0.64, 11.07)	(-1.33, 11.76)	(-2.17, 12.60)	(-3.29, 13.72)	(-5.05, 15.48)
Epidermal thickness (µm): Day 35	60.32	66.94	6.62	(-1.16, 14.41)	(-2.09, 15.34)	(-3.23, 16.47)	(-4.74, 17.99)	(-7.16, 20.40)

Cortisol (mcg/24 hours): Day 35	63.25	62.40	-0.85	(-28.55, 26.85)	(-31.96, 30.26)	(-36.19, 34.49)	(-41.91, 40.21)	(-51.28, 49.58)
Urinary [THF+alloTHF]/THE ratio: Day 35	0.91	0.10	-0.81	(-0.90, -0.72)	(-0.91, -0.70)	(-0.92, -0.69)	(-0.94, -0.67)	(-0.97, -0.64)
<b>Variable</b>	<b>Mean*</b>		<b>Difference*</b>		<b>Confidence interval*</b>			
	Placebo	AZD4017		75%	80%	85%	90%	95%
	n=14	n=14						
Wound gap diameter (mm): Day 2	1.49	0.98	-0.51	(-0.83, -0.20)	(-0.87, -0.16)	(-0.91, -0.11)	(-0.97, -0.05)	(-1.07, 0.04)
Wound depth (mm): Day 7	0.60	0.59	-0.01	(-0.10, 0.08)	(-0.11, 0.09)	(-0.12, 0.10)	(-0.14, 0.12)	(-0.17, 0.15)
Wound gap diameter (mm): Day 30	1.38	0.67	-0.71	(-1.02, -0.39)	(-1.06, -0.35)	(-1.10, -0.31)	(-1.16, -0.25)	(-1.26, -0.15)
Wound depth (mm): Day 35	0.61	0.54	-0.06	(-0.15, 0.02)	(-0.16, 0.04)	(-0.17, 0.05)	(-0.19, 0.06)	(-0.22, 0.09)
<b>Variable</b>	<b>Geometric mean*</b>		<b>Ratio*</b>		<b>Confidence interval*</b>			
	Placebo	AZD4017		75%	80%	85%	90%	95%
	n=14	n=14						
Hour 3 TEWL (Set 1; Day 0)	34.94	32.00	0.92	(0.82, 1.03)	(0.80, 1.04)	(0.79, 1.06)	(0.77, 1.08)	(0.75, 1.12)
Hour 48 TEWL (Set 1; Day 2)	19.79	21.37	1.08	(0.92, 1.27)	(0.90, 1.29)	(0.88, 1.32)	(0.86, 1.36)	(0.82, 1.43)
Hour 168 TEWL (Set 1; Day 7)	13.52	16.36	1.21	(0.94, 1.56)	(0.91, 1.61)	(0.88, 1.67)	(0.84, 1.75)	(0.77, 1.89)
Hour 3 TEWL (Set 2; Day 28)	23.52	29.83	1.27	(1.05, 1.53)	(1.03, 1.57)	(1.00, 1.61)	(0.96, 1.67)	(0.91, 1.76)
Hour 48 TEWL (Set 2; Day 30)	14.65	18.21	1.24	(1.03, 1.49)	(1.01, 1.53)	(0.99, 1.57)	(0.95, 1.62)	(0.90, 1.72)
Hour 168 TEWL (Set 2; Day 35)	9.98	10.88	1.09	(0.90, 1.31)	(0.89, 1.34)	(0.86, 1.38)	(0.83, 1.43)	(0.79, 1.51)
Hour 0 TEWL (Set 3; Day 35)	7.09	9.00	1.27	(1.05, 1.54)	(1.02, 1.58)	(0.99, 1.62)	(0.96, 1.68)	(0.90, 1.78)
Number of tapes required for barrier disruption: Day 28	38.58	55.55	1.44	(1.16, 1.79)	(1.13, 1.84)	(1.09, 1.90)	(1.05, 1.98)	(0.98, 2.11)

\*Estimated in imputed data



**Table S5: Sensitivity analysis of primary and secondary efficacy outcomes re-imputed after QC fails and outliers removed in the full analysis set**

Data were re-imputed after deleting two baseline radioassays which failed QC and one outlying ELISA assay result at day 28, TEWL readings that were potentially unreliable due to high temperatures and TEWL and WH measures which were collected earlier than scheduled. The comparison was adjusted for each variable's baseline value (this was not available for wound diameter and depth), age, sex and baseline HbA1c. All TEWL readings were adjusted using pre-disruption TEWL at baseline.

Variable	Median*		Difference*	Confidence interval*				
	Placebo n=14	AZD4017 n=14		75%	80%	85%	90%	95%
11bHSD1 activity radioassay (percent conversion per 24 hours): Day 28	11.42	12.88	1.47	(-1.67, 4.60)	(-2.04, 4.97)	(-2.50, 5.43)	(-3.10, 6.03)	(-4.07, 7.00)
11bHSD1 activity ELISA (percent conversion per 24 hours): Day 28	4.14	4.34	0.20	(-2.11, 2.51)	(-2.39, 2.79)	(-2.74, 3.13)	(-3.20, 3.59)	(-3.94, 4.33)
Sudomotor function Left Hand (µS): Day 35	55.83	65.47	9.64	(0.36, 18.92)	(-0.76, 20.04)	(-2.14, 21.41)	(-3.98, 23.25)	(-6.94, 26.21)
Sudomotor function Right Hand (µS): Day 35	55.96	59.94	3.98	(-4.24, 12.20)	(-5.22, 13.18)	(-6.41, 14.37)	(-7.99, 15.95)	(-10.50, 18.46)
Sudomotor function Hands (µS): Day 35	56.69	63.56	6.87	(-1.68, 15.42)	(-2.70, 16.44)	(-3.95, 17.68)	(-5.61, 19.34)	(-8.24, 21.98)
Sudomotor function Left Foot (µS): Day 35	74.99	69.07	-5.91	(-14.19, 2.36)	(-15.17, 3.34)	(-16.37, 4.54)	(-17.97, 6.14)	(-20.51, 8.69)
Sudomotor function Right Foot (µS): Day 35	73.98	70.17	-3.81	(-10.15, 2.53)	(-10.90, 3.28)	(-11.82, 4.20)	(-13.04, 5.42)	(-14.97, 7.36)
Sudomotor function Feet (µS): Day 35	74.99	69.64	-5.34	(-12.46, 1.77)	(-13.31, 2.62)	(-14.34, 3.65)	(-15.71, 5.02)	(-17.89, 7.20)
Sudomotor function Overall (µS): Day 35	65.24	63.96	-1.27	(-6.66, 4.11)	(-7.30, 4.75)	(-8.08, 5.53)	(-9.12, 6.57)	(-10.77, 8.22)
Skin hydration (A.U): Day 35	37.25	43.39	6.14	(0.41, 11.88)	(-0.27, 12.56)	(-1.12, 13.40)	(-2.23, 14.52)	(-4.02, 16.31)
Epidermal thickness (µm): Day 35	63.37	66.06	2.69	(-3.68, 9.05)	(-4.43, 9.80)	(-5.36, 10.73)	(-6.59, 11.96)	(-8.55, 13.92)

Cortisol (mcg/24 hours): Day 35	69.95	66.54	-3.41	(-27.29, 20.47)	(-30.13, 23.31)	(-33.61, 26.79)	(-38.22, 31.40)	(-45.56, 38.74)
Urinary [THF+alloTHF]/THE ratio: Day 35	0.99	0.13	-0.87	(-0.99, -0.75)	(-1.00, -0.73)	(-1.02, -0.72)	(-1.04, -0.69)	(-1.08, -0.66)
<b>Variable</b>	<b>Mean*</b>		<b>Difference*</b>		<b>Confidence interval*</b>			
	Placebo n=14	AZD4017 n=14		75%	80%	85%	90%	95%
Wound gap diameter (mm): Day 2	1.51	0.98	-0.52	(-0.82, -0.23)	(-0.85, -0.20)	(-0.89, -0.15)	(-0.95, -0.10)	(-1.04, -0.01)
Wound depth (mm): Day 7	0.60	0.59	-0.01	(-0.11, 0.09)	(-0.12, 0.10)	(-0.13, 0.11)	(-0.15, 0.13)	(-0.18, 0.16)
Wound gap diameter (mm): Day 30	1.35	0.71	-0.64	(-0.99, -0.30)	(-1.03, -0.25)	(-1.08, -0.20)	(-1.15, -0.13)	(-1.26, -0.02)
Wound depth (mm): Day 35	0.58	0.56	-0.03	(-0.11, 0.06)	(-0.12, 0.07)	(-0.14, 0.09)	(-0.15, 0.10)	(-0.18, 0.13)
<b>Variable</b>	<b>Geometric mean*</b>		<b>Ratio*</b>		<b>Confidence interval*</b>			
	Placebo n=14	AZD4017 n=14		75%	80%	85%	90%	95%
Hour 3 TEWL (Set 1; Day 0)	34.97	31.10	0.89	(0.79, 1.00)	(0.78, 1.02)	(0.76, 1.04)	(0.74, 1.06)	(0.72, 1.10)
Hour 48 TEWL (Set 1; Day 2)	20.20	17.72	0.88	(0.77, 1.00)	(0.75, 1.02)	(0.74, 1.04)	(0.72, 1.07)	(0.69, 1.12)
Hour 168 TEWL (Set 1; Day 7)	13.23	11.97	0.90	(0.75, 1.08)	(0.74, 1.11)	(0.72, 1.14)	(0.69, 1.18)	(0.66, 1.25)
Hour 3 TEWL (Set 2; Day 28)	23.09	30.68	1.33	(1.09, 1.63)	(1.06, 1.66)	(1.03, 1.71)	(0.99, 1.78)	(0.93, 1.89)
Hour 48 TEWL (Set 2; Day 30)	14.65	18.35	1.25	(1.02, 1.53)	(1.00, 1.57)	(0.97, 1.61)	(0.94, 1.68)	(0.88, 1.78)
Hour 168 TEWL (Set 2; Day 35)	9.85	10.70	1.09	(0.88, 1.34)	(0.86, 1.37)	(0.83, 1.42)	(0.80, 1.47)	(0.75, 1.57)
Hour 0 TEWL (Set 3; Day 35)	6.60	9.18	1.39	(1.13, 1.71)	(1.11, 1.75)	(1.07, 1.80)	(1.03, 1.88)	(0.97, 2.00)
Number of tapes required for barrier disruption: Day 28	38.98	55.79	1.43	(1.18, 1.74)	(1.15, 1.78)	(1.12, 1.84)	(1.08, 1.91)	(1.01, 2.02)

\*Estimated in imputed data, adjusted for baseline value, if applicable, and for age, sex, and baseline HbA1c.



**Table S6: Unadjusted differences in changes from baseline in primary and secondary efficacy outcomes in the full analysis set**

Multiple imputation was used to address missing data. For TEWL, integrity, wound depth and diameter, linear regression was used to estimate CIs around differences between the groups. TEWL and integrity measurements were log-transformed before analysis; for these variables changes from baseline are expressed as ratios of geometric means at follow-up to baseline and differences are expressed as ratios of geometric means between groups (AZD4017:placebo). For the remaining variables, which did not meet assumptions for linear regression, median regression was used.

Variable	Median*		Difference*	Confidence interval*				
	Placebo n=14	AZD4017 n=14		75%	80%	85%	90%	95%
11bHSD1 activity radioassay (percent conversion per 24 hours): Day 28	-3.10	-0.50	2.60	(-1.63, 6.83)	(-2.13, 7.33)	(-2.74, 7.94)	(-3.54, 8.74)	(-4.81, 10.01)
11bHSD1 activity ELISA (percent conversion per 24 hours): Day 28	-3.11	-1.80	1.31	(-2.68, 5.29)	(-3.15, 5.76)	(-3.73, 6.34)	(-4.48, 7.09)	(-5.68, 8.29)
Sudomotor function Left Hand (μS): Day 35	-0.30	1.70	2.00	(-7.20, 11.20)	(-8.28, 12.28)	(-9.60, 13.60)	(-11.35, 15.35)	(-14.11, 18.11)
Sudomotor function Right Hand (μS): Day 35	3.65	5.05	1.40	(-6.70, 9.50)	(-7.66, 10.46)	(-8.83, 11.63)	(-10.37, 13.17)	(-12.81, 15.61)
Sudomotor function Hands (μS): Day 35	0.45	4.03	3.58	(-4.65, 11.80)	(-5.62, 12.77)	(-6.81, 13.96)	(-8.38, 15.53)	(-10.86, 18.01)
Sudomotor function Left Foot (μS): Day 35	5.75	-4.00	-9.75	(-17.14, -2.36)	(-18.01, -1.49)	(-19.07, -0.43)	(-20.48, 0.98)	(-22.70, 3.20)
Sudomotor function Right Foot (μS): Day 35	6.80	-1.80	-8.60	(-14.55, -2.65)	(-15.26, -1.94)	(-16.11, -1.09)	(-17.24, 0.04)	(-19.03, 1.83)
Sudomotor function Feet (μS): Day 35	5.90	-3.45	-9.35	(-15.79, -2.91)	(-16.55, -2.15)	(-17.48, -1.22)	(-18.70, 0.00)	(-20.63, 1.93)
Sudomotor function Overall (μS): Day 35	4.71	0.93	-3.79	(-8.68, 1.10)	(-9.26, 1.68)	(-9.97, 2.40)	(-10.92, 3.34)	(-12.42, 4.84)

Skin hydration (A.U): Day 35	-2.88	3.06	5.94	(0.67, 11.21)	(0.05, 11.83)	(-0.71, 12.59)	(-1.71, 13.59)	(-3.29, 15.17)
Epidermal thickness (µm): Day 35	-0.43	-1.92	-1.49	(-11.12, 8.15)	(-12.25, 9.28)	(-13.64, 10.66)	(-15.46, 12.49)	(-18.35, 15.38)
Cortisol (mcg/24 hours): Day 35	-2.70	-1.00	1.70	(-31.61, 35.01)	(-35.54, 38.94)	(-40.33, 43.73)	(-46.66, 50.06)	(-56.65, 60.05)
Urinary [THF+alloTHF]/THE ratio: Day 35	0.01	-0.84	-0.85	(-0.94, -0.75)	(-0.95, -0.74)	(-0.96, -0.73)	(-0.98, -0.71)	(-1.01, -0.68)
Variable	Ratio FU:BL*		Ratio*	Confidence interval*				
	Placebo n=14	AZD4017 n=14		75%	80%	85%	90%	95%
Hour 3 TEWL (Set 1; Day 0)	4.24	3.49	0.82	(0.69, 0.98)	(0.68, 1.00)	(0.66, 1.02)	(0.64, 1.06)	(0.61, 1.12)
Hour 48 TEWL (Set 1; Day 2)	2.40	2.33	0.97	(0.80, 1.18)	(0.78, 1.21)	(0.75, 1.25)	(0.73, 1.29)	(0.68, 1.37)
Hour 168 TEWL (Set 1; Day 7)	1.64	1.78	1.09	(0.85, 1.39)	(0.82, 1.43)	(0.80, 1.48)	(0.76, 1.56)	(0.70, 1.68)
Hour 3 TEWL (Set 2; Day 28)	2.85	3.25	1.14	(0.89, 1.45)	(0.87, 1.49)	(0.84, 1.55)	(0.80, 1.62)	(0.74, 1.74)
Hour 48 TEWL (Set 2; Day 30)	1.78	1.98	1.12	(0.89, 1.40)	(0.87, 1.44)	(0.84, 1.48)	(0.80, 1.55)	(0.75, 1.66)
Hour 168 TEWL (Set 2; Day 35)	1.21	1.19	0.98	(0.78, 1.23)	(0.76, 1.26)	(0.73, 1.31)	(0.70, 1.37)	(0.66, 1.46)
Hour 0 TEWL (Set 3; Day 35)	0.86	0.98	1.14	(0.86, 1.51)	(0.83, 1.56)	(0.80, 1.62)	(0.76, 1.71)	(0.70, 1.86)
Number of tapes required for barrier disruption: Day 28	0.87	1.09	1.26	(1.01, 1.58)	(0.98, 1.63)	(0.95, 1.68)	(0.91, 1.75)	(0.85, 1.88)

\*Estimated in imputed data.

BL, baseline; FU, follow-up.

**Table S7: Adjusted differences in changes from baseline in primary and secondary efficacy outcomes in the full analysis set**

Multiple imputation was used to address missing data. For TEWL, integrity, wound depth and diameter, linear regression was used to estimate CIs around differences between the groups. TEWL and integrity measurements were log-transformed before analysis; for these variables changes from baseline are expressed as ratios of geometric means at follow-up to baseline and differences are expressed as ratios of geometric means between groups (AZD4017:placebo). For the remaining variables, which did not meet assumptions for linear regression, median regression was used. The comparison was adjusted for each variable's baseline value (this was not available for wound diameter and depth), age, sex and baseline HbA1c. All TEWL readings were adjusted using pre-disruption TEWL at baseline.

Variable	Median*		Difference*	Confidence interval*				
	Placebo n=14	AZD4017 n=14		75%	80%	85%	90%	95%
11bHSD1 activity radioassay (percent conversion per 24 hours): Day 28	-2.99	-1.94	1.05	(-1.98, 4.09)	(-2.34, 4.45)	(-2.78, 4.89)	(-3.37, 5.47)	(-4.30, 6.41)
11bHSD1 activity ELISA (percent conversion per 24 hours): Day 28	-3.93	-4.47	-0.54	(-2.78, 1.70)	(-3.05, 1.97)	(-3.38, 2.30)	(-3.82, 2.74)	(-4.53, 3.45)
Sudomotor function Left Hand (μS): Day 35	-0.01	10.38	10.39	(2.03, 18.74)	(1.04, 19.73)	(-0.18, 20.95)	(-1.80, 22.57)	(-4.38, 25.15)
Sudomotor function Right Hand (μS): Day 35	2.77	7.77	5.01	(-3.07, 13.08)	(-4.03, 14.04)	(-5.20, 15.21)	(-6.75, 16.76)	(-9.21, 19.23)
Sudomotor function Hands (μS): Day 35	1.71	8.96	7.25	(-1.05, 15.56)	(-2.04, 16.54)	(-3.24, 17.75)	(-4.84, 19.35)	(-7.39, 21.89)
Sudomotor function Left Foot (μS): Day 35	6.91	-0.10	-7.01	(-14.81, 0.79)	(-15.73, 1.71)	(-16.86, 2.84)	(-18.36, 4.34)	(-20.73, 6.71)
Sudomotor function Right Foot (μS): Day 35	5.49	1.43	-4.07	(-10.35, 2.21)	(-11.09, 2.96)	(-12.00, 3.87)	(-13.21, 5.07)	(-15.12, 6.99)
Sudomotor function Feet (μS): Day 35	5.77	1.24	-4.52	(-11.36, 2.32)	(-12.18, 3.13)	(-13.17, 4.12)	(-14.48, 5.43)	(-16.56, 7.51)
Sudomotor function Overall (μS): Day 35	3.99	2.66	-1.33	(-6.76, 4.10)	(-7.41, 4.75)	(-8.20, 5.54)	(-9.25, 6.59)	(-10.92, 8.25)

Skin hydration (A.U): Day 35	-2.85	2.82	5.67	(-0.08, 11.43)	(-0.77, 12.12)	(-1.62, 12.97)	(-2.75, 14.10)	(-4.57, 15.92)
Epidermal thickness (µm): Day 35	-2.38	3.20	5.58	(-1.54, 12.69)	(-2.40, 13.55)	(-3.45, 14.60)	(-4.85, 16.01)	(-7.11, 18.26)
Cortisol (mcg/24 hours): Day 35	-14.42	-9.12	5.29	(-19.05, 29.64)	(-21.94, 32.53)	(-25.47, 36.06)	(-30.15, 40.74)	(-37.58, 48.16)
Urinary [THF+alloTHF]/THE ratio: Day 35	0.01	-0.85	-0.87	(-0.98, -0.75)	(-1.00, -0.73)	(-1.01, -0.72)	(-1.04, -0.69)	(-1.07, -0.66)
Variable	Ratio FU:BL*		Ratio*	Confidence interval*				
	Placebo n=14	AZD4017 n=14		75%	80%	85%	90%	95%
Hour 3 TEWL (Set 1; Day 0)	4.03	3.68	0.91	(0.81, 1.03)	(0.79, 1.05)	(0.78, 1.07)	(0.76, 1.09)	(0.73, 1.13)
Hour 48 TEWL (Set 1; Day 2)	2.35	2.37	1.01	(0.86, 1.19)	(0.84, 1.21)	(0.82, 1.24)	(0.79, 1.28)	(0.76, 1.34)
Hour 168 TEWL (Set 1; Day 7)	1.62	1.80	1.11	(0.86, 1.44)	(0.83, 1.49)	(0.80, 1.54)	(0.76, 1.62)	(0.70, 1.76)
Hour 3 TEWL (Set 2; Day 28)	2.65	3.53	1.33	(1.09, 1.63)	(1.06, 1.67)	(1.03, 1.72)	(0.99, 1.79)	(0.93, 1.90)
Hour 48 TEWL (Set 2; Day 30)	1.68	2.11	1.26	(1.03, 1.53)	(1.01, 1.56)	(0.98, 1.61)	(0.94, 1.67)	(0.89, 1.77)
Hour 168 TEWL (Set 2; Day 35)	1.16	1.24	1.07	(0.87, 1.31)	(0.85, 1.34)	(0.82, 1.38)	(0.79, 1.44)	(0.74, 1.53)
Hour 0 TEWL (Set 3; Day 35)	0.80	1.06	1.33	(1.07, 1.65)	(1.04, 1.69)	(1.01, 1.75)	(0.97, 1.82)	(0.91, 1.95)
Number of tapes required for barrier disruption: Day 28	0.82	1.17	1.43	(1.18, 1.74)	(1.15, 1.78)	(1.12, 1.84)	(1.07, 1.91)	(1.01, 2.02)

\*Estimated in imputed data, adjusted for baseline value, age, sex, and baseline HbA1c.

BL, baseline; FU, follow-up.

**Table S8: Sensitivity analysis of TEWL that adjusts for the exact timing of post-disruption measurements in the full analysis set**

Analysis models included exact measurement times to account for variations in timings; results have been provided for a) data imputed including all observed values and b) data re-imputed after deleting TEWL readings that were potentially unreliable due to high temperatures.

Linear mixed models were used to model post-baseline TEWL readings (within each set of post-disruption measurements) as a function of time since disruption. Quadratic functions were added to allow for nonlinear change over time. Baseline values and changes over time were permitted to vary between participants. TEWL measurements were log-transformed prior to analysis; differences have been expressed as ratios of geometric means (AZD4017:placebo). For each variable, the comparison was adjusted for baseline (day 0, hour 0) TEWL, age, sex and baseline HbA1c.

Dataset	Disruption day	Post-disruption hour	Ratio	Confidence interval				
				75%	80%	85%	90%	95%
Imputed	0	3	0.89	(0.78, 1.00)	(0.77, 1.02)	(0.76, 1.03)	(0.74, 1.06)	(0.72, 1.09)
Imputed	0	48	1.00	(0.89, 1.14)	(0.88, 1.15)	(0.86, 1.17)	(0.84, 1.20)	(0.81, 1.24)
Imputed	0	168	1.17	(0.94, 1.45)	(0.91, 1.49)	(0.89, 1.53)	(0.85, 1.59)	(0.80, 1.69)
Imputed	28	3	1.28	(1.08, 1.52)	(1.06, 1.55)	(1.04, 1.59)	(1.01, 1.64)	(0.96, 1.72)
Imputed	28	48	1.25	(1.07, 1.47)	(1.05, 1.50)	(1.03, 1.53)	(1.00, 1.57)	(0.96, 1.64)
Imputed	28	168	1.12	(0.93, 1.34)	(0.92, 1.36)	(0.89, 1.40)	(0.86, 1.44)	(0.82, 1.52)
Re-imputed	0	3	0.88	(0.78, 1.00)	(0.77, 1.01)	(0.76, 1.03)	(0.74, 1.05)	(0.72, 1.08)
Re-imputed	0	48	0.90	(0.80, 1.01)	(0.79, 1.03)	(0.78, 1.04)	(0.76, 1.07)	(0.74, 1.10)
Re-imputed	0	168	0.90	(0.77, 1.04)	(0.76, 1.06)	(0.74, 1.08)	(0.72, 1.11)	(0.69, 1.16)
Re-imputed	28	3	1.28	(1.08, 1.51)	(1.06, 1.54)	(1.03, 1.58)	(1.00, 1.63)	(0.95, 1.71)

Dataset	Disruption day	Post-disruption hour	Ratio	Confidence interval				
				75%	80%	85%	90%	95%
Re-imputed	28	48	1.25	(1.07, 1.47)	(1.05, 1.50)	(1.02, 1.53)	(1.00, 1.58)	(0.95, 1.65)
Re-imputed	28	168	1.11	(0.93, 1.33)	(0.91, 1.36)	(0.89, 1.39)	(0.86, 1.44)	(0.82, 1.51)

**Table S9: Sensitivity analysis of primary and secondary efficacy outcomes in available case data in the full analysis set**

For TEWL, integrity, wound depth and diameter, linear regression was used to estimate CIs around differences between the groups. TEWL and integrity measurements were log-transformed before analysis; differences are expressed as ratios of geometric means (AZD4017:placebo). For the remaining variables, which did not meet assumptions for linear regression, median regression was used. The comparison was adjusted for each variable's baseline value (this was not available for wound diameter and depth), age, sex and baseline HbA1c. All TEWL readings were adjusted using pre-disruption TEWL at baseline.

Variable	Estimated median*		Difference*	Confidence interval*				
	Placebo	AZD4017		75%	80%	85%	90%	95%
11bHSD1 activity radioassay (percent conversion per 24 hours): Day 28	11.29 (n=13)	12.33 (n=14)	1.03	(-1.64, 3.71)	(-1.84, 3.91)	(-3.11, 5.17)	(-3.38, 5.44)	(-4.11, 6.18)
11bHSD1 activity ELISA (percent conversion per 24 hours): Day 28	5.83 (n=13)	4.44 (n=14)	-1.39	(-3.54, 0.75)	(-3.63, 0.85)	(-3.74, 0.95)	(-4.52, 1.73)	(-5.22, 2.43)
Sudomotor function Left Hand (µS): Day 35	55.60 (n=13)	65.98 (n=13)	10.39	(2.28, 18.50)	(1.66, 19.12)	(0.06, 20.72)	(-1.42, 22.19)	(-3.73, 24.51)
Sudomotor function Right Hand (µS): Day 35	55.71 (n=13)	59.12 (n=13)	3.41	(-5.25, 12.07)	(-5.60, 12.42)	(-7.50, 14.32)	(-8.09, 14.91)	(-9.75, 16.57)
Sudomotor function Hands (µS): Day 35	55.06 (n=13)	57.98 (n=13)	2.92	(-4.53, 10.37)	(-5.43, 11.27)	(-6.78, 12.62)	(-8.36, 14.20)	(-9.22, 15.05)
Sudomotor function Left Foot (µS): Day 35	75.91 (n=13)	68.68 (n=13)	-7.23	(-12.33, -2.14)	(-12.54, -1.93)	(-12.78, -1.69)	(-18.65, 4.18)	(-19.52, 5.05)
Sudomotor function Right Foot (µS): Day 35	72.69 (n=13)	67.83 (n=13)	-4.85	(-10.63, 0.92)	(-10.86, 1.16)	(-11.77, 2.07)	(-12.15, 2.44)	(-16.40, 6.70)
Sudomotor function Feet (µS): Day 35	74.14 (n=13)	69.14 (n=13)	-5.00	(-9.45, -0.55)	(-10.47, 0.47)	(-13.18, 3.18)	(-13.77, 3.78)	(-16.92, 6.93)
Sudomotor function Overall (µS): Day 35	64.51 (n=13)	64.64 (n=13)	0.13	(-5.02, 5.28)	(-7.17, 7.43)	(-7.54, 7.79)	(-7.95, 8.21)	(-9.27, 9.52)
Skin hydration (A.U): Day 35	38.89 (n=12)	43.30 (n=12)	4.41	(-0.99, 9.80)	(-1.21, 10.02)	(-1.92, 10.73)	(-3.40, 12.21)	(-5.83, 14.64)
Epidermal thickness (µm): Day 35	61.95 (n=13)	65.53 (n=12)	3.58	(-3.77, 10.93)	(-4.08, 11.23)	(-4.62, 11.78)	(-5.25, 12.41)	(-6.00, 13.15)

Cortisol (mcg/24 hours): Day 35	60.40 (n=13)	69.11 (n=13)	8.71	(-19.06, 36.48)	(-20.20, 37.61)	(-21.78, 39.19)	(-24.23, 41.65)	(-33.39, 50.80)	
Urinary [THF+alloTHF]/THE ratio: Day 35	0.99 (n=13)	0.17 (n=13)	-0.82	(-0.97, -0.67)	(-0.98, -0.66)	(-0.99, -0.65)	(-1.01, -0.63)	(-1.02, -0.62)	
	<b>Estimated mean*</b>		<b>Difference*</b>		<b>Confidence interval*</b>				
	Placebo	AZD4017		75%	80%	85%	90%	95%	
Wound gap diameter (mm): Day 2	1.51 (n=14)	0.98 (n=14)	-0.52	(-0.82, -0.23)	(-0.85, -0.20)	(-0.89, -0.15)	(-0.95, -0.10)	(-1.04, -0.01)	
Wound depth (mm): Day 7	0.60 (n=14)	0.59 (n=14)	-0.01	(-0.10, 0.09)	(-0.11, 0.10)	(-0.13, 0.11)	(-0.14, 0.13)	(-0.17, 0.16)	
Wound gap diameter (mm): Day 30	1.35 (n=11)	0.69 (n=12)	-0.66	(-1.00, -0.31)	(-1.05, -0.27)	(-1.10, -0.22)	(-1.16, -0.15)	(-1.27, -0.05)	
Wound depth (mm): Day 35	0.59 (n=13)	0.56 (n=12)	-0.02	(-0.11, 0.07)	(-0.12, 0.08)	(-0.14, 0.09)	(-0.15, 0.11)	(-0.18, 0.13)	
	<b>Estimated geometric mean*</b>		<b>Ratio*</b>		<b>Confidence interval*</b>				
	Placebo	AZD4017		75%	80%	85%	90%	95%	
Hour 3 TEWL (Set 1; Day 0)	34.95 (n=14)	31.26 (n=12)	0.89	(0.79, 1.01)	(0.78, 1.03)	(0.76, 1.05)	(0.74, 1.07)	(0.72, 1.12)	
Hour 48 TEWL (Set 1; Day 2)	20.37 (n=14)	20.13 (n=11)	0.99	(0.84, 1.17)	(0.82, 1.19)	(0.80, 1.22)	(0.77, 1.26)	(0.74, 1.33)	
Hour 168 TEWL (Set 1; Day 7)	14.23 (n=13)	15.25 (n=13)	1.07	(0.82, 1.40)	(0.79, 1.44)	(0.76, 1.50)	(0.73, 1.58)	(0.67, 1.71)	
Hour 3 TEWL (Set 2; Day 28)	23.47 (n=13)	30.51 (n=13)	1.30	(1.06, 1.60)	(1.03, 1.64)	(1.00, 1.69)	(0.96, 1.76)	(0.90, 1.87)	
Hour 48 TEWL (Set 2; Day 30)	14.44 (n=13)	18.28 (n=13)	1.27	(1.03, 1.56)	(1.00, 1.60)	(0.97, 1.64)	(0.94, 1.71)	(0.88, 1.82)	
Hour 168 TEWL (Set 2; Day 35)	10.11 (n=13)	10.88 (n=12)	1.08	(0.87, 1.33)	(0.85, 1.37)	(0.82, 1.41)	(0.79, 1.47)	(0.74, 1.57)	
Hour 0 TEWL (Set 3; Day 35)	6.88 (n=13)	9.02 (n=12)	1.31	(1.05, 1.65)	(1.02, 1.69)	(0.98, 1.75)	(0.94, 1.83)	(0.88, 1.96)	
Number of tapes required for barrier disruption: Day 28	38.37 (n=13)	55.37 (n=13)	1.44	(1.17, 1.78)	(1.14, 1.82)	(1.11, 1.88)	(1.07, 1.95)	(1.00, 2.08)	

\*Adjusted for baseline value if applicable, age, sex, and baseline HbA1c.

**Table S10: Sensitivity analysis of primary and secondary efficacy outcomes using last observation carried forward in the full analysis set**

For TEWL, integrity, wound depth and diameter, linear regression was used to estimate CIs around differences between the groups. TEWL and integrity measurements were log-transformed before analysis; for these variables changes from baseline are expressed as ratios of geometric means at follow-up to baseline and differences are expressed as ratios of geometric means between groups (AZD4017:placebo). For the remaining variables, which did not meet assumptions for linear regression, median regression was used. The comparison was adjusted for each variable's baseline value (this was not available for wound diameter and depth), age, sex and baseline HbA1c. All TEWL readings were adjusted using pre-disruption TEWL at baseline. TEWL was not measured in 1 participant at baseline as a result of an error and data could therefore only be carried forward for 27 participants.

Variable	Estimated median*		Difference*	Confidence interval*				
	Placebo	AZD4017		75%	80%	85%	90%	95%
11bHSD1 activity radioassay (percent conversion per 24 hours): Day 28	13.41 (n=14)	12.69 (n=14)	-0.72	(-3.71, 2.27)	(-3.83, 2.39)	(-4.59, 3.15)	(-5.13, 3.68)	(-5.73, 4.29)
11bHSD1 activity ELISA (percent conversion per 24 hours): Day 28	5.76 (n=14)	4.36 (n=14)	-1.39	(-3.65, 0.87)	(-3.76, 0.97)	(-3.86, 1.07)	(-4.39, 1.60)	(-4.79, 2.00)
Sudomotor function Left Hand (µS): Day 35	56.92 (n=14)	59.57 (n=14)	2.65	(-5.65, 10.96)	(-5.99, 11.29)	(-6.38, 11.68)	(-8.80, 14.10)	(-10.68, 15.98)
Sudomotor function Right Hand (µS): Day 35	54.60 (n=14)	59.45 (n=14)	4.85	(-1.92, 11.62)	(-3.00, 12.71)	(-3.35, 13.06)	(-6.44, 16.14)	(-8.12, 17.83)
Sudomotor function Hands (µS): Day 35	55.06 (n=14)	57.94 (n=14)	2.88	(-3.84, 9.60)	(-4.12, 9.89)	(-4.64, 10.40)	(-8.55, 14.31)	(-9.79, 15.55)
Sudomotor function Left Foot (µS): Day 35	75.20 (n=14)	69.34 (n=14)	-5.86	(-10.67, -1.06)	(-10.87, -0.86)	(-11.22, -0.51)	(-11.69, -0.04)	(-19.25, 7.53)
Sudomotor function Right Foot (µS): Day 35	73.12 (n=14)	69.90 (n=14)	-3.23	(-6.96, 0.51)	(-7.41, 0.95)	(-8.42, 1.97)	(-10.27, 3.82)	(-13.35, 6.89)
Sudomotor function Feet (µS): Day 35	74.01 (n=14)	69.70 (n=14)	-4.31	(-8.44, -0.18)	(-8.61, -0.01)	(-9.63, 1.01)	(-11.71, 3.10)	(-15.60, 6.98)

Sudomotor function Overall ( $\mu$ S): Day 35	64.24 (n=14)	63.79 (n=14)	-0.45	(-4.23, 3.32)	(-5.09, 4.19)	(-7.76, 6.86)	(-8.73, 7.83)	(-9.40, 8.50)	
Skin hydration (A.U): Day 35	38.34 (n=14)	43.42 (n=14)	5.08	(1.95, 8.21)	(0.66, 9.50)	(0.46, 9.70)	(-1.79, 11.94)	(-2.86, 13.02)	
Epidermal thickness ( $\mu$ m): Day 35	63.31 (n=14)	65.43 (n=14)	2.11	(-4.24, 8.46)	(-4.64, 8.87)	(-5.63, 9.86)	(-6.09, 10.32)	(-6.88, 11.11)	
Cortisol (mcg/24 hours): Day 35	64.34 (n=14)	68.42 (n=14)	4.08	(-18.81, 26.97)	(-23.30, 31.47)	(-26.68, 34.84)	(-28.32, 36.48)	(-37.79, 45.95)	
Urinary [THF+alloTHF]/THE ratio: Day 35	0.99 (n=14)	0.17 (n=14)	-0.82	(-0.96, -0.68)	(-0.96, -0.68)	(-1.01, -0.63)	(-1.02, -0.62)	(-1.04, -0.60)	
	<b>Estimated mean*</b>		<b>Difference*</b>		<b>Confidence interval*</b>				
	Placebo	AZD4017		75%	80%	85%	90%	95%	
Wound gap diameter (mm): Day 2	1.51 (n=14)	0.98 (n=14)	-0.52	(-0.82, -0.23)	(-0.85, -0.20)	(-0.89, -0.15)	(-0.95, -0.10)	(-1.04, -0.01)	
Wound depth (mm): Day 7	0.60 (n=14)	0.59 (n=14)	-0.01	(-0.10, 0.09)	(-0.11, 0.10)	(-0.13, 0.11)	(-0.14, 0.13)	(-0.17, 0.16)	
Wound gap diameter (mm): Day 30	1.32 (n=14)	0.66 (n=14)	-0.66	(-0.94, -0.37)	(-0.98, -0.34)	(-1.02, -0.30)	(-1.07, -0.24)	(-1.16, -0.16)	
Wound depth (mm): Day 35	0.59 (n=14)	0.56 (n=14)	-0.03	(-0.11, 0.05)	(-0.12, 0.06)	(-0.13, 0.07)	(-0.15, 0.09)	(-0.17, 0.11)	
	<b>Estimated geometric mean*</b>		<b>Ratio*</b>		<b>Confidence interval*</b>				
	Placebo	AZD4017		75%	80%	85%	90%	95%	
Hour 3 TEWL (Set 1; Day 0)	34.85 (n=14)	29.97 (n=13)	0.86	(0.75, 0.98)	(0.74, 1.00)	(0.73, 1.02)	(0.71, 1.04)	(0.68, 1.08)	
Hour 48 TEWL (Set 1; Day 2)	20.37 (n=14)	21.11 (n=13)	1.04	(0.89, 1.21)	(0.87, 1.23)	(0.85, 1.26)	(0.83, 1.30)	(0.79, 1.36)	
Hour 168 TEWL (Set 1; Day 7)	14.59 (n=14)	15.22 (n=13)	1.04	(0.81, 1.35)	(0.78, 1.39)	(0.75, 1.44)	(0.72, 1.52)	(0.66, 1.64)	
Hour 3 TEWL (Set 2; Day 28)	21.70 (n=14)	29.62 (n=13)	1.36	(1.08, 1.73)	(1.05, 1.78)	(1.01, 1.84)	(0.97, 1.93)	(0.90, 2.07)	
Hour 48 TEWL (Set 2; Day 30)	13.87 (n=14)	18.00 (n=13)	1.30	(1.05, 1.60)	(1.03, 1.64)	(1.00, 1.69)	(0.96, 1.76)	(0.90, 1.88)	
Hour 168 TEWL (Set 2; Day 35)	9.92 (n=14)	11.87 (n=13)	1.20	(0.95, 1.51)	(0.92, 1.56)	(0.89, 1.61)	(0.85, 1.68)	(0.79, 1.81)	
Hour 0 TEWL (Set 3; Day 35)	6.88 (n=14)	9.67 (n=13)	1.41	(1.12, 1.77)	(1.09, 1.81)	(1.05, 1.88)	(1.01, 1.96)	(0.94, 2.10)	
Number of tapes required for barrier disruption: Day 28	39.36 (n=14)	55.58 (n=13)	1.41	(1.15, 1.73)	(1.13, 1.77)	(1.09, 1.82)	(1.05, 1.90)	(0.99, 2.02)	

\*Adjusted for baseline value, if applicable, for age, sex, and baseline HbA1c.

**Table S11: Correlations between AZD4017 compliance and efficacy outcomes in the full analysis set (AZD4017 group only)**

Absolute rho values of at least 0.3 were considered preliminary evidence of an association. The sensitivity analysis excluded baseline radioimmunoassay samples that failed QC, an outlying ELISA assay result at day 28, TEWL readings recorded on very hot days, and results that were recorded 1 day earlier than planned, before imputation. Not all of these issues occurred in samples from the AZD4017 group, but issues that did occur could have affected imputed values for any incomplete variables.

Variable	All values		Excluding outliers/QC failures	
	Imputed	Available case	Imputed	Available case
11bHSD1 activity radioassay (percent conversion per 24 hours): Day 28	-0.04 (14)	-0.04 (14)	-0.04 (14)	-0.04 (14)
11bHSD1 activity ELISA (percent conversion per 24 hours): Day 28	-0.74 (14)	-0.74 (14)	-0.74 (14)	-0.74 (14)
Sudomotor function Left Hand ( $\mu$ S): Day 35	-0.05 (14)	-0.08 (13)	-0.03 (14)	-0.08 (13)
Sudomotor function Right Hand ( $\mu$ S): Day 35	-0.16 (14)	-0.23 (13)	-0.16 (14)	-0.23 (13)
Sudomotor function Hands ( $\mu$ S): Day 35	-0.03 (14)	-0.07 (13)	-0.03 (14)	-0.07 (13)
Sudomotor function Left Foot ( $\mu$ S): Day 35	-0.21 (14)	-0.20 (13)	-0.19 (14)	-0.20 (13)
Sudomotor function Right Foot ( $\mu$ S): Day 35	0.06 (14)	0.12 (13)	0.09 (14)	0.12 (13)
Sudomotor function Feet ( $\mu$ S): Day 35	-0.18 (14)	-0.17 (13)	-0.15 (14)	-0.17 (13)
Sudomotor function Overall ( $\mu$ S): Day 35	0.03 (14)	0.05 (13)	0.05 (14)	0.05 (13)
Skin hydration (A.U): Day 35	0.55 (14)	0.77 (12)	0.62 (14)	0.77 (12)
Epidermal thickness ( $\mu$ m): Day 35	-0.11 (14)	-0.15 (12)	-0.11 (14)	-0.15 (12)
Cortisol (mcg/24 hours): Day 35	-0.30 (14)	-0.31 (13)	-0.31 (14)	-0.31 (13)
Urinary [THF+alloTHF]/THE ratio: Day 35	-0.28 (14)	-0.34 (13)	-0.26 (14)	-0.34 (13)
Wound gap diameter (mm): Day 2	0.35 (14)	0.35 (14)	0.35 (14)	0.35 (14)

Variable	All values		Excluding outliers/QC failures	
	Imputed	Available case	Imputed	Available case
Wound depth (mm): Day 7	0.23 (14)	0.23 (14)	0.27 (14)	0.31 (13)
Wound gap diameter (mm): Day 30	-0.06 (14)	-0.01 (12)	-0.07 (14)	-0.01 (12)
Wound depth (mm): Day 35	0.09 (14)	0.10 (12)	0.09 (14)	0.10 (12)
Hour 0 TEWL (Set 1; Day 0)	-0.42 (14)	-0.43 (13)	-0.43 (14)	-0.43 (13)
Hour 3 TEWL (Set 1; Day 0)	-0.35 (14)	-0.39 (12)	-0.34 (14)	-0.39 (12)
Hour 48 TEWL (Set 1; Day 2)	-0.20 (14)	-0.13 (11)	-0.25 (14)	-0.17 (8)
Hour 168 TEWL (Set 1; Day 7)	-0.07 (14)	-0.01 (13)	0.18 (14)	0.38 (9)
Hour 0 TEWL (Set 2; Day 28)	-0.33 (14)	-0.33 (14)	-0.33 (14)	-0.33 (14)
Hour 3 TEWL (Set 2; Day 28)	-0.37 (14)	-0.37 (14)	-0.37 (14)	-0.37 (14)
Hour 48 TEWL (Set 2; Day 30)	0.29 (14)	0.29 (14)	0.29 (14)	0.29 (14)
Hour 168 TEWL (Set 2; Day 35)	0.37 (14)	0.38 (12)	0.34 (14)	0.38 (12)
Hour 0 TEWL (Set 3; Day 35)	0.30 (14)	0.39 (12)	0.31 (14)	0.39 (12)
Number of tapes required for barrier disruption: Day 28	-0.15 (14)	-0.15 (14)	-0.15 (14)	-0.15 (14)

All values presented as Spearman's rho (number of participants included).

**Table S12: Unadjusted differences in final values of longitudinal laboratory safety variables in the safety set**

Multiple imputation was used to address missing data; results are presented for placebo n=14, AZD4017 n=14. All point estimates and CIs were estimated using linear regression. For each visit, the values presented are: mean placebo group, mean AZD4017 group; difference AZD4017-placebo (90% CI).

Variable	Day 7	Day 28	Day 35	Day 42
Body mass index (kg/m <sup>2</sup> )	N/A	N/A	33.90, 35.55; 1.65 (-5.35, 8.65)	N/A
Waist-hip ratio	N/A	N/A	0.98, 1.02; 0.04 (-0.01, 0.09)	N/A
Systolic blood pressure (mm Hg)	N/A	N/A	143.66, 129.01; -14.64 (-22.83, -6.45)	136.56, 137.50; 0.94 (-7.02, 8.89)
Diastolic blood pressure (mm Hg)	N/A	N/A	79.95, 73.64; -6.31 (-11.24, -1.39)	80.11, 79.29; -0.83 (-8.02, 6.37)
HbA1c (mmol/mol)	71.88, 65.81; -6.07 (-17.14, 5.00)	70.14, 66.00; -4.14 (-14.73, 6.45)	70.64, 64.79; -5.85 (-17.14, 5.44)	69.37, 65.43; -3.94 (-14.93, 7.05)
High-density lipoprotein (mmol/l)	1.16, 1.05; -0.11 (-0.28, 0.07)	1.22, 1.11; -0.11 (-0.28, 0.07)	1.18, 1.01; -0.17 (-0.34, 0.00)	1.19, 1.21; 0.02 (-0.18, 0.22)
Cholesterol (mmol/l)	4.31, 3.59; -0.71 (-1.26, -0.17)	4.21, 3.54; -0.67 (-1.17, -0.16)	4.11, 3.44; -0.68 (-1.18, -0.17)	4.06, 3.84; -0.22 (-0.77, 0.33)
Triglycerides (mmol/l)	2.11, 2.39; 0.28 (-0.51, 1.07)	1.81, 1.71; -0.11 (-0.63, 0.42)	2.22, 2.37; 0.15 (-0.91, 1.21)	1.61, 1.94; 0.33 (-0.39, 1.06)
Hemoglobin (g/l)	136.07, 137.43; 1.36 (-6.38, 9.09)	138.46, 138.36; -0.10 (-6.97, 6.77)	134.84, 136.30; 1.46 (-6.54, 9.46)	136.56, 139.86; 3.29 (-5.51, 12.09)
White blood cells (x10 <sup>9</sup> /l)	6.71, 7.96; 1.26 (-0.02, 2.54)	6.52, 6.72; 0.20 (-0.97, 1.38)	6.68, 6.93; 0.25 (-1.00, 1.50)	6.55, 7.66; 1.12 (-0.23, 2.46)
Platelets (x10 <sup>9</sup> /l)	219.36, 275.29; 55.93 (8.28, 103.58)	219.37, 288.57; 69.20 (15.99, 122.41)	213.32, 265.82; 52.50 (2.98, 102.03)	220.63, 281.43; 60.80 (10.77, 110.82)
Red blood cells (x10 <sup>12</sup> /l)	4.74, 4.59; -0.16 (-0.48, 0.16)	4.81, 4.68; -0.13 (-0.41, 0.16)	4.67, 4.57; -0.10 (-0.39, 0.19)	4.73, 4.77; 0.04 (-0.29, 0.38)
Mean corpuscular volume (fl)	89.71, 92.14; 2.43 (-1.26, 6.12)	88.30, 91.21; 2.92 (-1.05, 6.88)	90.23, 92.20; 1.96 (-2.13, 6.06)	88.19, 90.50; 2.31 (-1.16, 5.78)
Hematocrit (packed cell volume)	0.43, 0.42; -0.01 (-0.03, 0.02)	0.42, 0.43; 0.00 (-0.02, 0.03)	0.42, 0.42; 0.00 (-0.03, 0.03)	0.42, 0.43; 0.02 (-0.01, 0.04)
Mean corpuscular hemoglobin (pg)	28.79, 30.13; 1.34 (-0.12, 2.80)	28.96, 29.68; 0.72 (-0.61, 2.05)	28.97, 29.99; 1.02 (-0.44, 2.48)	29.01, 29.42; 0.41 (-1.02, 1.85)
Corpuscular hemoglobin concentration (g/l)	321.07, 326.93; 5.86 (-0.96, 12.68)	328.44, 325.79; -2.66 (-9.90, 4.59)	321.93, 325.20; 3.27 (-3.47, 10.01)	328.81, 324.86; -3.95 (-11.54, 3.64)
Red blood cell distribution width (%)	14.43, 14.27; -0.16 (-0.94, 0.62)	13.98, 14.08; 0.10 (-0.45, 0.65)	14.21, 14.42; 0.21 (-0.38, 0.81)	13.76, 13.74; -0.02 (-0.68, 0.64)

Variable	Day 7	Day 28	Day 35	Day 42
Albumin (g/l)	39.50, 40.14; 0.64 (-1.23, 2.52)	38.94, 38.71; -0.22 (-1.95, 1.51)	39.88, 40.04; 0.16 (-1.65, 1.98)	38.29, 38.84; 0.56 (-0.80, 1.91)
Bilirubin (umol/l)	8.36, 8.64; 0.29 (-2.43, 3.00)	9.81, 9.86; 0.05 (-2.50, 2.60)	8.80, 8.36; -0.44 (-3.41, 2.53)	8.29, 8.40; 0.11 (-1.54, 1.75)
Alkaline phosphatase (U/l)	80.86, 80.14; -0.71 (-17.98, 16.56)	78.01, 68.93; -9.08 (-23.40, 5.24)	77.67, 68.18; -9.50 (-23.41, 4.41)	78.30, 76.94; -1.36 (-19.31, 16.60)
Alanine aminotransferase (iu/l)	22.93, 26.14; 3.21 (-2.22, 8.64)	23.19, 23.07; -0.12 (-5.46, 5.22)	22.81, 22.19; -0.61 (-6.76, 5.53)	21.74, 23.96; 2.23 (-3.55, 8.00)
Aspartate aminotransferase (iu/l)	21.07, 22.36; 1.29 (-1.98, 4.55)	20.63, 21.36; 0.73 (-1.56, 3.01)	20.76, 20.92; 0.16 (-2.17, 2.49)	19.15, 21.80; 2.65 (-0.73, 6.03)
Gamma-glutamyl transpeptidase (iu/l)	39.71, 37.71; -2.00 (-22.51, 18.51)	42.23, 29.86; -12.37 (-29.42, 4.68)	43.29, 28.10; -15.19 (-35.42, 5.05)	40.96, 28.82; -12.14 (-29.49, 5.21)
eGFR (ml/min/1.73m <sup>2</sup> )	77.50, 71.50; -6.00 (-14.97, 2.97)	80.49, 75.14; -5.34 (-13.52, 2.83)	76.61, 73.60; -3.02 (-13.42, 7.39)	78.28, 76.21; -2.06 (-10.63, 6.51)
Sodium (mmol/l)	139.29, 140.00; 0.71 (-0.83, 2.26)	138.12, 138.79; 0.66 (-0.62, 1.95)	140.05, 139.28; -0.78 (-2.63, 1.08)	138.86, 138.00; -0.86 (-2.24, 0.52)
Potassium (mmol/l)	4.79, 4.59; -0.20 (-0.50, 0.10)	4.50, 4.74; 0.24 (0.00, 0.49)	4.47, 4.52; 0.05 (-0.18, 0.28)	4.63, 4.63; -0.00 (-0.26, 0.26)
Urea (mmol/l)	6.91, 7.24; 0.33 (-1.18, 1.84)	6.71, 6.56; -0.15 (-2.04, 1.74)	7.68, 7.49; -0.20 (-2.70, 2.31)	7.04, 7.57; 0.53 (-1.33, 2.38)
Creatinine (umol/l)	82.36, 88.57; 6.21 (-6.95, 19.38)	77.83, 80.93; 3.10 (-8.58, 14.77)	84.69, 84.94; 0.25 (-14.58, 15.08)	81.18, 79.93; -1.25 (-12.61, 10.11)
Testosterone (nmol/l)	10.34, 6.43; -3.91 (-8.01, 0.18)	11.08, 6.46; -4.62 (-8.48, -0.75)	10.26, 6.46; -3.80 (-7.92, 0.31)	10.25, 7.66; -2.59 (-6.72, 1.53)
Dehydroepiandrosterone sulphate (umol/l)	3.56, 4.91; 1.36 (-0.58, 3.30)	3.25, 5.35; 2.10 (0.53, 3.66)	3.51, 4.91; 1.39 (-0.31, 3.10)	3.00, 3.55; 0.55 (-0.75, 1.85)
Free thyroxine (pmol/l)	14.63, 15.75; 1.12 (-0.28, 2.52)	14.64, 15.74; 1.10 (-0.05, 2.26)	14.39, 15.48; 1.09 (-0.05, 2.23)	14.00, 15.10; 1.10 (0.15, 2.06)
Thyroid-stimulating hormone (mIU/l)	1.68, 1.84; 0.16 (-0.27, 0.59)	1.89, 1.71; -0.18 (-0.71, 0.35)	1.77, 1.68; -0.09 (-0.54, 0.35)	1.79, 1.76; -0.03 (-0.57, 0.51)

**Table S13: Unadjusted differences in changes from baseline in longitudinal laboratory safety variables in the safety set**

Multiple imputation was used to address missing data; results are presented for placebo n=14, AZD4017 n=14. All point estimates and CIs were estimated using linear regression. For each visit, the values presented are: mean placebo group, mean AZD4017 group; difference AZD4017-placebo (90% CI).

Variable	Day 7	Day 28	Day 35	Day 42
Body mass index (kg/m <sup>2</sup> )	N/A	N/A	0.23, 0.51; 0.28 (-0.64, 1.19)	N/A
Waist-hip ratio	N/A	N/A	-0.00, -0.00; -0.00 (-0.03, 0.03)	N/A
Systolic blood pressure (mm Hg)	N/A	N/A	7.94, -11.41; -19.36 (-31.07, -7.64)	0.85, -2.93; -3.78 (-13.95, 6.39)
Diastolic blood pressure (mm Hg)	N/A	N/A	-3.90, 1.00; 4.90 (-1.16, 10.96)	-3.75, 6.64; 10.39 (2.27, 18.51)
HbA1c (mmol/mol)	-0.40, -0.19; 0.22 (-1.26, 1.69)	-2.15, 0.00; 2.15 (-0.89, 5.18)	-1.64, -1.21; 0.44 (-3.99, 4.86)	-2.92, -0.57; 2.35 (-2.59, 7.28)
High density lipoprotein (mmol/l)	-0.08, -0.14; -0.06 (-0.15, 0.02)	-0.01, -0.08; -0.07 (-0.14, 0.01)	-0.06, -0.19; -0.13 (-0.21, -0.05)	-0.04, 0.02; 0.06 (-0.04, 0.17)
Cholesterol (mmol/l)	-0.05, -0.36; -0.31 (-0.51, -0.10)	-0.15, -0.41; -0.26 (-0.66, 0.14)	-0.24, -0.51; -0.27 (-0.70, 0.17)	-0.29, -0.11; 0.19 (-0.34, 0.71)
Triglycerides (mmol/l)	0.44, 0.37; -0.06 (-0.54, 0.41)	0.13, -0.31; -0.45 (-0.85, -0.05)	0.54, 0.35; -0.19 (-0.89, 0.50)	-0.07, -0.08; -0.01 (-0.50, 0.48)
Hemoglobin (g/l)	-3.14, -2.00; 1.14 (-2.06, 4.34)	-0.76, -1.07; -0.31 (-4.32, 3.69)	-4.38, -3.13; 1.24 (-3.57, 6.06)	-2.65, 0.43; 3.08 (-0.70, 6.86)
White blood cells (x10 <sup>9</sup> /l)	0.25, 0.63; 0.37 (-0.33, 1.08)	0.06, -0.62; -0.68 (-1.27, -0.09)	0.22, -0.41; -0.63 (-1.40, 0.13)	0.09, 0.33; 0.23 (-0.58, 1.05)
Platelets (x10 <sup>9</sup> /l)	0.64, 2.14; 1.50 (-12.40, 15.40)	0.66, 15.43; 14.77 (-6.85, 36.40)	-5.40, -7.32; -1.93 (-23.02, 19.17)	1.92, 8.29; 6.37 (-10.84, 23.58)
Red blood cells (x10 <sup>12</sup> /l)	-0.10, -0.13; -0.03 (-0.13, 0.07)	-0.03, -0.03; 0.00 (-0.11, 0.11)	-0.17, -0.14; 0.03 (-0.11, 0.16)	-0.11, 0.06; 0.17 (0.06, 0.29)
Mean corpuscular volume (fl)	1.29, 0.93; -0.36 (-2.12, 1.41)	-0.13, 0.00; 0.13 (-1.68, 1.94)	1.80, 0.98; -0.82 (-2.99, 1.35)	-0.24, -0.71; -0.48 (-2.01, 1.06)
Hematocrit (packed cell volume)	-0.00, -0.01; -0.01 (-0.02, 0.01)	-0.01, -0.00; 0.01 (-0.01, 0.02)	-0.01, -0.01; 0.00 (-0.01, 0.02)	-0.01, 0.01; 0.02 (0.00, 0.03)
Mean corpuscular hemoglobin (pg)	-0.03, 0.39; 0.42 (0.07, 0.78)	0.14, -0.06; -0.19 (-0.59, 0.20)	0.15, 0.25; 0.10 (-0.38, 0.59)	0.19, -0.31; -0.50 (-0.99, -0.01)
Corpuscular hemoglobin concentration (g/l)	-4.50, 0.29; 4.79 (-1.61, 11.19)	2.87, -0.86; -3.73 (-10.81, 3.35)	-3.64, -1.44; 2.20 (-5.76, 10.16)	3.24, -1.79; -5.03 (-11.66, 1.61)
Red blood cell distribution width (%)	0.55, 0.15; -0.40 (-0.89, 0.09)	0.10, -0.04; -0.14 (-0.62, 0.34)	0.33, 0.30; -0.03 (-0.46, 0.40)	-0.12, -0.38; -0.26 (-0.73, 0.21)

Variable	Day 7	Day 28	Day 35	Day 42
Albumin (g/l)	0.07, 0.64; 0.57 (-0.61, 1.75)	-0.49, -0.79; -0.29 (-1.70, 1.12)	0.45, 0.54; 0.09 (-1.45, 1.63)	-1.14, -0.66; 0.49 (-0.62, 1.59)
Bilirubin (umol/l)	-0.57, 0.50; 1.07 (-0.75, 2.90)	0.88, 1.71; 0.83 (-0.69, 2.35)	-0.13, 0.21; 0.35 (-2.19, 2.88)	-0.64, 0.26; 0.89 (-0.85, 2.64)
Alkaline phosphatase (U/l)	0.43, -4.93; -5.36 (-11.92, 1.20)	-2.42, -16.14; -13.72 (-22.00, -5.44)	-2.75, -16.89; -14.14 (-21.88, -6.39)	-2.13, -8.13; -6.00 (-16.68, 4.68)
Alanine aminotransferase (iu/l)	-1.71, -1.29; 0.43 (-2.53, 3.38)	-1.45, -4.36; -2.90 (-6.02, 0.21)	-1.84, -5.24; -3.40 (-8.09, 1.29)	-2.91, -3.47; -0.56 (-4.51, 3.39)
Aspartate aminotransferase (iu/l)	0.07, -0.29; -0.36 (-3.22, 2.51)	-0.37, -1.29; -0.92 (-3.59, 1.75)	-0.24, -1.73; -1.48 (-4.90, 1.94)	-1.85, -0.85; 1.01 (-2.75, 4.76)
Gamma-glutamyl transpeptidase (iu/l)	-2.14, -1.57; 0.57 (-2.73, 3.87)	0.37, -9.43; -9.80 (-17.09, -2.51)	1.43, -11.18; -12.61 (-25.48, 0.26)	-0.90, -10.47; -9.57 (-17.50, -1.64)
eGFR (ml/min/1.73m <sup>2</sup> )	-4.36, -7.71; -3.36 (-7.87, 1.15)	-1.37, -4.07; -2.70 (-5.83, 0.43)	-5.24, -5.62; -0.38 (-5.36, 4.61)	-3.58, -3.00; 0.58 (-3.91, 5.08)
Sodium (mmol/l)	0.36, -0.71; -1.07 (-3.83, 1.69)	-0.81, -1.93; -1.12 (-3.94, 1.70)	1.13, -1.44; -2.56 (-5.46, 0.33)	-0.07, -2.71; -2.65 (-5.44, 0.15)
Potassium (mmol/l)	0.33, -0.04; -0.36 (-0.62, -0.11)	0.03, 0.11; 0.08 (-0.16, 0.32)	0.01, -0.11; -0.11 (-0.37, 0.14)	0.17, 0.01; -0.16 (-0.43, 0.10)
Urea (mmol/l)	-0.04, -0.01; 0.04 (-0.87, 0.94)	-0.25, -0.69; -0.45 (-1.34, 0.45)	0.72, 0.24; -0.49 (-1.84, 0.87)	0.09, 0.32; 0.23 (-0.82, 1.29)
Creatinine (umol/l)	5.71, 12.36; 6.64 (0.17, 13.12)	1.19, 4.71; 3.53 (-0.64, 7.69)	8.05, 8.72; 0.68 (-6.83, 8.18)	4.54, 3.71; -0.82 (-7.40, 5.75)
Testosterone (nmol/l)	-0.76, -0.54; 0.21 (-1.52, 1.94)	-0.02, -0.51; -0.49 (-1.83, 0.86)	-0.84, -0.51; 0.33 (-1.61, 2.26)	-0.85, 0.69; 1.53 (-0.41, 3.48)
Dehydroepiandrosterone sulphate (umol/l)	0.03, 2.00; 1.97 (1.04, 2.91)	-0.28, 2.44; 2.71 (1.98, 3.44)	-0.02, 1.99; 2.01 (1.14, 2.88)	-0.53, 0.64; 1.16 (0.51, 1.82)
Free thyroxine (pmol/l)	-0.24, 0.02; 0.26 (-0.89, 1.40)	-0.22, 0.01; 0.24 (-0.76, 1.23)	-0.47, -0.24; 0.23 (-0.94, 1.39)	-0.87, -0.63; 0.24 (-0.67, 1.15)
Thyroid-stimulating hormone (mIU/l)	-0.06, 0.12; 0.18 (-0.17, 0.52)	0.15, -0.01; -0.16 (-0.51, 0.18)	0.03, -0.05; -0.08 (-0.48, 0.33)	0.05, 0.04; -0.01 (-0.40, 0.37)

\*Estimated in imputed data.

**Table S14: Adjusted differences in changes from baseline in longitudinal laboratory safety variables in the safety set**

Multiple imputation was used to address missing data; results are presented for placebo n=14, AZD4017 n=14. All point estimates and CIs were estimated using linear regression, adjusted for the variable's baseline value, age, sex, and baseline HbA1c. For each visit, the values presented are: mean placebo group, mean AZD4017 group; difference AZD4017-placebo (90% CI).

Variable	Day 7	Day 28	Day 35	Day 42
Body mass index (kg/m <sup>2</sup> )	N/A	N/A	0.17, 0.58; 0.41 (-0.51, 1.34)	N/A
Waist-hip ratio	N/A	N/A	-0.01, 0.01; 0.02 (-0.01, 0.05)	N/A
Systolic blood pressure (mm Hg)	N/A	N/A	5.61, -9.13; -14.74 (-23.00, -6.47)	89.67, 90.44; 0.77 (-6.58, 8.11)
Diastolic blood pressure (mm Hg)	N/A	N/A	-0.25, -2.69; -2.43 (-7.67, 2.80)	58.31, 60.40; 2.09 (-6.77, 10.95)
HbA1c (mmol/mol)	-0.38, -0.19; 0.18 (-1.51, 1.88)	-2.10, 0.08; 2.17 (-0.64, 4.99)	-1.71, -0.99; 0.72 (-3.64, 5.09)	-2.87, -0.45; 2.42 (-2.38, 7.22)
High-density lipoprotein (mmol/l)	-0.08, -0.14; -0.06 (-0.14, 0.02)	0.18, 0.10; -0.08 (-0.16, 0.00)	0.10, -0.03; -0.13 (-0.21, -0.05)	0.06, 0.11; 0.05 (-0.07, 0.16)
Cholesterol (mmol/l)	0.00, -0.41; -0.42 (-0.60, -0.23)	1.55, 1.10; -0.46 (-0.79, -0.12)	0.97, 0.46; -0.51 (-0.87, -0.15)	1.28, 1.18; -0.10 (-0.54, 0.34)
Triglycerides (mmol/l)	0.47, 0.33; -0.14 (-0.67, 0.40)	0.62, 0.43; -0.19 (-0.56, 0.18)	-0.03, -0.52; -0.48 (-1.21, 0.24)	0.05, 0.07; 0.02 (-0.51, 0.55)
Hemoglobin (g/l)	-2.90, -2.24; 0.67 (-2.12, 3.45)	45.08, 44.10; -0.98 (-4.13, 2.17)	15.89, 16.53; 0.64 (-3.96, 5.24)	-3.55, -1.48; 2.07 (-1.62, 5.76)
White blood cells (x10 <sup>9</sup> /l)	0.17, 0.71; 0.54 (-0.14, 1.22)	1.76, 1.36; -0.40 (-0.87, 0.08)	1.51, 1.21; -0.31 (-0.96, 0.34)	1.07, 1.40; 0.33 (-0.41, 1.07)
Platelets (x10 <sup>9</sup> /l)	0.10, 2.52; 2.42 (-13.65, 18.50)	7.72, 21.04; 13.32 (-9.56, 36.20)	9.47, 8.55; -0.91 (-25.20, 23.37)	2.42, 3.89; 1.47 (-16.74, 19.68)
Red blood cells (x10 <sup>12</sup> /l)	-0.09, -0.14; -0.05 (-0.17, 0.06)	0.93, 0.88; -0.05 (-0.15, 0.04)	0.42, 0.40; -0.02 (-0.15, 0.12)	-0.29, -0.15; 0.15 (0.03, 0.26)
Mean corpuscular volume (fl)	1.06, 1.17; 0.11 (-1.83, 2.05)	6.03, 6.55; 0.52 (-1.49, 2.53)	9.58, 9.41; -0.17 (-2.53, 2.19)	12.90, 13.06; 0.16 (-1.42, 1.73)
Hematocrit (packed cell volume)	-0.00, -0.01; -0.01 (-0.02, 0.01)	0.12, 0.12; 0.00 (-0.01, 0.02)	0.03, 0.03; 0.00 (-0.02, 0.02)	-0.02, -0.01; 0.02 (0.00, 0.03)
Mean corpuscular hemoglobin (pg)	-0.02, 0.39; 0.41 (0.08, 0.75)	3.58, 3.51; -0.07 (-0.44, 0.31)	1.34, 1.51; 0.17 (-0.28, 0.62)	2.42, 2.00; -0.42 (-0.95, 0.10)
Corpuscular hemoglobin concentration (g/l)	-4.52, 0.39; 4.91 (-1.41, 11.22)	150.85, 147.06; -3.80 (-10.80, 3.21)	121.63, 123.38; 1.75 (-4.85, 8.35)	62.90, 57.67; -5.22 (-12.18, 1.74)
Red blood cell distribution width (%)	0.52, 0.17; -0.36 (-0.89, 0.18)	6.04, 5.95; -0.09 (-0.49, 0.31)	2.59, 2.70; 0.11 (-0.28, 0.51)	2.84, 2.64; -0.21 (-0.68, 0.26)

Variable	Day 7	Day 28	Day 35	Day 42
Albumin (g/l)	0.18, 0.54; 0.37 (-0.82, 1.55)	10.87, 10.50; -0.37 (-1.82, 1.09)	9.36, 9.35; -0.01 (-1.60, 1.59)	11.80, 12.19; 0.40 (-0.59, 1.38)
Bilirubin (umol/l)	-0.50, 0.43; 0.93 (-1.14, 3.00)	1.36, 1.97; 0.60 (-0.89, 2.09)	4.14, 3.50; -0.64 (-3.01, 1.73)	2.16, 2.50; 0.35 (-1.17, 1.87)
Alkaline phosphatase (U/l)	0.66, -5.34; -6.00 (-12.44, 0.44)	18.33, 5.94; -12.39 (-20.21, -4.56)	12.99, -0.10; -13.09 (-20.43, -5.75)	8.43, 2.78; -5.65 (-15.25, 3.95)
Alanine aminotransferase (iu/l)	-2.09, -0.94; 1.16 (-1.84, 4.15)	4.23, 2.27; -1.96 (-4.94, 1.03)	5.83, 4.19; -1.64 (-5.88, 2.61)	1.56, 2.34; 0.78 (-3.00, 4.56)
Aspartate aminotransferase (iu/l)	-0.33, 0.13; 0.46 (-2.29, 3.21)	11.62, 11.74; 0.12 (-1.81, 2.05)	6.93, 6.90; -0.04 (-2.52, 2.45)	6.53, 8.74; 2.21 (-1.02, 5.44)
Gamma-glutamyl transpeptidase (iu/l)	-2.23, -1.47; 0.76 (-2.83, 4.35)	10.09, -0.19; -10.28 (-14.96, -5.60)	7.96, -4.02; -11.97 (-22.80, -1.15)	6.46, -3.09; -9.55 (-14.88, -4.22)
eGFR (ml/min/1.73m <sup>2</sup> )	-4.42, -7.60; -3.18 (-8.30, 1.94)	2.79, 0.60; -2.19 (-5.38, 1.01)	-14.06, -13.79; 0.27 (-4.57, 5.10)	4.24, 5.86; 1.62 (-2.77, 6.01)
Sodium (mmol/l)	-0.23, -0.12; 0.10 (-1.23, 1.44)	138.48, 138.64; 0.16 (-0.98, 1.29)	1.57, 0.37; -1.19 (-3.21, 0.82)	135.61, 134.37; -1.25 (-2.42, -0.07)
Potassium (mmol/l)	0.30, -0.00; -0.31 (-0.58, -0.03)	2.17, 2.35; 0.18 (-0.06, 0.43)	1.61, 1.63; 0.01 (-0.22, 0.25)	1.85, 1.80; -0.04 (-0.31, 0.22)
Urea (mmol/l)	-0.08, 0.04; 0.13 (-0.79, 1.05)	-0.33, -0.68; -0.35 (-1.31, 0.61)	-1.47, -1.99; -0.52 (-1.88, 0.83)	0.16, 0.18; 0.02 (-1.04, 1.08)
Creatinine (umol/l)	5.30, 12.74; 7.43 (0.79, 14.08)	-1.29, 2.14; 3.43 (-0.98, 7.85)	-8.65, -6.87; 1.78 (-5.65, 9.22)	9.36, 7.78; -1.58 (-8.24, 5.07)
Testosterone (nmol/l)	-0.34, -0.97; -0.63 (-2.52, 1.25)	0.86, -0.20; -1.06 (-2.58, 0.45)	0.38, -0.02; -0.40 (-2.66, 1.85)	0.44, 1.57; 1.12 (-1.20, 3.45)
Dehydroepiandrosterone sulphate (umol/l)	-0.13, 2.17; 2.30 (1.52, 3.08)	-0.50, 2.36; 2.86 (2.09, 3.64)	-0.15, 2.02; 2.16 (1.29, 3.04)	0.32, 1.41; 1.09 (0.43, 1.75)
Free thyroxine (pmol/l)	-0.36, 0.14; 0.50 (-0.63, 1.64)	5.32, 5.82; 0.51 (-0.43, 1.44)	4.33, 4.99; 0.65 (-0.45, 1.76)	3.77, 4.56; 0.79 (0.07, 1.52)
Thyroid stimulating hormone (mIU/l)	-0.02, 0.08; 0.10 (-0.22, 0.42)	0.12, -0.07; -0.20 (-0.58, 0.19)	0.52, 0.36; -0.15 (-0.54, 0.23)	0.09, 0.05; -0.04 (-0.46, 0.38)

**Table S15: Absolute and relative frequencies of values below or above normal limits for laboratory safety variables in the safety set**

Variable	LLN	ULN	Summary	Day 0		Day 7		Day 28		Day 35		Day 42	
				Placebo	AZD4017								
Body mass index	N/A	N/A	Total, n	14	14					13	13		
Waist hip ratio	N/A	N/A	Total, n	14	14					13	13		
Systolic blood pressure	N/A	150	Total, n	14	14					13	13	13	14
			Above normal, n	3	2					4	1	3	
			Above normal, %	21	14					31	8	23	
Diastolic blood pressure	N/A	90	Total, n	14	14					13	13	13	14
			Above normal, n	2						1	1	2	3
			Above normal, %	14						8	8	15	21
HbA1c	N/A	41	Total, n	14	14	13	13	13	14	11	12	13	14
			Above normal, n	14	14	13	12	13	14	11	12	13	14
			Above normal, %	100	100	100	92	100	100	100	100	100	100
High-density lipoprotein	1.5	N/A	Total, n	14	14	14	14	13	14	12	12	12	13
			Below normal, n	12	12	12	14	11	14	10	12	10	10
			Below normal, %	86	86	86	100	85	100	83	100	83	77
Cholesterol	2.6	5.2	Total, n	14	14	14	14	13	14	12	12	12	13
			Below normal, n										1
			Below normal, %										8
			Above normal, n	2	1	2		1		1	1	1	
			Above normal, %	14	7	14		8		8	8	8	
Triglycerides	N/A	N/A	Total, n	14	14	14	14	13	14	12	12	12	13

Variable	LLN	ULN	Summary	Day 0		Day 7		Day 28		Day 35		Day 42		
				Placebo	AZD4017									
Hemoglobin	114	160	Total, n	14	14	14	14	13	14	12	13	13	14	
			Below normal, n	1				1		1		1		
			Below normal, %	7				8		8		8		
			Above normal, n	1	1	1	1		1		1		1	
			Above normal, %	7	7	7	7		7		8		7	
White blood cells	4	11	Total, n	14	14	14	14	13	14	12	13	13	14	
			Below normal, n	1	1		1	1	1	1	1	1	1	
			Below normal, %	7	7		7	8	7	8	8	8	7	
			Above normal, n	1	1									1
			Above normal, %	7	7									7
Platelets	150	400	Total, n	14	14	14	14	13	14	12	13	13	14	
			Below normal, n	1	1	2	1	1	1	1	1	1	1	
			Below normal, %	7	7	14	7	8	7	8	8	8	7	
			Above normal, n		1		2		2		2		2	
			Above normal, %		7		14		14		15		14	
Red blood cells	3.8	5.8	Total, n	14	14	14	14	13	14	12	13	13	14	
			Below normal, n		1		1		1		1		1	
			Below normal, %		7		7		7		8		7	
			Above normal, n											1
			Above normal, %											7
Mean corpuscular volume	78	100	Total, n	14	14	14	14	13	14	12	13	13	14	



Variable	LLN	ULN	Summary	Day 0		Day 7		Day 28		Day 35		Day 42	
				Placebo	AZD4017								
			Below normal, %										
			Above normal, n	1	4	3	3	1	1	3	3	1	1
			Above normal, %	7	29	21	21	8	7	25	23	8	7
Albumin	35	50	Total, n	14	14	14	14	13	14	12	13	13	13
			Below normal, n					1					
			Below normal, %					8					
			Above normal, n										
			Above normal, %										
Bilirubin	2	21	Total, n	14	14	14	14	13	14	12	13	13	13
			Below normal, n										
			Below normal, %										
			Above normal, n				1		1	1			
			Above normal, %				7		7	8			
Alkaline phosphatase	30	130	Total, n	14	14	14	14	13	14	12	13	13	13
			Below normal, n						1		1		
			Below normal, %						7		8		
			Above normal, n	1		1						1	1
			Above normal, %	7		7						8	8
Alanine aminotransferase	N/A	40	Total, n	14	14	14	14	13	14	12	13	13	13
			Above normal, n		2		1		2		1		2
			Above normal, %		14		7		14		8		15



Variable	LLN	ULN	Summary	Day 0		Day 7		Day 28		Day 35		Day 42	
				Placebo	AZD4017								
			Below normal, %										
			Above normal, n		1	3		2				1	
			Above normal, %		7	21		14				8	
Urea	2.5	7.8	Total, n	14	14	14	14	13	14	12	13	13	14
			Below normal, n										
			Below normal, %										
			Above normal, n	3	5	4	5	3	4	2	7	3	5
			Above normal, %	21	36	29	36	23	29	17	54	23	36
Creatinine_M	64	104	Total, n	12	10	12	10	11	10	10	9	11	10
			Below normal, n	2	3	2	1	2	1	1	1	1	2
			Below normal, %	17	30	17	10	18	10	10	11	9	20
			Above normal, n		2	2	3	1	2	2	3	1	1
			Above normal, %		20	17	30	9	20	20	33	9	10
Creatinine_F	49	90	Total, n	2	4	2	4	2	4	2	4	2	4
			Below normal, n										
			Below normal, %										
			Above normal, n								1		1
			Above normal, %								25		25
Testosterone_M	8	30	Total, n	12	10	12	10	11	10	10	9	11	10
			Below normal, n	1	2	2	4	2	4	1	3	3	2
			Below normal, %	8	20	17	40	18	40	10	33	27	20

Variable	LLN	ULN	Summary	Day 0		Day 7		Day 28		Day 35		Day 42	
				Placebo	AZD4017								
			Above normal, n							1			
			Above normal, %							10			
Testosterone_F	N/A	2.8	Total, n	2	4	2	4	1	4	2	4	2	4
			Above normal, n										
			Above normal, %										
Dehydroepiandrosterone sulphate (males)	3.6	13	Total, n	12	10	12	10	11	10	10	9	11	10
			Below normal, n	5	7	5	4	6	2	4	2	8	6
			Below normal, %	42	70	42	40	55	20	40	22	73	60
			Above normal, n				1						
			Above normal, %				10						
Dehydroepiandrosterone sulphate (females)	2.7	11	Total, n	2	4	2	4	2	4	2	4	2	4
			Below normal, n	2	3	2	1	2	2	2	2	2	3
			Below normal, %	100	75	100	25	100	50	100	50	100	75
			Above normal, n										
			Above normal, %										
Free thyroxine	10	20	Total, n	14	14	14	13	12	12	12	13	13	14
			Below normal, n										
			Below normal, %										
			Above normal, n				1						

Variable	LLN	ULN	Summary	Day 0		Day 7		Day 28		Day 35		Day 42	
				Placebo	AZD4017								
			Above normal, %				8						
Thyroid-stimulating hormone	.2	4	Total, n	14	14	14	13	12	12	12	13	13	14
			Below normal, n										
			Below normal, %										
			Above normal, n										
			Above normal, %										

LLN, lower limit of normal; ULN, upper limit of normal.

**Table S16: Sample sizes for future trials based on estimates from available case data in full analysis set**

At an alpha of 0.05 (5% significance) and 1-beta of 0.90 (90% power), sample sizes for a range of substantive between-group differences are presented that allow for a 10% dropout rate. For TEWL and integrity variables, means and standard deviations (SDs) are presented on the log scale. For all variables, sample size is based on mean and SD (and Pearson's r where applicable), as specified in the statistical analysis plan. However, some variables were not normally distributed which may limit the accuracy of these estimates. Sample size estimates presented here should be considered preliminary.

Variable	Relative difference	Placebo mean	AZD4017 mean	Pooled SD	R*	N per arm
11bHSD1 activity radioassay (percent conversion per 24 hours): Day 28	10%	12.38	11.14	5.13	0.07	399
	20%	12.38	9.90	5.13	0.07	100
	30%	12.38	8.66	5.13	0.07	46
11bHSD1 activity ELISA (percent conversion per 24 hours): Day 28	10%	15.27	13.74	25.85	0.36	5821
	20%	15.27	12.22	25.85	0.36	1456
	30%	15.27	10.69	25.85	0.36	648
Sudomotor function Left Hand (μS): Day 35	10%	56.46	62.11	12.83	0.42	100
	20%	56.46	67.75	12.83	0.42	26
	30%	56.46	73.40	12.83	0.42	12
Sudomotor function Right Hand (μS): Day 35	10%	54.08	59.48	14.07	0.61	100
	20%	54.08	64.89	14.07	0.61	26
	30%	54.08	70.30	14.07	0.61	11
Sudomotor function Hands (μS): Day 35	10%	55.27	60.80	13.26	0.52	99
	20%	55.27	66.32	13.26	0.52	26
	30%	55.27	71.85	13.26	0.52	11
Sudomotor function Left Foot (μS): Day 35	10%	68.69	75.56	15.26	0.67	63
	20%	68.69	82.43	15.26	0.67	16
	30%	68.69	89.30	15.26	0.67	8
Sudomotor function Right Foot (μS): Day 35	10%	69.31	76.24	16.69	0.77	56
	20%	69.31	83.17	16.69	0.77	14

<b>Variable</b>	<b>Relative difference</b>	<b>Placebo mean</b>	<b>AZD4017 mean</b>	<b>Pooled SD</b>	<b>R*</b>	<b>N per arm</b>
	30%	69.31	90.10	16.69	0.77	7
Sudomotor function Feet ( $\mu$ S): Day 35	10%	69.00	75.90	15.82	0.72	59
	20%	69.00	82.80	15.82	0.72	14
	30%	69.00	89.70	15.82	0.72	7
Sudomotor function Overall ( $\mu$ S): Day 35	10%	62.13	68.35	12.82	0.70	50
	20%	62.13	74.56	12.82	0.70	13
	30%	62.13	80.78	12.82	0.70	6
Skin hydration (A.U): Day 35	10%	38.19	42.01	9.90	0.55	110
	20%	38.19	45.83	9.90	0.55	28
	30%	38.19	49.65	9.90	0.55	12
Epidermal thickness ( $\mu$ m): Day 35	10%	61.72	67.90	9.43	0.07	56
	20%	61.72	74.07	9.43	0.07	14
	30%	61.72	80.24	9.43	0.07	7
Wound gap diameter (mm): Day 2	10%	1.49	1.34	0.71	N/A	529
	20%	1.49	1.19	0.71	N/A	132
	30%	1.49	1.04	0.71	N/A	59
Wound depth (mm): Day 7	10%	0.60	0.54	0.20	N/A	262
	20%	0.60	0.48	0.20	N/A	66
	30%	0.60	0.42	0.20	N/A	30
Wound gap diameter (mm): Day 30	10%	1.44	1.30	0.60	N/A	409
	20%	1.44	1.16	0.60	N/A	102
	30%	1.44	1.01	0.60	N/A	46
Wound depth (mm): Day 35	10%	0.60	0.54	0.19	N/A	233
	20%	0.60	0.48	0.19	N/A	59
	30%	0.60	0.42	0.19	N/A	27
Hour 3 TEWL (Set 1; Day 0)	10%	3.55	3.45	0.24	0.25	119
	20%	3.55	3.33	0.24	0.25	27
	30%	3.55	3.20	0.24	0.25	10
Hour 48 TEWL (Set 1; Day 2)	10%	2.99	2.88	0.34	0.32	220
	20%	2.99	2.76	0.34	0.32	50
	30%	2.99	2.63	0.34	0.32	20
Hour 168 TEWL (Set 1; Day 7)	10%	2.61	2.50	0.55	0.40	541
	20%	2.61	2.38	0.55	0.40	121
	30%	2.61	2.25	0.55	0.40	48
Hour 3 TEWL (Set 2; Day 28)	10%	3.17	3.06	0.41	0.12	351

<b>Variable</b>	<b>Relative difference</b>	<b>Placebo mean</b>	<b>AZD4017 mean</b>	<b>Pooled SD</b>	<b>R*</b>	<b>N per arm</b>
	20%	3.17	2.95	0.41	0.12	79
	30%	3.17	2.81	0.41	0.12	31
Hour 48 TEWL (Set 2; Day 30)	10%	2.67	2.56	0.41	0.26	329
	20%	2.67	2.45	0.41	0.26	73
	30%	2.67	2.31	0.41	0.26	29
Hour 168 TEWL (Set 2; Day 35)	10%	2.30	2.20	0.40	0.17	334
	20%	2.30	2.08	0.40	0.17	74
	30%	2.30	1.95	0.40	0.17	29
Hour 0 TEWL (Set 3; Day 35)	10%	1.94	1.84	0.42	-0.12	374
	20%	1.94	1.72	0.42	-0.12	84
	30%	1.94	1.59	0.42	-0.12	33
Number of tapes required for barrier disruption: Day 28	10%	3.63	3.73	0.49	0.42	500
	20%	3.63	3.82	0.49	0.42	138
	30%	3.63	3.90	0.49	0.42	66

\*Correlation with baseline value (not applicable for wound healing measures)

Figure S1. Correlation between the different methods of assessing 24-hour 11 $\beta$ -HSD1 activity (percent conversion per 24 hours) in the full analysis set






Figure S2. Correlation between AZD4017 levels in the biopsy at day 28 and in plasma at day 35 in the full analysis set (AZD4017 group only)





## CONSORT 2010 checklist of information to include when reporting a pilot or feasibility randomized trial in a journal or conference abstract

Item	Description	Reported on line number
Title	Identification of study as randomised pilot or feasibility trial	1
Authors *	Contact details for the corresponding author	26-27
Trial design	Description of pilot trial design (eg, parallel, cluster)	39-40
Methods		
Participants	Eligibility criteria for participants and the settings where the pilot trial was conducted	41-43
Interventions	Interventions intended for each group	42-43
Objective	Specific objectives of the pilot trial	38-39
Outcome	Prespecified assessment or measurement to address the pilot trial objectives**	47-54
Randomization	How participants were allocated to interventions	44-45
Blinding (masking)	Whether or not participants, care givers, and those assessing the outcomes were blinded to group assignment	40
Results		
Numbers randomized	Number of participants screened and randomised to each group for the pilot trial objectives**	46
Recruitment	Trial status <sup>†</sup>	N/A
Numbers analysed	Number of participants analysed in each group for the pilot objectives**	42-43
Outcome	Results for the pilot objectives, including any expressions of uncertainty**	47-54
Harms	Important adverse events or side effects	52
Conclusions	General interpretation of the results of pilot trial and their implications for the future definitive trial	54-55
Trial registration	Registration number for pilot trial and name of trial register	56
Funding	Source of funding for pilot trial	57

Citation: Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, et al. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. *BMJ*. 2016;355.

*\*this item is specific to conference abstracts*

*\*\*Space permitting, list all pilot trial objectives and give the results for each. Otherwise, report those that are a priori agreed as the most important to the decision to proceed with the future definitive RCT.*

*†For conference abstracts.*



## CONSORT 2010 checklist of information to include when reporting a pilot or feasibility trial\*

Section/topic	Item no	Checklist item	Reported on page no
<b>Title and abstract</b>			
	1a	Identification as a pilot or feasibility randomized trial in the title	1
	1b	Structured summary of pilot trial design, methods, results, and conclusions (for specific guidance, see CONSORT abstract extension for pilot trials)	2-3
<b>Introduction</b>			
Background and objectives	2a	Scientific background and explanation of rationale for future definitive trial, and reasons for randomized pilot trial	4-5
	2b	Specific objectives or research questions for pilot trial	5-7
<b>Methods</b>			
Trial design	3a	Description of pilot trial design (such as parallel, factorial), including allocation ratio	5
	3b	Important changes to methods after pilot trial commencement (such as eligibility criteria), with reasons	S2 1.4
Participants	4a	Eligibility criteria for participants	S1 6.3
	4b	Settings and locations where the data were collected	S1 6.4.1

	4c	How participants were identified and consented	S1 6.4
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	S1 8.0
Outcomes	6a	Completely defined prespecified assessments or measurements to address each pilot trial objective specified in 2b, including how and when they were assessed	S1 4.0 and 9.0
	6b	Any changes to pilot trial assessments or measurements after the pilot trial commenced, with reasons	S2 1.4
	6c	If applicable, prespecified criteria used to judge whether, or how, to proceed with future definitive trial	N/A
Sample size	7a	Rationale for numbers in the pilot trial	S1 13.9
	7b	When applicable, explanation of any interim analyses and stopping guidelines	S1 13.8
Randomization			
Sequence generation	8a	Method used to generate the random allocation sequence	S1 6.4.3
	8b	Type of randomization(s) and details of any restriction (such as blocking and block size)	S1 6.4.3
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	S1 6.4.3
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	S1 6.4.3
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those	S1 7.0

		assessing outcomes) and how	
	11b	If relevant, description of the similarity of interventions	N/A
Statistical methods	12	Methods used to address each pilot trial objective and whether qualitative or quantitative	S1 13.0 and S3
<b>Results</b>			
Participant flow (a diagram is strongly recommended)	13a	For each group, the numbers of participants who were approached and/or assessed for eligibility, randomly assigned, received intended treatment, and were assessed for each objective	Figure 1
	13b	For each group, losses and exclusions after randomization, together with reasons	Figure 1
Recruitment	14a	Dates defining the periods of recruitment and follow-up	5
	14b	Why the pilot trial ended or was stopped	S2 1.4
Baseline data	15	A table showing baseline demographic and clinical characteristics for each group	25-28
Numbers analyzed	16	For each objective, number of participants (denominator) included in each analysis. If relevant, these numbers should be by randomized group.	29-34
Outcomes and estimation	17	For each objective, results, including expressions of uncertainty (such as 95% confidence interval), for any estimates. If relevant, these results should be by randomized group.	29-34
Ancillary analyses	18	Results of any other analyses performed that could be used to inform the future definitive trial	Tables S1-S16 and Figures S1-S2
Harms	19	All important harms or unintended effects in each group (for specific guidance, see CONSORT for harms)	35
	19a	If relevant, other important unintended consequences	N/A

<b>Discussion</b>			
Limitations	20	Pilot trial limitations, addressing sources of potential bias and remaining uncertainty about feasibility	17-18
Generalizability	21	Generalizability (applicability) of pilot trial methods and findings to future definitive trial and other studies	14-18
Interpretation	22	Interpretation consistent with pilot trial objectives and findings, balancing potential benefits and harms, and considering other relevant evidence	14-18
	22a	Implications for progression from pilot to future definitive trial, including any proposed amendments	18
<b>Other information</b>			
Registration	23	Registration number for pilot trial and name of trial registry	3
Protocol	24	Where the pilot trial protocol can be accessed, if available	S1
Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	3, 18
	26	Ethical approval or approval by research review committee, confirmed with reference number	5

Citation: Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, et al. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. *BMJ*. 2016;355.

\*We strongly recommend reading this statement in conjunction with the CONSORT 2010, extension to randomized pilot and feasibility trials, explanation and elaboration. for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomized trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming; for those and for up-to-date references relevant to this checklist, see [www.consort-statement.org](http://www.consort-statement.org).